



# **Semaglutide and Tirzepatide for Obesity: Effectiveness and Value**

**Draft Evidence Report**

**SEPTEMBER 9, 2025**

**Prepared for**



**AUTHORS:**

**Grace A. Lin, MD**

Medical Director for Health Technology Assessment  
Institute for Clinical and Economic Review

**Woojung Lee, PharmD, PhD**

Associate Director of Health Economics and Decision Modeling  
Institute for Clinical and Economic Review

**Shahariar Mohammed Fahim, PhD, MSc**

Senior Research Lead  
Institute for Clinical and Economic Review

**Marina Richardson, PhD, MSc**

Associate Director, HTA Methods and Health Economics  
Institute for Clinical and Economic Review

**Marie Phillips, BA**

Health Economics Research Assistant  
Institute for Clinical and Economic Review

**Finn Raymond, BS**

Research Assistant  
Institute for Clinical and Economic Review

**David Rind, MD, MSc**

Chief Medical Officer  
Institute for Clinical and Economic Review

ICER's value assessments are free from financial conflicts of interest from health care companies. As an organization, we value transparency and hold ourselves, and our collaborators, to high standards for conducting our work. Our full policy to manage potential conflicts of interest can be found [here](#). You can find ICER's Code of Ethics [here](#). Any conflicts reported by the authors of this report, contributing staff members, or expert reviewers, can be found on [page vi](#).

**DATE OF****PUBLICATION:** September 9, 2025

**How to cite this document:** Lin GA, Lee W, Fahim SM, Richardson M, Phillips M, Raymond F, Rind DM. Semaglutide and Tirzepatide for Obesity: Effectiveness and Value; Draft Evidence Report. Institute for Clinical and Economic Review, September 9, 2025. [https://icer.org/wp-content/uploads/2025/09/ICER\\_Obesity\\_Draft-Report\\_For-Publication\\_090925.pdf](https://icer.org/wp-content/uploads/2025/09/ICER_Obesity_Draft-Report_For-Publication_090925.pdf)

Grace Lin served as the lead author for the report. Shahariar Mohammed Fahim led the systematic review and authorship of the comparative effectiveness section of this report with assistance from Finn Raymond. Woojung Lee developed the cost-effectiveness model and authored corresponding sections of the report with support from Marina Richardson. Marie Phillips conducted the analysis for the budget impact model. David Rind provided methodologic guidance on the clinical and economic evaluations. We would also like to thank Becca Piltch, Anna Geiger, and Grace Ham for their contributions to this report.

## About ICER

The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research institute that conducts evidence-based reviews of health care interventions, including prescription drugs, other treatments, and diagnostic tests. In collaboration with patients, clinical experts, and other key stakeholders, ICER analyzes the available evidence on the benefits and risks of these interventions to measure their value and suggest fair prices. ICER also regularly reports on the barriers to care for patients and recommends solutions to ensure fair access to prescription drugs. For more information about ICER, please visit [ICER's website](#).

The funding for this report comes from non-profit foundations, with the largest single funder being the Arnold Ventures. No funding for this work comes from health insurers, pharmacy benefit managers (PBMs), or life science companies. ICER receives approximately 22% of its overall revenue from these health industry organizations to run a separate Policy Summit program, with funding approximately equally split between insurers/PBMs and life science companies. Life science companies relevant to this review who participate in this program include: Novo Nordisk. A complete list of funders and more information on ICER's support, is available on the [funding page](#) of the ICER website.

For drug topics, in addition to receiving recommendations [from the public](#), ICER scans publicly available information and also benefits from a collaboration with [IPD Analytics](#), an independent organization that performs analyses of the emerging drug pipeline for a diverse group of industry stakeholders, including payers, pharmaceutical manufacturers, providers, and wholesalers. IPD provides a tailored report on the drug pipeline on a courtesy basis to ICER but does not prioritize topics for specific ICER assessments.

## About NE CEPAC

The New England Comparative Effectiveness Public Advisory Council ([NE CEPAC](#)) – a core program of ICER – provides a public venue in which the evidence on the effectiveness and value of health care services can be discussed with the input of all stakeholders. The NE CEPAC seeks to help patients, clinicians, insurers, and policymakers interpret and use evidence to improve the quality and value of health care. The NE CEPAC is an independent committee of medical evidence experts from across New England, with a mix of practicing clinicians, methodologists, and leaders in patient engagement and advocacy. All Panel members meet strict conflict of interest guidelines and are convened to discuss the evidence summarized in ICER reports and vote on the comparative clinical effectiveness and value of medical interventions.

The findings contained within this report are current as of the date of publication. Readers should be aware that new evidence may emerge following the publication of this report that could potentially influence the results. ICER may revisit its analyses in a formal update to this report in the future.

The economic models used in ICER reports are intended to compare the clinical outcomes, expected costs, and cost-effectiveness of different care pathways for broad groups of patients. Model results therefore represent average findings across patients and should not be presumed to represent the clinical or cost outcomes for any specific patient. In addition, data inputs to ICER models often come from clinical trials; patients in these trials may differ in real-world practice settings

*In the development of this report, ICER's researchers consulted with clinical experts, patients, manufacturers, and other stakeholders. The following individuals served as external reviewers of the draft evidence report:*

## **Expert Reviewers**

**David Kim, PhD**  
**Assistant Professor of Medicine and Public Health Sciences**  
**University of Chicago**

**Joe Nadglowski Jr.**  
**President and CEO**  
**Obesity Action Coalition**

**Gitanjali Srivastava, MD, FACP, FAAP**  
**Professor of Medicine**  
**Department of Medicine, Division of Diabetes, Endocrinology & Metabolism**  
**Vanderbilt University School of Medicine**

**Michele Tedder, MSN, RN**  
**Director of Chronic Disease**  
**Black Women's Health Imperative**

**Dan Touchette, PharmD, MA**  
**Professor**  
**University of Illinois, Chicago**

**Alexa Triot, MD**  
**Clinical Director of HCA Embedded Primary Care Weight Management Programs, Section of**  
**Primary Care, Division of General Medicine**  
**Beth Israel Deaconess Medical Center**

*None of the external reviewers or other experts we spoke to are responsible for the final contents of this report, nor should it be assumed that they support any part of it. Furthermore, it is possible that external reviewers may not have had the opportunity to review all portions of the draft report. The report should be viewed as attributable solely to the ICER team and its affiliated researchers.*

*To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.*

*For a list of stakeholders from whom we requested input, or who have submitted public comments so far, please visit: [https://icer.org/wp-content/uploads/2025/04/ICER\\_Obesity\\_Stakeholder-List\\_For-Publication\\_052925.pdf](https://icer.org/wp-content/uploads/2025/04/ICER_Obesity_Stakeholder-List_For-Publication_052925.pdf)*

# Conflict of Interest Disclosures for the Report

**Table 1. ICER Staff and External Collaborators Conflict of Interest Disclosures**

ICER Staff and External Collaborators	Conflict of Interest
<b>Shahariar Mohammed Fahim, PhD, MSc</b> , Senior Research Lead, Institute for Clinical and Economic Review	No conflicts to disclose.
<b>Woojung Lee, PharmD, PhD</b> , Associate Director of Health Economics and Decision Modeling, Institute for Clinical and Economic Review	No conflicts to disclose.
<b>Grace A. Lin, MD</b> , Medical Director for Health Technology Assessment, Institute for Clinical and Economic Review	Dr. Lin receives research funding through UCSF from the National Institutes of Health, Mt. Zion Health Fund, and GRAIL.
<b>Marie Phillips, BA</b> , Health Economics Research Assistant, Institute for Clinical and Economic Review	No conflicts to disclose.
<b>Finn Raymond, BS</b> , Research Assistant, Institute for Clinical and Economic Review	No conflicts to disclose.
<b>Marina Richardson, PhD, MSc</b> , Associate Director, HTA Methods and Health Economics, Institute for Clinical and Economic Review	No conflicts to disclose.
<b>David Rind, MD, MSc</b> , Chief Medical Officer, Institute for Clinical and Economic Review	No conflicts to disclose.

**Table 2. Expert Reviewers of the Draft Evidence Report Conflict of Interest Disclosures**

Expert Reviewer	Conflict of Interest
<b>David Kim, PhD</b> , Assistant Professor of Medicine and Public Health Sciences, University of Chicago	No conflicts to disclose.
<b>Joe Nadglowski Jr.</b> , President and CEO, Obesity Action Coalition	The Obesity Action Coalition receives 25% of financial support from healthcare companies including, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Amgen, Pfizer, AstraZeneca, Boston Scientific, Currax, Genentech, Intuitive, Kailera Therapeutics, Madrigal Pharmaceuticals, Medtronic, Regeneron, Rhythm Pharmaceuticals, Structure Therapeutics, Wave Life Sciences and Zealand Pharma.
<b>Gitanjali Srivastava, MD, FACP, FAAP</b> , Professor of Medicine, Department of Medicine, Division of Diabetes, Endocrinology & Metabolism, Vanderbilt University School of Medicine	Dr. Srivastava receives less than \$10,000 in advisory fees from Eli Lilly and Novo Nordisk, in addition to Speaker's Bureau fees from Novo Nordisk. Her academic institution receives research grant support from Eli Lilly, Recordati, and Rhythm.
<b>Michele Tedder, MSN, RN</b> , Director of Chronic Disease, Black Women's Health Imperative	Michele Tedder is an Obesity Action Coalition board member.
<b>Dan Touchette, PharmD, MA</b> , Professor, University of Illinois, Chicago	No conflicts to disclose.
<b>Alexa Triot, MD</b> , Clinical Director of HCA Embedded Primary Care Weight Management Programs, Section of Primary Care, Division of General Medicine, Beth Israel Deaconess Medical Center	No conflicts to disclose.

# Table of Contents

Conflict of Interest Disclosures for the Report .....	vi
Executive Summary.....	ES1
1. Background .....	1
2. Patient and Other Stakeholder Input.....	4
2.1 Patient Community Insights.....	4
2.2 Health Equity Considerations.....	5
2.3 Comments from Other Stakeholders.....	6
3. Comparative Clinical Effectiveness .....	7
3.1. Methods Overview.....	7
Scope of Review .....	7
Evidence Base .....	8
3.2. Results.....	12
Clinical Benefits.....	12
Harms.....	16
Subgroup Analyses and Heterogeneity.....	19
Uncertainty and Controversies .....	20
3.3. Summary and Comment .....	22
4. Long-Term Cost Effectiveness.....	25
4.1. Methods Overview.....	25
4.2. Key Model Assumptions and Inputs .....	27
Key Model Inputs .....	29
4.3. Results.....	35
Base-Case Results.....	35
Sensitivity Analyses.....	36
Scenario Analyses.....	39
Threshold Analyses .....	41
Model Validation.....	42
Uncertainty and Controversies .....	42
4.4 Summary and Comment .....	44

5. Benefits Beyond Health and Special Ethical Priorities .....	45
6. Health Benefit Price Benchmark .....	47
7. Potential Budget Impact .....	48
7.1. Overview of Key Assumptions .....	48
7.2. Results .....	49
References .....	51
A. Background: Supplemental Information .....	A1
A1. Definitions.....	A1
Important Outcomes.....	A1
Other Relevant Definitions .....	A2
A2. Potential Cost-Saving Measures in Obesity.....	A3
A3. Patient Input on Clinical Trial Design.....	A3
B. Stakeholder Input: Supplemental Information.....	B1
B1. Patient Community Insights: Methods .....	B1
B2. Clinical Expert Input: Methods .....	B1
C. Clinical Guidelines .....	C1
American Gastroenterology Association (AGA) Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity <sup>15</sup> .....	C1
American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity <sup>130</sup> .....	C1
American Heart Association (AHA)/American College of Cardiology (ACC)/The Obesity Society (TOS) Guideline for the Management of Overweight and Obesity in Adults <sup>141</sup> .....	C2
D. Comparative Clinical Effectiveness: Supplemental Information .....	D1
D1. Detailed Methods .....	D1
PICOTS.....	D1
Data Sources and Searches .....	D7
Study Selection.....	D10
Data Extraction.....	D10
Evaluation of Clinical Trial Diversity.....	D15
Results.....	D16

Assessment of Level of Certainty in Evidence .....	D20
Assessment of Bias.....	D20
Data Synthesis and Statistical Analyses .....	D21
D2. Additional Clinical Effectiveness Results .....	D22
Additional Evidence Base .....	D22
Additional Clinical Benefits .....	D32
Additional Harms .....	D37
Additional Evidence from Observational Studies .....	D38
D2. Evidence Tables .....	D40
D3. Ongoing Studies.....	D105
D4. Previous Systematic Reviews and Technology Assessments .....	D106
Qin, W., et al. (2024) “Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial” <sup>163</sup> .....	D106
Dutta, D., et al. (2024) “Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis” <sup>164</sup> .....	D106
Müllertz, A., et al. (2024) “Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety” <sup>165</sup> .....	D107
E. Long-Term Cost-Effectiveness: Supplemental Information.....	E1
E1. Detailed Methods.....	E1
Description of evLY Calculations.....	E2
Target Population.....	E2
Treatment Strategies .....	E3
E2. Model Inputs and Assumptions .....	E3
Clinical Inputs .....	E3
Health State Utilities .....	E14
Drug Utilization .....	E17
Cost Inputs .....	E17
E3. Results .....	E20
E4. Sensitivity Analyses .....	E20

E5. Scenario Analyses.....	E21
Scenario Analysis 1.....	E21
Scenario Analysis 2.....	E22
Scenario Analysis 3.....	E22
Scenario Analysis 4.....	E23
Scenario Analysis 5.....	E24
Scenario Analysis 6.....	E25
E6. Prior Economic Models .....	E28
F. Potential Budget Impact: Supplemental Information.....	F1
Methods.....	F1

## List of Acronyms and Abbreviations Used in this Report

6MWT	6 minute walk test
ACE	American College of Endocrinology
AACE	American Association of Clinical Endocrinologists
AE	Adverse event
AGA	American Gastroenterology Association
AHI	Apnea-hypopnea index
AHRQ	Agency for Healthcare Research and Quality
AIAN	American Indian or Alaskan Native
ALT	Alanine aminotransferase
ASCVD	Atherosclerotic cardiovascular disease
AST	Aspartate aminotransferase
BMI	Body mass index
CE	Cost-effectiveness
CDR	Clinical trial Diversity Rating
CI	Confidence interval
CKD	Chronic kidney disease
CM	Centimeter
COPD	Chronic obstructive pulmonary disease
CRP	C-reactive protein
CV	Cardiovascular
CV	Coefficient of variation
CVOT	Cardiovascular outcomes trials
DEXA	Dual energy X-ray absorptiometry
DGT	Dulaglutide
DM	Type 2 diabetes
DSU	Decision Support Unit
EDS	Excessive Daytime Sleepiness
eGFR	Estimated glomerular filtration rate
EHR	Electronic health record
EQ-5D-5L	EuroQol-5 Dimension-5 Level
ESKD	End-stage kidney disease
evLY	Equal-value life year
evLYG	Equal-value life year gained
G3-4	Grade 3-4
G	Gram
GERD	Gastroesophageal Reflux Disease
GFR	Glomerular filtration rate
GI	Gastrointestinal
GIP	Glucose-dependent insulinotropic polypeptide
GIP RA	Glucose-dependent insulinotropic polypeptide receptor agonist
GLP-1	Glucagon-like peptide-1
GLP-1 RA	Glucagon-like peptide-1 receptor agonists
HbA1C	Hemoglobin A1C
HDL	High-density lipoprotein
HF	Heart failure
HFpEF	Heart failure with preserved ejection fraction
HIDI	Health Improvement Distribution Index
HR	Hazard ratio
HRQoL	Health-related quality of life
hsCRP	high-sensitivity C-reactive protein

HTN	Hypertension
ICER MA	ICER's Meta Analysis
IDR	Interquartile range
ITT	Intention-to-treat
IWQOL-Lite-CT	Impact of Weight on Quality of Life-Lite Clinical Trials
KCCQ	Kansas City Cardiomyopathy Questionnaire
kg	Kilogram
kg/m <sup>2</sup>	Kilograms divided by height squared in meters squared
LDL	Low-density lipoprotein
LSM	Lifestyle modification
LVEF	Left ventricular ejection fraction
M	Meter
MACE	Major adverse cardiovascular events
MASH	Metabolic Dysfunction-Associated Steatohepatitis
MASLD	Metabolic dysfunction-associated steatotic liver disease
MCS	Mental component summary
Mg	Milligrams
Mg/dl	milligrams per deciliter
MI	Myocardial infarction
Min	Minute
ml	Milliliter
mIU/liter	milli-international units per liter
mmHg	Millimeter of mercury
mmol/L	Millimoles per liter
NICE	National Institute for Health and Care Excellence
NA	Not applicable
NAS	Nonalcoholic fatty liver disease activity score
NC	Not calculated
NE	Not estimated
NHPI	Native Hawaiian or Pacific Islander
NMA	Network meta-analysis
No	Number
NR	Not reported
NT-proBNP	N-terminal pro B-type natriuretic peptide
NYHA	New York Heart Association
OA	Osteoarthritis
OR	Odds ratio
OSA	Obstructive sleep apnea
PAD	Peripheral arterial disease
PBO	Placebo
PCS	Physical component summary
PDRR	Participant to Disease-prevalence Representation Ratio
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PROMIS	Patient-Reported Outcomes Measurement Information System
PSG	Polysomnography
QALY	Quality-adjusted life year
QoL	Quality of life
RCT	Randomized controlled trial
SAE	Serious adverse event
SBP	Systolic blood pressure
SC	Subcutaneous
SD	Standard deviation
SE	Standard error

SEM	Semaglutide
SF-36	Short Form 36 v2 Health Survey
STEP-HFpEF	STEP-Heart Failure with Preserved Ejection Fraction
T1D	Type 1 diabetes
T2D	Type 2 diabetes
TBD	To be determined
TOS	The Obesity Society
TZP	Tirzepatide
UACR	Urine albumin to creatinine ratio
US	United States
VLDL	very-low-density lipoprotein
WAC	Wholesale acquisition cost
WOMAC	Western Ontario and McMaster Universities Osteoarthritis Index

# Executive Summary

---

Obesity is a complex, chronic, and costly disease that affects physical and mental health and can result in an increased risk for other conditions such as diabetes, hypertension, liver disease, sleep apnea, cancer, and cardiovascular disease. Around 40% of the US population is currently living with obesity; there are racial and ethnic differences in obesity prevalence, with Black and Hispanic adults having higher rates of obesity.<sup>1</sup> Adults living with obesity often have comorbidities – more than half have hypertension and nearly one-quarter have diabetes.<sup>2</sup> Thus, the consequences of obesity are costly to both patients and to the healthcare system.

Obesity can start in childhood and thus can have lifelong effects on an individual's education, work, and social interactions. People living with obesity face substantial social stigma from the disease, with discrimination in workplace, education, and healthcare settings resulting in high rates of depression and anxiety.<sup>3</sup> Additionally, individuals living with obesity shared that the healthcare system is ill-equipped to treat obesity, particularly as a lifelong, chronic disease. We heard that weight bias leads to delays in diagnosis and treatment and contributes to poorer health outcomes. Historically marginalized populations may have particular difficulty obtaining treatment for obesity and its complications. Finally, variable insurance coverage and high out-of-pocket costs substantially limit access to semaglutide and tirzepatide.

Comprehensive care for obesity includes lifestyle modifications (e.g., nutrition therapy, physical activity, behavioral modifications), medications, and bariatric surgery, alone or in combination. The emergence of GLP-1 receptor agonists (GLP-1 RA) like semaglutide and dual GLP-1/GIP RA like tirzepatide have dramatically altered the landscape of obesity treatment. We evaluated the net health benefits of injectable semaglutide 2.4 mg, oral semaglutide 25 mg, and tirzepatide 15 mg in individuals with obesity and without diabetes. Treatment with all three drugs resulted in substantial weight loss compared with placebo, with a mean difference in weight loss compared with placebo of -17.8% with tirzepatide treatment, -13.1% with injectable semaglutide treatment, and -11.4% with oral semaglutide treatment. Greater weight loss with tirzepatide than injectable semaglutide was also seen in a head-to-head trial (-20.2% vs. -13.7%).

In patients with obesity and established cardiovascular (CV) disease, injectable semaglutide has been shown to reduce the risk of major cardiovascular events (MACE) (HR 0.80, 95% CI 0.72, 0.90) and all-cause mortality (HR 0.81, 95% CI 0.71, 0.93). Whether this CV risk reduction extends to oral semaglutide 25 mg is not clear, as this dose results in less weight loss than the injectable form, and a lower dose (14 mg) resulted in smaller CV risk reduction in a diabetes population. For tirzepatide, topline results from a CV outcomes trial in patients with diabetes showed an 8% reduction in MACE and a 16% reduction in all-cause mortality compared with dulaglutide, a GLP-1 RA, but the full trial results have yet to be published.

All three drugs generally improved health-related quality of life, as well as metabolic risk factors such as blood pressure, blood glucose, and lipids. However, stopping semaglutide or tirzepatide appears to result in weight regain and regression of improvement in metabolic risk factors.

Treatment with injectable semaglutide and tirzepatide have also been associated with improvements in obesity-related complications. Injectable semaglutide has been shown to improve outcomes in knee osteoarthritis, metabolic-associated steatohepatitis (MASH), and heart failure with preserved ejection fraction, as well as reduce the risk of diabetes and chronic kidney disease. Tirzepatide has been shown to reduce the risk of diabetes and improve symptoms of obstructive sleep apnea.

The most common harms of both semaglutide and tirzepatide are gastrointestinal (GI) side effects, with around three-quarters of participants taking either injectable or oral semaglutide reporting GI side effects. For tirzepatide, 20-40% of participants reported nausea, diarrhea, or constipation in clinical trials. However, serious adverse events were uncommon, occurring in 3-7% of participants in the semaglutide trials and 4-7% in the tirzepatide trials. Finally, discontinuation due to adverse events was also less than 10% for all three drugs.

Because treatment with all three drugs results in substantial weight loss and improvement in metabolic risk factors, we have high certainty that all three drugs have substantial net health benefit over lifestyle modifications alone (**A**) (Table ES1). There is less certainty about the relative effects of the drugs to each other, particularly for outcomes beyond weight loss (e.g., CV outcomes), and thus we have judged the comparison between tirzepatide and semaglutide as “promising but inconclusive” (**P/I**). Treatment with oral semaglutide results in slightly lower amounts of weight loss compared with injectable semaglutide, with uncertainty about the degree of CV benefit, and thus we judged oral semaglutide to be “comparable or worse” than injectable semaglutide (**C-**).

**Table ES1. Evidence Ratings**

Treatment	Comparator	Evidence Rating
<b>Population: Adults with Obesity or Overweight with <math>\geq 1</math> Obesity-Related Comorbidity</b>		
<b>Injectable Semaglutide</b>	Lifestyle modifications	A
<b>Oral Semaglutide</b>	Lifestyle modifications	A
<b>Tirzepatide</b>	Lifestyle modifications	A
<b>Tirzepatide</b>	Injectable semaglutide	P/I
<b>Tirzepatide</b>	Oral semaglutide	P/I
<b>Oral Semaglutide</b>	Injectable semaglutide	C-

In cost-effectiveness analyses, we used estimated net prices from SSR Health of \$6,830 for injectable semaglutide and \$7,973 for tirzepatide; we assumed the price of oral semaglutide was the same as injectable semaglutide. Treatment with injectable semaglutide, oral semaglutide, and tirzepatide resulted in increased QALYs, eVLYs and life-years and fewer CV events compared with

treatment with lifestyle modifications alone, with tirzepatide treatment resulting in the greatest gains. The incremental cost-effectiveness ratios for each drug are listed in Table ES2. All drugs were cost-effective at the \$100,000 per QALY and evLY gained thresholds.

**Table ES2. Incremental Cost-Effectiveness Ratios**

<b>Treatment</b>	<b>Comparator</b>	<b>Cost per QALY Gained</b>	<b>Cost per evLY Gained</b>
<b>Injectable Semaglutide</b>	Lifestyle Modification	\$61,400	\$60,300
<b>Oral Semaglutide*</b>	Lifestyle Modification	\$69,300	\$68,000
<b>Tirzepatide</b>	Lifestyle Modification	\$53,400	\$52,700

\*Using a placeholder price for oral semaglutide

Despite these therapies being highly cost-effective, their potential budget impact is large. We estimate that fewer than 1% of eligible patients could be treated at current and assumed net prices before crossing the ICER budget impact threshold of \$880,000,000 annually. This raises serious concerns about affordability.































### Oral Semaglutide

In the OASIS-4 trial, participants treated with semaglutide saw improvements in HbA1C, waist circumference, and LDL cholesterol from baseline at week 64 in a prespecified analysis. A greater proportion of participants with prediabetes reverted to normoglycemia in the semaglutide group compared with placebo (71% vs 33%).<sup>39</sup> See [Supplement Table D2.23](#).

### Tirzepatide

Participants treated with tirzepatide in SURMOUNT 1 had greater reductions in SBP (mean difference -6.4 mmHg) and HbA1C (mean difference -0.44%) compared to placebo.<sup>42</sup> See [Supplement Table D2.24](#).

In long-term follow-up of the SURMOUNT 1 trial, only ten (1%) participants in the pooled tirzepatide group (5 mg, 10 mg, or 15 mg) with prediabetes developed T2D compared to 36 (13%) participants in the placebo group (HR 0.07) at 176 weeks.<sup>59</sup>

In the two SURMOUNT OSA trials, the primary endpoint was the mean change in apnea-hypopnea index (i.e., the number of apneas and hypopneas during an hour of sleep). At week 52, there was a reduction in the number of AHI events from baseline in the groups treated with tirzepatide in both trials (Trial 1 treatment difference from placebo -20; Trial 2 treatment difference from placebo -23.8).<sup>20</sup> See [Supplement Table D2.28](#).

## **Harms**

### ***Injectable Semaglutide***

Although follow-up varied (52 weeks to 104 weeks), all STEP trials reported largely similar proportions of any adverse events across the arms. Serious adverse events were generally more common in the semaglutide arm (8-10%) than in the placebo arm (3-9%), except for STEP 5.<sup>22,23,25,26</sup> Across all trials, discontinuations due to adverse events were higher in the semaglutide (3-7%) than in the placebo arms (0-5%).<sup>22,23,25,26</sup> Gastrointestinal side effects are among the most common side effects for GLP-1 RAs. Participants treated with semaglutide experienced more GI side effects (74-84%) than those receiving placebo (48-63%). Similarly, severe GI side effects were more common in the semaglutide arms (3-5%) than placebo arms (0-4%).<sup>22,23,25,26</sup> See Table 3.4. and [Supplement Table D2.32](#).





effects than those receiving tirzepatide (2.7%). Serious GI-related side effects and serious gallbladder disease were infrequent and similar across arms. The most frequent adverse events, occurring at similar rates in both arms, were nausea (44%), constipation (28%), diarrhea (24%), COVID-19 (13%), and fatigue (11%).<sup>44</sup> See [Supplement Table D2.35](#).

### ***Adherence and Persistence***

Data on adherence and persistence were obtained from four observational studies, most of which were conducted during a time of considerable supply shortages. Gleason et al 2024 measured adherence and persistence at one year to GLP-1 agonists among non-diabetic patients with obesity. Among 419 commercially insured adults who used injectable semaglutide for weight loss, 36% remained on treatment without a 60-day gap at one year. The mean proportion of days covered (PDC) for injectable semaglutide users was 53% (SD 33) and approximately 32% of them had PDC  $\geq$  80%. A total of 285 patients used oral semaglutide (Rybelsus<sup>®</sup>) as an off-label indication for weight loss. Approximately one-quarter of those patients remained on treatment without a 60-day gap at 1 year. The mean PDC for oral semaglutide users was 45% (SD 31) and about 20% of them had PDC  $\geq$  80%.<sup>37</sup> Three real-world observational studies showed that 54-74% of patients initiating tirzepatide persisted on the therapy for six months, defined as no 60-day gap in therapy.<sup>48-50</sup> Around 56% of the patients achieved a PDC of at least 80% at six months.<sup>50</sup>

### **Subgroup Analyses and Heterogeneity**

We did not find evidence of major differences in the balance of benefits and risks for the following subgroups: age, sex at birth, race and ethnicity, BMI categories, use and intensity of lifestyle interventions, established CV disease, and prior bariatric surgery. Post-hoc analyses of STEP trials showed no statistically significant differences in the change in body weight from baseline regardless of age, sex, race or ethnicity, though Black, Asian, and Hispanic participants in the STEP 1 trial had numerically less weight loss than White participants.<sup>24,60-62</sup> Semaglutide maintained favorable effects on weight loss, glycemic status, and cardiometabolic risk factors across subgroups based on baseline BMI and the presence of comorbidities.<sup>62,63</sup> Tirzepatide also demonstrated consistent percent changes in body weight from baseline versus placebo in BMI-defined subgroups (BMI <30, BMI 30-35, BMI 35-40, and BMI >40).<sup>64-66</sup>

## Uncertainty and Controversies


- Although current data from clinical trials demonstrate that treatment with either semaglutide and tirzepatide can result in substantial weight loss in adults living with obesity, for key CV outcomes, there are limitations to the evidence base. Injectable semaglutide reduces CV events in the population with obesity and known CV disease; whether this benefit extends to primary prevention is not known but is reasonable to assume given the improvements in CV risk factors (e.g., SBP, HbA1c, progression to diabetes). For oral semaglutide, data are limited to a trial in the T2D population with CV disease or CKD, using a lower dose (14 mg) than proposed dose obesity treatment. The magnitude of benefit treating people with obesity without T2D with a higher dose (25 mg) is not known. Tirzepatide reduces CV events in people with T2D and existing CV disease, but only limited results are currently available and the comparator was with another GLP-1 RA, dulaglutide, making comparisons with semaglutide more indirect.
- Obesity is a lifelong disease; however, there are a lack of long-term follow-up data for both benefits and harms. For example, there are few data from clinical trials on outcomes beyond 2-3 years, particularly for weight maintenance. One concern about long-term safety that has been raised is the loss of muscle mass (sarcopenia) with substantial weight loss, particularly in older adults. Sarcopenia has been associated with functional decline, an increased risk of falls and death, and reduced quality of life.<sup>67</sup> Longer-term data are needed to understand the magnitude of risk and whether those risks can be mitigated. Additionally, animal models and the mechanism of action of GLP-1s raise the concern of an increased risk of pancreatitis, as well as pancreatic and thyroid cancer. Although clinical trial and observational data have not found increased risks thus far, longer-term follow-up from both clinical trials and observational data are needed to confirm the risks or lack thereof.
- Data continue to emerge about the impact of GLP-1 RA and GLP-1/GIP RA drugs on various obesity-related complications (e.g., OSA, HFpEF, knee OA, etc.). However, many of the trials were done in a diabetes population and thus efficacy in non-diabetic populations is often less clear. Additionally, some trials rely on surrogate markers rather than patient-important outcomes (e.g., liver histology rather than cirrhosis; eGFR rather than end-stage kidney disease) due to the infeasibility of measuring outcomes with a long lead time in a time-limited clinical trial. Some surrogate markers have strong associations with clinical outcomes (e.g., liver histology in MASH predicts progression to cirrhosis; decline in eGFR is associated with an increased risk of ESKD); for others, the correlation is less clear. For example, the WOMAC scale is generally used to assess joint pain and function after joint replacement surgery; correlation with preventing joint replacement surgery is not clear. Observational data may help close some gaps.



### 3.3. Summary and Comment

An explanation of the ICER Evidence Rating Matrix (Figure 3.1) is provided [here](#).

Figure 3.1. ICER Evidence Rating Matrix



#### Comparative Net Health Benefit

- A = "Superior" - High certainty of a substantial (moderate-large) net health benefit
- B = "Incremental" - High certainty of a small net health benefit
- C = "Comparable" - High certainty of a comparable net health benefit
- D = "Negative" - High certainty of an inferior net health benefit
- B+ = "Incremental or Better" - Moderate certainty of a small or substantial net health benefit, with high certainty of at least a small net health benefit
- C+ = "Comparable or Incremental" - Moderate certainty of a comparable or small net health benefit, with high certainty of at least a comparable net health benefit
- C- = "Comparable or Inferior" - Moderate certainty that the net health benefit is either comparable or inferior with high certainty of at best a comparable net health benefit
- C++ = "Comparable or Better" - Moderate certainty of a comparable, small, or substantial net health benefit, with high certainty of at least a comparable net health benefit
- P/I = "Promising but Inconclusive" - Moderate certainty of a small or substantial net health benefit, small (but nonzero) likelihood of a negative net health benefit
- I = "Insufficient" - Any situation in which the level of certainty in the evidence is low

The evidence base for semaglutide and tirzepatide is constantly evolving, not only with clinical trials examining obesity-related outcomes, but real-world studies reporting comparative effectiveness data and adherence. Our assessments are based on the data currently available; these may change based on the emergence of more data.





## 4. Long-Term Cost Effectiveness

---

### 4.1. Methods Overview

The primary aim of this analysis was to estimate the cost-effectiveness of three weight-lowering medications over a lifetime horizon. We developed a *de novo* decision analytic Markov cohort model for this evaluation, informed by key clinical trials and prior relevant economic models, with primary reference to ICER's previously developed obesity model.<sup>69</sup> The model focused on an intention-to-treat (ITT) analysis, with a hypothetical cohort of patients living with obesity or with overweight and at least one obesity-related comorbidity, excluding those with already established type 2 diabetes (T2D), being treated with one of the three weight-lowering medications (injectable semaglutide, oral semaglutide, or tirzepatide) added on to lifestyle modification (e.g., caloric restriction and increased physical activity) or lifestyle modification alone. Model cycle length was one year, based on what was observed in prior published economic models and clinical data.

The model was primarily designed to simulate the treatment's impact on weight and on preventing the onset of key obesity-related outcomes. Based on clinical evidence, expert opinion, and public comments, the model focused on the following obesity-related outcomes: T2D, CV disease and events, end-stage kidney disease (ESKD), cirrhosis, hip or knee replacement, and OSA. Additionally, quality of life changes based on BMI, independent of the obesity-related outcomes included in the model, were applied to account for residual treatment benefits not fully represented in the model, such as effects on obesity-related outcomes not captured as health states or acute events, functional status, or mental health.

The model consisted of health states representing one or more combinations of obesity-related outcomes of interest (Figure 4.1). Patients enter the model in a non-diabetic health state and may, over time, develop obesity-related outcomes and transition to more advanced health states. Some patients may also develop diabetes and move to a corresponding diabetic health state. Multiple outcomes can develop within a single cycle, and patients may die from any health state. Each health state was associated with specific mortality risks, quality of life values, and costs. In any health state, patients may experience OSA or undergo knee or hip replacement, with the model tracking the proportions of patients with these conditions. Within the CV disease health state, patient distribution across specific subtypes was tracked over time, using the same categories as ICER's [previous obesity model](#): post-MI, post-stroke, post-MI and post-stroke, heart failure (HF) post-MI, post-stroke and HF post-MI, and other CV disease (including other forms of HF, peripheral artery disease, angina, and transient ischemic attack).<sup>69</sup> To estimate the distribution of CV disease subtypes among patients with CVD over time, we used a simplified Markov tracker model with health states for CV disease subtypes and death, incorporating differing CV disease risks by diabetes status. This approach avoided the need to model every possible combination of CV disease



## 4.2. Key Model Assumptions and Inputs

Our model includes several assumptions, as stated in Table 4.1.

**Table 4.1. Model Assumptions**

Assumption	Rationale
<p><b>The included obesity-related outcomes (i.e., T2D, CV disease, ESKD, cirrhosis, hip or knee replacement, and OSA) and the direct impact of BMI on QoL are expected to reasonably capture the clinical benefits of weight-lowering medications.</b></p>	<p>Although weight-lowering medications may provide a broad range of clinical benefits, the selected obesity-related outcomes reflect those most likely impacted by weight loss—based on clinical trial data and expert opinion—and are associated with significant effects on life expectancy, quality of life, and healthcare costs.<sup>58,70-74</sup> While prior models have focused primarily on cardiovascular disease and T2D, our model was expanded to include additional obesity-related outcomes informed by emerging evidence to more comprehensively capture treatment effects.<sup>69,75-77</sup> Including further outcomes could enhance comprehensiveness but may also add unnecessary complexity and increase the risk of double-counting. To account for residual benefits from outcomes not explicitly modeled, we incorporated BMI-based quality-of-life improvements that are independent of the modeled outcomes.</p>
<p><b>Weight-lowering medications may have direct effects on preventing obesity-related outcomes, independent of weight loss-mediated benefits.</b></p>	<p>Studies suggest that weight-loss treatments may prevent obesity-related outcomes through direct mechanisms independent of weight loss or metabolic changes, particularly for cardiovascular outcomes and diabetes.<sup>40,56,59,74</sup> Whenever possible, we used direct treatment effects on these outcomes—beyond weight and modeled metabolic risk factors—rather than indirect effects estimated through risk functions or weight-related associations. Relying solely on indirect mechanisms may incorrectly estimate the exact benefits of treatment.</p>
<p><b>Direct cardiovascular effects of weight-lowering medications demonstrated in patients with diabetes can be extrapolated to estimate effects in obesity populations where direct measurements have not been performed.</b></p>	<p>The direct cardiovascular effects of oral semaglutide and tirzepatide have been evaluated only in populations with T2D.<sup>40,45</sup> However, these effects may reasonably be extrapolated to individuals with obesity without T2D, given the doses used and the overlapping cardiovascular risk profiles of the two populations, as well as data on semaglutide in patients with and without T2D. In the absence of dedicated cardiovascular outcomes trials in people without T2D, this serves as the best available evidence for the potential direct cardiovascular effects of weight-lowering medications. How these extrapolations were executed is discussed in the text.</p>
<p><b>Treatment discontinuation rates are based on the trial's intention-to-treat (ITT) population.</b></p>	<p>Obesity is widely recognized by experts as a chronic metabolic condition requiring long-term treatment.</p>



Assumption	Rationale
	quality-of-life and cost inputs that were, where possible, adjusted for relevant clinical characteristics and comorbidities.

BMI: Body mass index, CVD: Cardiovascular Diseases, ESKD: End-stage kidney disease, QoL: Quality of life, US: United States

## Key Model Inputs

Key model inputs are shown in Table 4.2.

### *Clinical Inputs*

The percentage change in body weight from baseline for each treatment was derived from the ICER meta-analysis of intention to treat (ITT) populations, as well as the ITT populations of relevant clinical trials. The model assumed weight reduction occurs during the first year after treatment initiation, reaching maximum reduction by year two. From year two onward, BMI remained stable, reflecting sustained weight maintenance with continued treatment in the base case. Natural age-related weight gain from year two was explored in a sensitivity analysis.

The metabolic risk factors used to estimate the risk of obesity-related outcomes included the proportion of patients treated for hypertension (HTN), systolic blood pressure (SBP) among those treated and untreated for HTN, and glycemic control. The prevalence of treated HTN was estimated as a function of BMI, based on relationships reported in the literature and consistent with the approach used in the previous ICER model.<sup>69,86</sup> An average systolic blood pressure (SBP) of 125 mmHg and 135 mmHg was assumed for patients without HTN and with (treated) HTN, respectively.<sup>69,87,88</sup> Treatment effects on glycemic control were captured through the modeled risk of developing T2D. The annual probability of developing diabetes without interventions was derived from studies tracking incident T2D among individuals with obesity who were diabetes-free at baseline and received lifestyle modification alone.<sup>56 59,89-91</sup> The direct antidiabetic effect of the interventions was estimated using trial data comparing the interventions to lifestyle modification in this population.<sup>56,59</sup>

The risk of developing obesity-related outcomes was estimated using direct effects of treatment on obesity-related outcomes beyond those mediated by weight loss (e.g., direct CV effects), where data allowed. Otherwise, these effects were estimated indirectly through changes in weight and related risk factors, using existing risk equations or established associations between weight and the risk of onset.











## 4.3. Results

### Base-Case Results

Table 4.3 presents the discounted intervention costs, total costs, quality-adjusted life years (QALYs), equal-value life years (evLYs), and life years, as well as the undiscounted number of stroke and MI events, for injectable semaglutide, oral semaglutide, and tirzepatide added to lifestyle modification compared with lifestyle modification alone. Tables 4.4 and 4.5 present the discounted incremental results as well as incremental cost-effectiveness ratios estimated based on the clinical and cost outcomes shown in Table 4.3. For oral semaglutide, the results are based on the assumption that its price is equal to that of injectable semaglutide.

**Table 4.3. Discounted Base-Case Results for the Interventions versus Lifestyle Modification**

Treatment	Intervention Acquisition Costs	Total Costs	Number of Stroke or MI Events (per 100) <sup>†</sup>	QALYs	evLYs	Life Years
<b>Injectable Semaglutide*</b>	\$132,229	\$452,971	47	16.61	16.63	20.39
<b>Oral Semaglutide*‡</b>	\$132,475	\$455,086	51	16.50	16.52	20.35
<b>Tirzepatide*</b>	\$158,493	\$464,470	45	17.02	17.04	20.49
<b>Lifestyle Modification</b>	\$9,036	\$376,503	69	15.37	15.37	20.01

evLYs: equal value of life years, QALY: quality-adjusted life year, MI: Myocardial infarction

\*Each treatment is added to lifestyle modification; therefore, intervention acquisition costs also include the costs of lifestyle modification.

<sup>†</sup>Undiscounted values are shown. Per 100 individuals.

<sup>‡</sup>Based on an assumed price

**Table 4.4. Discounted Incremental Results for the Interventions versus Lifestyle Modification**

Treatment	Intervention Acquisition Costs	Total Costs	Number of Stroke or MI Events (per 100)†	QALYs	evLYs	Life Years
<b>Injectable Semaglutide*</b>	\$123,193	\$76,468	-22	1.24	1.27	0.38
<b>Oral Semaglutide*‡</b>	\$123,438	\$78,583	-18	1.13	1.16	0.34
<b>Tirzepatide*</b>	\$149,456	\$87,967	-24	1.65	1.67	0.48
<b>Lifestyle Modification</b>	Reference					

evLYs: equal value of life years, QALY: quality-adjusted life year, MI: Myocardial infarction

\*Each treatment is added to lifestyle modification; therefore, intervention acquisition costs also include the costs of lifestyle modification.

†Undiscounted values are shown. Per 100 individuals.

‡Based on an assumed price

**Table 4.5. Incremental Cost-Effectiveness Ratios for the Base Case**

Treatment	Comparator	Cost per QALY Gained	Cost per evLY Gained	Cost per Life Year Gained	Cost per MI or Stroke avoided†
<b>Injectable Semaglutide*</b>	Lifestyle Modification	\$61,400	\$60,300	\$201,000	\$663,000
<b>Oral Semaglutide*‡</b>	Lifestyle Modification	\$69,300	\$68,000	\$232,000	\$853,000
<b>Tirzepatide*</b>	Lifestyle Modification	\$53,400	\$52,700	\$183,000	\$704,000

evLYs: equal value of life years, QALY: quality-adjusted life year, MI: Myocardial infarction

\*Each treatment is added to lifestyle modification

†Estimated using discounted values for the number of stroke or MI events to ensure consistency with the discounted costs used in the numerator: 25, 27, 24, and 36 per 100 individuals for injectable semaglutide, oral semaglutide, tirzepatide, and lifestyle modification, respectively.

‡Based on an assumed price

## Sensitivity Analyses

Figures 4.2, 4.3, and 4.4 show the inputs with the greatest influence on the incremental cost-effectiveness ratio per QALY for injectable semaglutide, oral semaglutide, and tirzepatide, respectively. The parameters with the greatest influence on the cost-effectiveness results across all three interventions were the treatment effect on BMI at Year 2 and the quality-of-life change associated with BMI independent of modeled outcomes.





**Table 4.7. Probabilistic Sensitivity Analysis Cost per evLY Gained Results: Injectable Semaglutide, Oral Semaglutide, and Tirzepatide Added to Lifestyle Modification versus Lifestyle Modification Alone**

	Cost Effective at \$50,000 per evLY Gained	Cost Effective at \$100,000 per evLY Gained	Cost Effective at \$150,000 per evLY Gained	Cost Effective at \$200,000 per evLY Gained
<b>Injectable Semaglutide</b>	27.4%	100.0%	100.0%	100.0%
<b>Oral Semaglutide*</b>	13.4%	98.9%	100.0%	100.0%
<b>Tirzepatide</b>	52.9%	100.0%	100.0%	100.0%

evLYs: equal value of life years gained

\*Based on an assumed price

## Scenario Analyses

We conducted several scenario analyses to examine the uncertainty and potential variations in the findings. Additionally, the cost-effectiveness of treatment was estimated separately based on baseline obesity status (e.g., overweight, obesity, and severe obesity), as individuals with higher initial BMI tend to achieve greater absolute weight loss or may experience differential treatment effects. We performed a subgroup analysis for patient groups stratified by the following baseline BMI: BMI <30, BMI ≥30, BMI ≥35, and BMI ≥40.

The scenario analyses examined are outlined below in Tables 4.8 to 4.10. Additional details are detailed in [Supplement Section E5](#).

1. Modified societal perspective that includes patient productivity costs
2. Exclusion of unrelated health care costs
3. Alternative source for the association between BMI and ESKD risk: Hsu 2006<sup>118</sup>
4. Alternative direct diabetic impacts of injectable and oral semaglutide to account for differences in the source populations between semaglutide and tirzepatide
5. Alternative baseline incidence of diabetes: Edelman 2004<sup>91</sup>.
6. Subgroup analysis based on the baseline BMI:
  - BMI <30
  - BMI ≥30
  - BMI ≥35



**Table 4.10. Scenario and Subgroup Analysis Results for Tirzepatide Added to Lifestyle Modification versus Lifestyle Modification Alone**

Scenario	Cost per QALY Gained	Cost per evLY Gained
Base-Case	\$53,355	\$52,743
Modified Societal Perspective	\$41,490	\$41,015
Exclusion of Unrelated Medical Costs	\$49,222	\$48,657
Alternative Source for the Impact of BMI on ESKD Risk	\$46,485	\$45,902
Alternative Baseline Incidence of Diabetes	\$38,968	\$38,440
Subgroup Analysis: BMI <30	\$70,819	\$70,931
Subgroup Analysis: BMI ≥30	\$56,336	\$55,632
Subgroup Analysis: BMI ≥35	\$49,621	\$48,881
Subgroup Analysis: BMI ≥40	\$49,680	\$48,663

QALY: quality-adjusted life year, evLY: equal value of life year; BMI: Body mass index; ESKD: End-stage kidney disease

## Threshold Analyses

Tables 4.11 and 4.12 report the threshold prices at \$50,000, \$100,000, \$150,000, and \$200,000 per QALY and evLY gained, respectively.

**Table 4.11. QALY-Based Threshold Analysis Results**

	Annual Net Price*	Annual Price to Achieve \$50,000 per QALY Gained	Annual Price to Achieve \$100,000 per QALY Gained	Annual Price to Achieve \$150,000 per QALY Gained	Annual Price to Achieve \$200,000 per QALY Gained
Injectable Semaglutide	\$6,829	\$6,000	\$9,600	\$13,100	\$16,700
Oral Semaglutide <sup>†</sup>	\$6,829	\$5,600	\$8,800	\$12,000	\$15,300
Tirzepatide	\$7,973	\$7,700	\$12,200	\$16,700	\$21,200

QALY: quality-adjusted life year

\*Annual price paid by payers after accounting for all discounts, rebates, coupons, or other financial concessions as estimated by SSR Health.

<sup>†</sup>The annual net price of oral semaglutide was assumed to be the same as that of injectable semaglutide.

**Table 4.12. evLY-Based Threshold Analysis Results**

	Annual Net Price*	Annual Price to Achieve \$50,000 per evLY Gained	Annual Price to Achieve \$100,000 per evLY Gained	Annual Price to Achieve \$150,000 per evLY Gained	Annual Price to Achieve \$200,000 per evLY Gained
<b>Injectable Semaglutide</b>	\$6,829	\$6,100	\$9,700	\$13,300	\$16,900
<b>Oral Semaglutide†</b>	\$6,829	\$5,600	\$8,900	\$12,200	\$15,500
<b>Tirzepatide</b>	\$7,973	\$7,700	\$12,300	\$16,800	\$21,400

evLYs: equal value of life years gained, WAC: wholesale acquisition cost

\*Annual price paid by payers after accounting for all discounts, rebates, coupons, or other financial concessions as estimated by SSR Health.

†The annual net price of oral semaglutide was assumed to be the same as that of injectable semaglutide.

## Model Validation

Model validation followed standard practices in the field. All mathematical functions were tested to ensure consistency with the report and supplemental appendix materials. Stress testing using null input values confirmed that the model produced results aligned with expectations. An independent modeler also verified the mathematical functions, inputs, and outputs. Validation also included comparisons with findings from similar models identified in the literature, focusing on those with comparable populations, settings, perspectives, and treatments. Specifically, we compared our model's outcomes, inputs, and assumptions with other published models to evaluate face validity and identify key similarities and differences ([Supplement E6](#)). Additionally, the model analysis plan and/or draft evidence report were reviewed by multiple stakeholders—including manufacturers and clinical and economic experts—and changes were made based on their feedback.

## Uncertainty and Controversies

There are several limitations and areas of uncertainty in our model:

- Uncertainty around long-term treatment effects beyond the trial period: We assumed that weight loss achieved by year 2 is maintained throughout the treatment duration. Similarly, direct treatment effects on diabetes and CV diseases observed in the trials were maintained lifelong. These assumptions were informed by the longest available follow-up trial data—104 weeks for semaglutide and 176 weeks for tirzepatide—which showed sustained weight reduction while patients remained on treatment.<sup>59,119</sup> However, more data on the long-term durability of treatment benefits are needed to accurately capture the lifetime impact of these interventions. Depending on the long-term trajectory of treatment effects, our results could be biased in either direction, with the magnitude of bias remaining uncertain.



condition that requires long-term management. During the scoping phase, most clinical experts indicated that lifelong pharmacologic treatment is the preferred approach for managing obesity, given the high likelihood of weight regain after discontinuation. Moreover, although earlier real-world studies suggested low persistence with weight-lowering medications, experts noted recent improvements in drug utilization following the resolution of barriers like drug shortages.<sup>37,78,79</sup> Finally, limited data on long-term real-world treatment patterns and their effects on weight and obesity-related outcomes make it difficult to accurately model real-world use. While studies demonstrate that treatment discontinuation leads to weight regain, insufficient evidence exists regarding complex real-world patterns—such as treatment switching, restarting, or drug holidays—and their effects on BMI. Additionally, the impact of these patterns on direct obesity-related outcomes (e.g., cardiovascular or antidiabetic effects) has not been studied. Therefore, modeling alternative real-world scenarios would be premature given the numerous assumptions and high uncertainty required. Treatment persistence in this model may be higher than in real-world settings, resulting in greater clinical benefits and costs of the treatments.

- Uncertainty around net drug prices: Although SSR pricing data provides the best available estimate of net prices, these values may be volatile given the rapidly evolving pricing environment and the recent implementation of direct purchase programs such as Novocare and Lilly Direct.
- Comparison limited to lifestyle modification: Comparisons between interventions were out of scope and therefore not conducted. The results presented cannot be used to estimate the cost-effectiveness of one intervention versus another. Such comparisons were conducted only for the comparative clinical effectiveness assessment.

## 4.4 Summary and Comment

Cost-effectiveness analyses indicate that injectable semaglutide, oral semaglutide, and tirzepatide, when added on to lifestyle modification, provide greater clinical benefits than lifestyle modification alone. Although these treatments increase intervention costs, they yield long-term savings in non-intervention costs. At current net prices, their incremental cost-effectiveness ratios were below commonly used cost-effectiveness thresholds. Results were most influenced by the treatment effect on BMI at Year 2 and the quality-of-life change associated with BMI independent of modeled outcomes, though the overall conclusions remained unchanged across all sensitivity and scenario analyses. The model also found that these interventions were generally cost-effective across a range of BMI cut points, although there was somewhat greater cost effectiveness in patients with higher baseline BMI.















Energy Regulation. *The American Journal of Medicine*. 2025;138(6):934-940.

doi:10.1016/j.amjmed.2025.01.021

18. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *The New England journal of medicine*. 2023-01-01 2023;389(24):2221-2232.

doi:10.1056/nejmoa2307563

19. Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. *Nature medicine*. 2024-01-01 2024;30(7):2058-2066.

doi:10.1038/s41591-024-03015-5

20. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. *The New England journal of medicine*. 2024-01-01 2024;391(13):1193-1205.

doi:10.1056/nejmoa2404881

21. Atlas SJ, Kim K, Beinfeld M, et al. *Medications for Obesity Management: Effectiveness and Value; Final Evidence Report*. 2022. October 20, 2022. <https://www.bmj.com/content/383/bmj-2022-071027>

22. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *The New England journal of medicine*. 2021-01-01 2021;384(11):989-1002.

doi:10.1056/nejmoa2032183

23. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. *Jama*. 2021-01-01 2021;325(14):1403-1413. doi:10.1001/jama.2021.1831

24. Garvey WT, Hesse D, Koroleva A, et al. Abstract #1003901: once-Weekly Subcutaneous Semaglutide 2.4 mg Plus Intensive Behavioral Therapy Produces Clinically Meaningful Weight Loss in Adults with Overweight/Obesity Regardless of Baseline Characteristics and Weight History. *Endocr Pract*. 2021-01-01 2021;27(6):S80. doi:10.1016/j.eprac.2021.04.638

25. McGowan BM, Bruun JM, Capehorn M, et al. Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. *The lancet Diabetes & endocrinology*. 2024-01-01 2024;12(9):631-642. doi:10.1016/s2213-8587(24)00182-7

26. Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. *Jama*. 2022-01-01 2022;327(2):138-150. doi:10.1001/jama.2021.23619

27. Bliddal H, Bays H, Czernichow S, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. *The New England journal of medicine*. 2024-01-01 2024;391(17):1573-1583.

doi:10.1056/nejmoa2403664

28. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. *N Engl J Med*. Jun 5 2025;392(21):2089-2099. doi:10.1056/NEJMoa2413258

29. Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. *The New England journal of medicine*. 2023-01-01 2023;389(12):1069-1084. doi:10.1056/nejmoa2306963

30. Anson M, Henney AE, Broadwell N, et al. Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study. *EClinicalMedicine*. 2024-01-01 2024;75:102777.

doi:10.1016/j.eclinm.2024.102777

31. Baser O, Rodchenko K, Vivier E, Baser I, Lu Y, Mohamed M. The impact of approved anti-obesity medications on osteoarthritis. *Expert opinion on pharmacotherapy*. 2024-01-01 2024;25(11):1565-1573.

doi:10.1080/14656566.2024.2391524

32. Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. *JAMA internal medicine*. 2024-01-01 2024;184(9):1056-1064. doi:10.1001/jamainternmed.2024.2525
33. Huang YN, Chen JC, Li PH, et al. Comparative Analysis of Tirzepatide, Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, And Phentermine on Ocular Health in Individuals with Obesity: A Propensity-Score Matched Cohort Study. *SSRN*. 2024-01-01 2024;doi:10.2139/ssrn.5065542
34. Able C, Liao B, Saffati G, et al. Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study. *International journal of impotence research*. 2025-01-01 2025;37(4):315-319. doi:10.1038/s41443-024-00895-6
35. Baser O, Isenman L, Baser S, Samayoa G. Impact of semaglutide on osteoarthritis risk in patients with obesity: A retrospective cohort study. *Obes Sci Pract*. 2024-01-01 2024;10(3)doi:10.1002/osp4.762
36. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. *Nature medicine*. 2024-01-01 2024;30(1):168-176. doi:10.1038/s41591-023-02672-2
37. Gleason PP, Urick BY, Marshall LZ, Friedlander N, Qiu Y, Leslie RS. Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. *Journal of managed care & specialty pharmacy*. 2024-01-01 2024;30(8):860-867. doi:10.18553/jmcp.2024.23332
38. Ruseva A, Dabbous F, Ding N, et al. Semaglutide 2.4 mg long-term clinical outcomes in patients with obesity or overweight: a real-world retrospective cohort study in the United States (SCOPE 12 months). *Postgraduate Medicine*. 2025;137(3-4):251-260.
39. Garvey. Efficacy and safety of oral semaglutide 25 mg in adults with overweight/obesity: the OASIS 4 RCT. 2024-11-03 2024;
40. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *New England Journal of Medicine*. 2019;381(9):841-851.
41. McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. *New England Journal of Medicine*. 2025;392(20):2001-2012.
42. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *The New England journal of medicine*. 2022-01-01 2022;387(3):205-216. doi:10.1056/nejmoa2206038
43. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. *Nature medicine*. 2023-01-01 2023;29(11):2909-2918. doi:10.1038/s41591-023-02597-w
44. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. *The New England journal of medicine*. 2025-01-01 2025;doi:10.1056/nejmoa2416394
45. Nicholls SJ, Bhatt DL, Buse JB, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. *American Heart Journal*. 2024;267:1-11.
46. Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease. PR Newswire; 2025. <https://www.prnewswire.com/news-releases/lillys-mounjaro-tirzepatide-a-gipglp-1-dual-agonist-demonstrated-cardiovascular-protection-in-landmark-head-to-head-trial-reinforcing-its-benefit-in-patients-with-type-2-diabetes-and-heart-disease-302517872.html>

47. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. *The New England journal of medicine*. 2025-01-01 2025;392(5):427-437. doi:10.1056/nejmoa2410027
48. Hankosky ER, Chinthammit C, Meeks A, et al. Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database. *Diabetes, obesity & metabolism*. 2025-01-01 2025;27(5):2810-2821. doi:10.1111/dom.16290
49. Hankosky ER, Desai K, Chinthammit C, et al. Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States. *Diabetes & metabolism*. 2025-01-01 2025;51(3):101636. doi:10.1016/j.diabet.2025.101636
50. Hunter Gibble T, Chinthammit C, Ward JM, et al. Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm R database. *Diabetes, obesity & metabolism*. 2025-01-01 2025;27(6):3185-3194. doi:10.1111/dom.16330
51. Agboola FW, AC. A Framework for Evaluating the Diversity of Clinical Trials. *Journal of Clinical Epidemiology*. 2024:111299.
52. Clinicaltrials.gov. Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program (STEP 3). <https://clinicaltrials.gov/study/NCT03611582>
53. Clinicaltrials.gov. STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (STEP 1). <https://clinicaltrials.gov/study/NCT03548935>
54. Gudzone KA, Stefanski A, Cao D, et al. Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study. *Diabetes, obesity & metabolism*. 2025-01-01 2025;27(2):539-550. doi:10.1111/dom.16046
55. Gibble TH, Cao D, Forrester T, Fraseur Brumm J, Chao AM. Tirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial. *Diabetes, obesity & metabolism*. 2025-01-01 2025;doi:10.1111/dom.16463
56. Kahn SE, Deanfield JE, Jeppesen OK, et al. Effect of semaglutide on regression and progression of glycemia in people with overweight or obesity but without diabetes in the SELECT trial. *Diabetes Care*. 2024;47(8):1350-1359.
57. Kim MS, Koh IJ, Choi KY, et al. The Minimal Clinically Important Difference (MCID) for the WOMAC and Factors Related to Achievement of the MCID After Medial Opening Wedge High Tibial Osteotomy for Knee Osteoarthritis. *Am J Sports Med*. Jul 2021;49(9):2406-2415. doi:10.1177/03635465211016853
58. Bliddal H, Bays H, Czernichow S, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. *New England Journal of Medicine*. 2024;391(17):1573-1583.
59. Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for obesity treatment and diabetes prevention. *New England Journal of Medicine*. 2025;392(10):958-971.
60. Stuart K, Dicker D, Batterham RL, et al. Semaglutide 2.4 mg Induces Weight Loss and Improves Body Composition Across Age Groups in Adults with Overweight or Obesity: post-Hoc Analysis of the STEP 1 Trial. *Int J Obes*. 2023-01-01 2023;47:25. doi:10.1038/s41366-023-01306-4
61. Rubino D, Angelene H, Fabricatore A, Ard J. Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials. *Obesity (Silver Spring, Md)*. 2024-01-01 2024;32(7):1268-1280. doi:10.1002/oby.24042
62. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. *Diabetes, obesity & metabolism*. 2022-01-01 2022;24(8):1553-1564. doi:10.1111/dom.14725

63. McGowan BM, Houshmand-Oeregaard A, Laursen PN, Zeuthen N, Baker-Knight J. Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial. *Obesity (Silver Spring, Md)*. 2023-01-01 2023;31(4):990-999. doi:10.1002/oby.23732
64. Le Roux C, Aronne LJ, Jaouimaa F, et al. Tirzepatide for the treatment of obesity reduced body weight across body mass index categories: post hoc analysis of the SURMOUNT 1-4 trials. *Obes Facts*. 2024-01-01 2024;17:27. doi:10.1159/000538577
65. Aronne L, Jastreboff A, Le Roux C, et al. Tirzepatide Reduces Body Weight Across BMI Categories: a SURMOUNT-1 Pre-Specified Analysis. *Obesity*. 2022-01-01 2022;30:49. doi:10.1002/oby.23625
66. Aronne LJ, Jastreboff AM, Le Roux CW, et al. Tirzepatide reduces body weight across body mass index (BMI) categories: a SURMOUNT-1 prespecified analysis. *Diabetol Stoffwechsel*. 2023-01-01 2023;18:S44. doi:10.1055/s-0043-1767938
67. Linge J, Birkenfeld AL, Neeland IJ. Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? *Circulation*. Oct 15 2024;150(16):1288-1298. doi:10.1161/CIRCULATIONAHA.124.067676
68. Jódar E, Michelsen M, Polonsky W, et al. Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6). *Diabetes, Obesity and Metabolism*. 2020/08/01 2020;22(8):1339-1347. doi:<https://doi.org/10.1111/dom.14039>
69. Steven J Atlas KK, Emily Nhan, Daniel R Touchette, Ashton Moradi, Foluso Agboola, David M Rind, Francesca L Beaudoin, Steven D Pearson. Medications for Obesity Management: Effectiveness and Value. [https://icer.org/wp-content/uploads/2022/03/ICER\\_Obesity\\_Final\\_Evidence\\_Report\\_and\\_Meeting\\_Summary\\_122223.pdf](https://icer.org/wp-content/uploads/2022/03/ICER_Obesity_Final_Evidence_Report_and_Meeting_Summary_122223.pdf)
70. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction–associated steatohepatitis with liver fibrosis. *New England Journal of Medicine*. 2024;391(4):299-310.
71. Lilly E. A study of tirzepatide (LY3298176) in participants with overweight or obesity and chronic kidney disease with or without type 2 diabetes (TREASURE-CKD). 2025;
72. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. *New England Journal of Medicine*. 2024;391(13):1193-1205.
73. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction–associated steatohepatitis. *New England Journal of Medicine*. 2025;392(21):2089-2099.
74. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *New England Journal of Medicine*. 2023;389(24):2221-2232.
75. Hwang JH, Laiteerapong N, Huang ES, Kim DD. Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. American Medical Association; 2025:e245586-e245586.
76. Silva Miguel L, Soares M, Olivieri A, et al. Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal. *Diabetology & Metabolic Syndrome*. 2024;16(1):97.
77. Sandhu H, Xu W, Olivieri A-V, Lübker C, Smith I, Antavali V. Once-weekly subcutaneous semaglutide 2.4 mg injection is cost-effective for weight management in the United Kingdom. *Advances in Therapy*. 2023;40(3):1282-1291.
78. Do D, Lee T, Peasah SK, Good CB, Inneh A, Patel U. GLP-1 receptor agonist discontinuation among patients with obesity and/or type 2 diabetes. *JAMA network open*. 2024;7(5):e2413172-e2413172.
79. Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. *JAMA Network Open*. 2025;8(1):e2457349-e2457349.

80. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. *Nature medicine*. 2022;28(10):2083-2091.
81. Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. *Nature medicine*. 2024;30(7):2049-2057.
82. Kim N, Wang J, Burudpakdee C, et al. Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. *Journal of managed care & specialty pharmacy*. 2022;28(7):740-752.
83. *Single Technology Appraisal, Tirzepatide for managing overweight and obesity [ID6179], Committee Papers*. 2023. <https://www.nice.org.uk/guidance/ta1026/evidence/appraisal-consultation-committee-papers-pdf-13613614237>
84. *Single Technology Appraisal, Semaglutide for managing overweight and obesity [ID3850], Committee Papers*. 2021. <https://www.nice.org.uk/guidance/ta875/evidence/appraisal-consultation-committee-papers-pdf-11381311261>
85. Ara R, Wailoo A. NICE DSU Technical Support Document 12: the use of health state utility values in decision models. 2017;
86. Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. *Archives of internal medicine*. 2004;164(19):2126-2134.
87. Mackenzie IS, Rogers A, Poulter NR, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. *The Lancet*. 2022;400(10361):1417-1425.
88. Rodriguez CJ, Swett K, Agarwal SK, et al. Systolic blood pressure levels among adults with hypertension and incident cardiovascular events: the atherosclerosis risk in communities study. *JAMA internal medicine*. 2014;174(8):1252-1261.
89. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Clinical Diabetology*. 2004;5(2):95-104.
90. Le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *The Lancet*. 2017;389(10077):1399-1409.
91. Edelman D, Olsen MK, Dudley TK, Harris AC, Oddone EZ. Utility of hemoglobin A1c in predicting diabetes risk. *Journal of general internal medicine*. 2004;19(12):1175-1180.
92. D'Agostino Sr RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation*. 2008;117(6):743-753.
93. Kolmos M, Christoffersen L, Kruuse C. Recurrent ischemic stroke—a systematic review and meta-analysis. *Journal of Stroke and Cerebrovascular Diseases*. 2021;30(8):105935.
94. Peters SA, Colantonio LD, Dai Y, et al. Trends in recurrent coronary heart disease after myocardial infarction among US women and men between 2008 and 2017. *Circulation*. 2021;143(7):650-660.
95. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *New England Journal of Medicine*. 2016;375(19):1834-1844.
96. Yeboyo HG, Aschmann HE, Kaufmann M, Puhon MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. *American heart journal*. 2019;210:18-28.



115. Jiao B, Basu A. Catalog of age-and medical condition—specific healthcare costs in the United States to inform future costs calculations in cost-effectiveness analysis. *Value in Health*. 2021;24(7):957-965.
116. Statistics UBoL. Consumer Price Index. US Bureau of Labor Statistics. Accessed 2025, July. <https://www.bls.gov/cpi/>
117. TOBACCO PRODUCT USE AMONG ADULTS—United States, 2022. 2022. <https://www.cdc.gov/tobacco/media/pdfs/2024/09/cdc-osh-ncis-data-report-508.pdf>
118. Hsu C-y, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. *Annals of internal medicine*. 2006;144(1):21-28.
119. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. *Nature medicine*. 2022-01-01 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4
120. Hurley LP, Dickinson LM, Estacio RO, Steiner JF, Havranek EP. Prediction of cardiovascular death in racial/ethnic minorities using Framingham risk factors. *Circulation: Cardiovascular Quality and Outcomes*. 2010;3(2):181-187.
121. Ndumele CE, Ferdinand KC, Khan SS. The Role of Race in Cardiovascular Disease Risk Prediction. *Circulation*. 2025;151(11):741-743.
122. Fryar CD CM, Afful J. Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960–1962 through 2017–2018. *NCHS Health E-Stats*. 2020;
123. Ezendu K, Pohl G, Lee CJ, Wang H, Li X, Dunn JP. Prevalence of obesity-related multimorbidity and its health care costs among adults in the United States. *Journal of Managed Care & Specialty Pharmacy*. 2025;31(2):179-188. doi:10.18553/jmcp.2025.31.2.179
124. Montero A, Sparks, G., Presiado, M., Hamel, L. *KFF Health Tracking Poll May 2024: The Public's Use and Views of GLP-1 Drugs*. 2024. <https://www.kff.org/health-costs/poll-finding/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/>
125. Cowie CC, Casagrande SS, Geiss LS. Prevalence and Incidence of Type 2 Diabetes and Prediabetes. In: Cowie CC, Casagrande SS, Menke A, et al, eds. *Diabetes in America*. National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018.
126. Thingholm LB, Rühlemann MC, Koch M, et al. Obese Individuals with and without Type 2 Diabetes Show Different Gut Microbial Functional Capacity and Composition. *Cell Host & Microbe*. 2019/08/14/ 2019;26(2):252-264.e10. doi:<https://doi.org/10.1016/j.chom.2019.07.004>
127. Boye KS, Lage MJ, Thieu V, Shinde S, Dhamija S, Bae JP. Obesity and glycemic control among people with type 2 diabetes in the United States: A retrospective cohort study using insurance claims data. *Journal of Diabetes and its Complications*. 2021/09/01/ 2021;35(9):107975. doi:<https://doi.org/10.1016/j.jdiacomp.2021.107975>
128. Potter AW, Chin GC, Looney DP, Friedl KE. Defining Overweight and Obesity by Percent Body Fat Instead of Body Mass Index. *J Clin Endocrinol Metab*. Mar 17 2025;110(4):e1103-e1107. doi:10.1210/clinem/dgae341
129. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity. *Endocrine practice*. 2016;22:1-203. doi:10.4158/EP161365.GL
130. Kolotkin RL, Ervin CM, Meincke HH, Højbjerg L, Fehnel SE. Development of a clinical trials version of the Impact of Weight on Quality of Life-Lite questionnaire (IWQOL-Lite Clinical Trials Version): results from two qualitative studies. *Clin Obes*. Oct 2017;7(5):290-299. doi:10.1111/cob.12197
131. Kolotkin RL, Williams VSL, Ervin CM, et al. Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version. *Clin Obes*. Jun 2019;9(3):e12310. doi:10.1111/cob.12310





164. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. *Jama*. Sep 13 2016;316(10):1093-103. doi:10.1001/jama.2016.12195
165. Pickard AS, Law EH, Jiang R, et al. United States Valuation of EQ-5D-5L Health States Using an International Protocol. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*. Aug 2019;22(8):931-941. doi:10.1016/j.jval.2019.02.009
166. Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. *Signal transduction and targeted therapy*. 2024;9(1):234.
167. Schultz BG, Tilton J, Jun J, Scott-Horton T, Quach D, Touchette DR. Cost-effectiveness analysis of a pharmacist-led medication therapy management program: hypertension management. *Value in Health*. 2021;24(4):522-529.
168. Sulo G, Iglund J, Vollset SE, et al. Heart failure complicating acute myocardial infarction; burden and timing of occurrence: a nation-wide analysis including 86 771 patients from the Cardiovascular Disease in Norway (CVDNOR) Project. *Journal of the American Heart Association*. 2016;5(1):e002667.
169. Gerber Y, Weston SA, Enriquez-Sarano M, et al. Mortality associated with heart failure after myocardial infarction: a contemporary community perspective. *Circulation: Heart Failure*. 2016;9(1):e002460.
170. Institute for Clinical and Economic Review. 2020-2023 Value Assessment Framework. <https://icer.org/our-approach/methods-process/value-assessment-framework/>
171. Ioannou GN, Weiss NS, Kowdley KV, Dominitz JA. Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. *Gastroenterology*. 2003;125(4):1053-1059.
172. Majed B, Montaye M, Wagner A, et al. All-cause mortality up to and after coronary heart disease and stroke events in European middle-aged men: the PRIME study. *Stroke*. 2015;46(5):1371-1373.
173. Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. *Circulation*. 2011;124(1):17-23.
174. Raghavan S, Vassy JL, Ho YL, et al. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. *Journal of the American Heart Association*. 2019;8(4):e011295.
175. Lee Y-C, Lin C-W, Ho L-C, et al. All-cause standardized mortality ratio in hemodialysis and peritoneal dialysis patients: a nationwide population-based cohort study. *International journal of environmental research and public health*. 2023;20(3):2347.
176. Simon TG, Roelstraete B, Khalili H, Hagström H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. *Gut*. 2021;70(7):1375-1382.
177. *Health at a Glance 2023, OECD INDICATORS*. 2023. [https://www.oecd.org/en/publications/2023/11/health-at-a-glance-2023\\_e04f8239/full-report/mortality-following-acute-myocardial-infarction-ami\\_999cd0f3.html](https://www.oecd.org/en/publications/2023/11/health-at-a-glance-2023_e04f8239/full-report/mortality-following-acute-myocardial-infarction-ami_999cd0f3.html)
178. Kushner RF, Ryan DH, Deanfield J, et al. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. *Obesity*. 2025;33(3):452-462.
179. Van Dooren FE, Nefs G, Schram MT, Verhey FR, Denollet J, Pouwer F. Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. *PLoS one*. 2013;8(3):e57058.
180. Hoog MM, Kan H, Deger KA, et al. Modeling potential cost-effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity. *Obesity*. 2025;
181. Yang F, Lau T, Lee E, Vathsala A, Chia KS, Luo N. Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD). *The European Journal of Health Economics*. 2015;16:1019-1026.







**Short Form-36 v2® Health Survey, Acute Version (SF-36):** The SF-36 is a generic quality of life measure widely used to assess patient-reported functional outcomes.<sup>133</sup> It includes 36 questions across eight domains (physical functioning, role limitations due to physical health problems, body pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health). The SF-36 domains can be aggregated into two scores, the Physical Component Summary (PCS) and the Mental Component Summary (MCS). For the SF-36, an increase in score reflects an improvement in health status, with a 3.7-point increase representing the threshold for a clinically meaningful improvement.<sup>22</sup>

**EQ-5D-5L:** The EQ-5D-5L is a standardized five-item tool used to assess health-related quality of life (HRQoL) across various conditions. It covers mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. A single index score is derived, ranging from less than 0 (worse than death) to 1 (perfect health). Additionally, a visual analogue scale (0–100) captures the respondent’s self-rated health.<sup>134</sup>

**Western Ontario and McMaster Universities Osteoarthritis (WOMAC) pain subscale:** A clinical tool used to measure the severity of knee pain during daily activities. It includes 5 items assessing pain during walking, stair climbing, sitting, lying down, and standing, rated on a 5-point Likert scale from “none” to “extreme.” Higher total scores indicate greater pain, stiffness, and functional limitations. The minimal clinically important difference for the WOMAC is 4.2 points for the pain subscale.<sup>57,135</sup>

## Other Relevant Definitions

**Absolute and Proportional Shortfalls:** Absolute and proportional shortfalls are empirical measurements that capture different aspects of society’s instincts for prioritization related to the severity or burden of an illness. The absolute shortfall is defined as the total absolute amount of future health patients with a condition are expected to lose without the treatment that is being assessed.<sup>136</sup> The ethical consequences of using absolute shortfall to prioritize treatments is that conditions that cause early death or that have very serious lifelong effects on quality of life receive the greatest prioritization. Thus, certain kinds of treatments, such as treatments for rapidly fatal conditions of children, or for lifelong disabling conditions, score highest on the scale of absolute shortfall. The proportional shortfall is measured by calculating the proportion of the total health units of remaining life expectancy that would be lost due to untreated illness.<sup>137,138</sup> The proportional shortfall reflects the ethical instinct to prioritize treatments for patients whose illness would rob them of a large percentage of their expected remaining lifetime. As with absolute shortfall, rapidly fatal conditions of childhood have high proportional shortfalls, but high numbers can also often arise from severe conditions among older adults who may have only a few years left of average life expectancy but would lose much of that to the illness without treatment. Details on how to calculate the absolute and proportional QALY and evLY shortfalls can be found in [ICER’s reference case](#). Shortfalls will be highlighted when asking the independent appraisal committees to

vote on unmet need despite current treatment options as part of characterizing a treatment's benefits beyond health and special ethical priorities (Section 5).

**Health Improvement Distribution Index (HIDI):** The HIDI identifies a subpopulation that has a higher prevalence of the disease of interest and therefore, creates an opportunity for proportionately more health gains within the subpopulation. This opportunity may be realized by achieving equal access both within and outside the identified subpopulation to an intervention that is known to improve health. The HIDI is defined as the disease prevalence in the subpopulation divided by the disease prevalence in the overall population. For example, if a disease has a prevalence of 10% among Black Americans whereas the disease prevalence among all Americans is 4%, then the Health Improvement Distribution Index is  $10\%/4\%=2.5$ . In this example, a HIDI of 2.5 means that Black Americans as a subpopulation would benefit more on a relative basis (2.5 times more) from a new effective intervention compared with the overall population. HIDs above 1 suggest that more health may be gained on the relative scale in the subpopulation of interest when compared to the population as a whole. The HIDI may be helpful in characterizing a treatment's benefits beyond health and special ethical priorities (Section 5).

## **A2. Potential Cost-Saving Measures in Obesity**

ICER includes in its reports information on wasteful or lower-value services in the same clinical area that could be reduced or eliminated to create headroom in health care budgets for higher-value innovative services (for more information, please reference ICER's [Value Assessment Framework](#)). These services are ones that would not be directly affected by therapies for obesity (e.g., hospitalizations for myocardial infarction), as these services will be captured in the economic model. Rather, we are seeking services used in the current management of obesity beyond the potential offsets that arise from a new intervention. During stakeholder engagement and public comment periods, ICER encouraged all stakeholders to suggest services (including treatments and mechanisms of care) currently used for patients with obesity that could be reduced, eliminated, or made more efficient. No suggestions were received.

## **A3. Patient Input on Clinical Trial Design**

Manufacturers were asked to submit a written explanation of how they engaged patients in the design of their clinical trials, including the methods used to gather patient experience data and how they determined the outcomes that matter most to patients. ICER did not receive any feedback on this inquiry.

## B. Stakeholder Input: Supplemental Information

### **B1. Patient Community Insights: Methods**

We spoke with eight individuals living with obesity and two patient advocacy groups to gain perspectives on living with obesity and experiences with obesity treatment. The eight individuals were men and women living in various areas of the US and at various life stages and were recommended by patient advocacy groups.

### **B2. Clinical Expert Input: Methods**

We spoke with clinical experts ranging from primary care physicians who are board-certified in obesity medicine to endocrinologists specializing in the treatment of genetic obesity syndromes. Clinical experts practiced in a variety of settings, from academic medical centers to weight management companies. We also spoke with one clinical specialty society, as well as one payer.

## C. Clinical Guidelines

---

Clinical practice guidelines for obesity range cover topics ranging from diagnosis and treatment to recommendations for addressing weight stigma and bias. We targeted clinical practice guidelines focused on the treatment of obesity, and these guidelines are summarized below.

### **American Gastroenterology Association (AGA) Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity<sup>15</sup>**

The 2022 AGA Clinical Practice Guidelines focused on reviewing evidence on pharmacological interventions for adults with obesity. The guidelines were developed by a multidisciplinary panel of content experts and guideline methodologists, and drugs evaluated for this guideline included semaglutide, liraglutide, phentermine-topiramate, naltrexone-bupropion, orlistat, and phentermine. The panel made the following recommendations for adults with obesity or overweight with weight-related complications: 1) The addition of pharmacological agents to treatment is recommended if there is an inadequate response to lifestyle interventions alone; 2) Semaglutide 2.4 mg should be prioritized over other approved anti-obesity medications for the long-term treatment of obesity for most patients; 3) Liraglutide, phentermine-topiramate, and naltrexone-bupropion are also recommended for long-term management of obesity; 4) Orlistat is not recommended for treatment of obesity; 5) Phentermine monotherapy is approved for short-term management of obesity (12 weeks) and is recommended for management of obesity.

### **American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity<sup>129</sup>**

The 2016 AACE/ACE clinical practice guidelines provides evidence-based recommendations about the management of obesity as a chronic disease, targeting both weight-related complications and adiposity to improve overall health and quality of life. The guidelines cover screening and diagnosis of obesity and obesity-related complications, recommendations for lifestyle modifications, pharmacotherapy, and bariatric surgery. The guidelines recommend that pharmacotherapy be used as an adjunct to lifestyle modifications and should be used for the chronic treatment of the disease. The guidelines further recommend that pharmacotherapy decisions should be individualized and clinicians and their patients should have access to all approved medications to allow for appropriate individualization of therapy. The guideline further evaluates and recommends treatment based on specific clinical scenarios (e.g., chronic kidney disease, liver disease, hypertension, cardiovascular disease, etc.). Finally, individuals with a BMI  $\geq 40$  or BMI  $\geq 35$  and 1 or more severe obesity-related complication should be eligible for bariatric surgery.

## **American Heart Association (AHA)/American College of Cardiology (ACC)/The Obesity Society (TOS) Guideline for the Management of Overweight and Obesity in Adults<sup>139</sup>**

The 2013 AHA/ACC/TOS guidelines offered comprehensive recommendations on identifying and treating individuals living with obesity. Recommendations included both counseling about lifestyle modifications and pharmacologic treatment, including offering or referring for high-intensity comprehensive lifestyle interventions, adding pharmacotherapy as an adjunct in individuals with BMI  $\geq 30$  or BMI  $\geq 27$  and  $\geq 1$  obesity-associated comorbid condition(s), and offering referral to a bariatric surgeon for consultation for individuals with BMI  $\geq 40$  or BMI  $\geq 35$  with obesity-related comorbid conditions. The guideline did not make recommendations for specific pharmacotherapy, though many modern drugs were approved after the publication of this clinical practice guideline.

# D. Comparative Clinical Effectiveness: Supplemental Information

## **D1. Detailed Methods**

### **PICOTS**

#### ***Population***

The population of focus for this review is adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, who are actively seeking medical management for weight loss; adults with established diabetes are excluded.

Data permitting, we will seek to examine the following patient subgroups, including but not limited to: age, sex at birth, race and ethnicity, BMI categories, use and intensity of lifestyle interventions, established cardiovascular disease, and prior bariatric surgery.

#### ***Interventions***

The full list of interventions is as follows:

- Semaglutide, injectable administered weekly
- Semaglutide, oral administered daily
- Tirzepatide, injectable administered weekly

Each of these may be administered in combination with lifestyle modification (e.g., reduced calorie diet and increased physical activity) or alone.

#### ***Comparators***

We intend to compare these interventions to lifestyle modification alone, to no treatment, and to each other.

## Outcomes

The outcomes of interest are described in the list below.

- Patient-Important Outcomes
  - Weight reduction (e.g., mean % change in body weight loss, categorical weight loss [e.g., ≥5%, ≥10%, ≥15%, ≥20% etc.], and change in BMI from baseline)
  - Weight re-gain
  - Quality of life (e.g., short form [SF]-36, impact of weight on quality of life-lite for clinical trial [IWQoL-Lite-CT], impact of weight on daily activities questionnaire [IWDAQ]) and functional status)
  - Mental health outcomes (e.g., anxiety and depression)
  - Physical functioning (e.g., six-minute walk test)
  - Obesity-related complications, including but not limited to:
    - Cardiovascular events (e.g., major adverse cardiovascular events [MACE]-3 or MACE-5, non-fatal MI, and non-fatal stroke)
    - Sleep apnea
    - Diabetes requiring treatment
    - Heart failure
    - Hyperlipidemia requiring treatment
    - Hypertension requiring treatment
    - End-stage kidney disease
    - Cirrhosis
    - Symptomatic degenerative joint disease
    - Joint replacement surgery
    - Fractures
    - Infertility
    - Cancer
    - Mortality
  - Adverse events including
    - Gastrointestinal events (e.g., nausea, vomiting, diarrhea, constipation, etc.)
    - Muscle loss leading to weakness
    - Serious adverse events
    - Adverse events leading to treatment discontinuation
- Other Outcomes
  - Body composition
  - Bone density
  - Chronic kidney disease (CKD)
  - Metabolic-associated liver disease
  - Polycystic ovarian syndrome

### ***Timing***

Evidence on intervention effectiveness will be derived from studies of at least 26 weeks duration and evidence on harms from studies of any duration.

### ***Settings***

All relevant settings will be considered, with a focus on outpatient settings in the United States.

### ***Study Design***

Randomized controlled trials and non-randomized controlled trials with any sample size will be included. High-quality comparative observational studies will also be included.

**Table D1.1 PRISMA 2020 Checklist**

Section and Topic	Item #	Checklist Item
<b>TITLE</b>		
<b>Title</b>	1	Identify the report as a systematic review.
<b>ABSTRACT</b>		
<b>Abstract</b>	2	See the PRISMA 2020 for Abstracts checklist.
<b>INTRODUCTION</b>		
<b>Rationale</b>	3	Describe the rationale for the review in the context of existing knowledge.
<b>Objectives</b>	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.
<b>METHODS</b>		
<b>Eligibility Criteria</b>	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.
<b>Information Sources</b>	6	Specify all databases, registers, websites, organizations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.
<b>Search Strategy</b>	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.
<b>Selection Process</b>	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.
<b>Data Collection Process</b>	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.
<b>Data Items</b>	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.
<b>Study Risk of Bias Assessment</b>	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.
<b>Effect Measures</b>	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.
<b>Synthesis Methods</b>	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.

Section and Topic	Item #	Checklist Item
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.
<b>Reporting Bias Assessment</b>	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).
<b>Certainty Assessment</b>	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.
<b>RESULTS</b>		
<b>Study Selection</b>	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.
<b>Study Characteristics</b>	17	Cite each included study and present its characteristics.
<b>Risk of Bias in Studies</b>	18	Present assessments of risk of bias for each included study.
<b>Results of Individual Studies</b>	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.
<b>Results of Syntheses</b>	20a	For each synthesis, briefly summarize the characteristics and risk of bias among contributing studies.
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g., confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.
	20c	Present results of all investigations of possible causes of heterogeneity among study results.
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.
<b>Reporting Biases</b>	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.
<b>Certainty of Evidence</b>	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.
<b>DISCUSSION</b>		
<b>Discussion</b>	23a	Provide a general interpretation of the results in the context of other evidence.
	23b	Discuss any limitations of the evidence included in the review.
	23c	Discuss any limitations of the review processes used.
	23d	Discuss implications of the results for practice, policy, and future research.

Section and Topic	Item #	Checklist Item
<b>OTHER INFORMATION</b>		
<b>Registration and Protocol</b>	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.
	24c	Describe and explain any amendments to information provided at registration or in the protocol.
<b>Support</b>	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.
<b>Competing Interests</b>	26	Declare any competing interests of review authors.
<b>Availability of Data, Code, and Other Materials</b>	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.

From: Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *PLoS Med.* 2021;18(3):e1003583.

## Data Sources and Searches

Procedures for the systematic literature review assessing the evidence on injectable semaglutide, oral semaglutide, and tirzepatide for obesity followed established best research methods.<sup>140,141</sup> We reported the review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.<sup>142</sup> The PRISMA guidelines include a checklist of 27 items (see **Table D1.1**).

We searched MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials for relevant studies. Each search was limited to English-language studies of human subjects and excluded articles indexed as guidelines, letters, editorials, narrative reviews, case reports, or news items. We included abstracts from conference proceedings identified from the systematic literature search. All search strategies were generated utilizing the Population, Intervention, Comparator, and Study Design elements described above. The proposed search strategies included a combination of indexing terms (MeSH terms in MEDLINE and Emtree terms in EMBASE), as well as free-text terms.

To supplement the database searches, we performed manual checks of the reference lists of included trials and systematic reviews and invited key stakeholders to share references germane to the scope of this project. We also supplemented our review of published studies with data from conference proceedings, regulatory documents, information submitted by manufacturers, and other grey literature when the evidence met ICER standards (for more information, see the [Policy on Inclusion of Grey Literature in Evidence Reviews](#)).

**Table D1.2. Search Strategy of Medline 1996 to Present with Daily Update and Cochrane Central Register of Controlled Trials**

#	Search Term
1	exp Obesity/
2	exp Weight Loss/
3	exp Overweight/
4	(obes* or overweight or "over weight" or "over-weight" or "body mass ind*" or "BMI").ti,ab.
5	1 or 2 or 3 or 4
6	('ozempic' or 'rybelsus' or 'wegovy' or 'semaglutide' or 'NN 9535' or 'NN9535' or 'NN-9535').ti,ab.
7	('tirzepatide' or 'zepbound' or 'mounjaro' or 'LY 3298176' or 'LY3298176' or 'LY-3298176').ti,ab.
8	6 or 7
9	5 and 8
10	9 not ("address" or "autobiography" or "bibliography" or "biography" or "case reports" or "comment" or "congress" or "consensus development conference" or "duplicate publication" or "editorial" or "interview" or "lecture" or "legal case" or "legislation" or "letter" or "news" or "newspaper article" or "patient education handout" or "periodical index" or "personal narrative" or "portrait" or "video-audio media").pt.
11	10 not (animals not (humans and animals)).sh.
12	limit 11 to english language
13	remove duplicates from 12


Date of last search: 06/05/2025

**Table D1.3. Search Strategy of EMBASE SEARCH**

#	Search Term
1	'obesity'/exp OR 'obesity'
2	'body weight loss'/exp OR 'body weight loss'
3	'overweight'/exp OR 'overweight' OR 'over-weight' OR 'over-weight'
4	'obes*':ti,ab OR 'body mass ind*':ti,ab OR 'BMI':ti,ab
5	#1 OR #2 OR #3 OR #4
6	('ozempic' OR 'rybelsus' OR 'wegovy' OR 'semaglutide' OR 'NN 9535' OR 'NN9535' OR 'NN-9535'):ti,ab
7	('tirzepatide' OR 'zepbound' OR 'mounjaro' OR 'LY 3298176' OR 'LY3298176' OR 'LY-3298176'):ti,ab
8	#6 OR #7
9	#5 AND #8
10	#9 NOT ('chapter'/it OR 'conference review'/it OR 'editorial'/it OR 'letter'/it OR 'short survey'/it OR 'erratum'/it OR 'note'/it)
11	('animal'/exp OR 'nonhuman'/exp OR 'animal experiment'/exp) NOT 'human'/exp
12	#10 NOT #11
13	#12 AND [english]/lim
14	#13 NOT [medline]/lim

Date of last search: 06/05/2025

**Figure D1.1. PRISMA Flow Chart Showing Results of Literature Search**



## Study Selection

We performed screening at both the abstract and full-text level. Two investigators independently screened all titles and abstracts identified through electronic searches according to the inclusion and exclusion criteria described earlier using Nested Knowledge (Nested Knowledge, Inc, St. Paul, Minnesota); a third reviewer worked with the initial two reviewers to resolve any issues of disagreement through consensus. We did not exclude any study at abstract-level screening due to insufficient information. For example, an abstract that did not report an outcome of interest would be accepted for further review in full text. We retrieved the citations that were accepted during abstract-level screening for full text appraisal. One investigator reviewed full papers and provided justification for exclusion of each excluded study.

## Data Extraction

Data were extracted into Microsoft Word and Microsoft Excel. The basic design and elements of the extraction forms followed those used for other ICER reports. Elements included a description of patient populations, sample size, duration of follow-up, funding source, study design features, interventions (agent, dosage, frequency, schedules), concomitant therapy allowed and used (agent, dosage, frequency, schedules), outcome assessments, results, and risk of bias. The data extraction was performed in the following steps:

1. One reviewer extracted information from the full articles, and a second reviewer validated the extracted data.
2. Extracted data were reviewed for logic, and a random proportion of data were validated by a third investigator for additional quality assurance.

## Risk of Bias Assessment

We examined the risk of bias for each randomized trial in this review using criteria published in the Cochrane Risk of Bias Assessment Tool Version 2.<sup>141,143</sup> Risk of bias was assessed by study outcome for each of the following aspects of the trials: randomization process, deviation from the intended interventions, missing outcome data, measurement of the outcome, selection of the reported results, and overall risk of bias. Two reviewers independently assessed these domains. Any disagreements were resolved through discussion or by consulting a third reviewer. We did not assess the risk of bias in trials where we only had access to conference abstracts/presentations.

To assess the risk of bias in trials, we rated the categories as: “low risk of bias,” “some concerns,” or “high risk of bias.” Guidance for risk of bias ratings using these criteria is presented below:

**Low risk of bias:** *The study is judged to be at low risk of bias for all domains for this result.*

**Some concerns:** *The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.*

**High risk of bias:** *The study is judged to be at high risk of bias in at least one domain for this result or the study is judged to have some concerns for multiple domains in a way that substantially lowers confidence in the result.*

We examined the risk of bias for the primary outcomes of all key trials included in this review. See Table D1.4-D1.5.

**Table D1.4. Risk of Bias Assessments for Primary Endpoints of Key Trials Assessing Body Weight Change from Baseline**

Study	Randomization Process	Deviation from the Intended Interventions	Missing Outcome Data	Measurement of the Outcome	Selection of the Reported Result	Overall Risk of Bias
<b>Injectable Semaglutide</b>						
<b>STEP 1</b>	Low	Low	Low	Low	Low	Low
	Notes:					
<b>STEP 3</b>	Low	Low	Low	Low	Low	Low
	Notes:					
<b>STEP 4</b>	Low	Some concerns	Low	Low	Low	Some concerns
	Notes: Participants may have been unblinded by changes in weight and side effects due to switching to a placebo after treatment with injectable semaglutide in the 20 week lead-in period.					
<b>STEP 5</b>	Low	Low	Some concerns	Low	Low	Some concerns
	Notes: More participants had missing data and discontinued the trial in the placebo group for documented reasons (i.e., lack of efficacy, withdrawal of consent, and lost to follow-up) compared to the semaglutide group.					
<b>STEP 8</b>	Low	Low	Low	Low	Low	Low
	Notes: Our rating only reflects the semaglutide versus placebo comparison; we did not consider the other trial arms in our ratings.					
<b>STEP 10</b>	Low	Low	Low	Low	Low	Low
	Notes:					
<b>Tirzepatide</b>						
<b>SURMOUNT 1</b>	Low	Low	Some concerns	Low	Low	Some concerns
	Notes: More participants had missing data and discontinued the trial in the placebo group for documented reasons (lost to follow-up and withdrawal of consent) compared to the tirzepatide group.					
<b>SURMOUNT 3</b>	Low	Low	Low	Low	Low	Low
	Notes:					
<b>SURMOUNT 4</b>	Low	Some concerns	Low	Low	Low	Some concerns
	Notes: Participants may have been unblinded based on changes in weight and adverse events due to switching to placebo after taking tirzepatide for the 36 weeks lead-in period.					
<b>Direct Comparison</b>						
<b>SURMOUNT 5</b>	Low	Some Concerns	Low	Low	Low	Some Concerns

Study	Randomization Process	Deviation from the Intended Interventions	Missing Outcome Data	Measurement of the Outcome	Selection of the Reported Result	Overall Risk of Bias
	Notes: Due to open-label study design					

OASIS-4 was excluded due to the lack of availability of a publication and a protocol.

**Table D1.5. Risk of Bias Assessments for Primary Endpoints of Key Trials Assessing Cardiovascular Outcomes and Obesity-Related Complications**

Studies (Author, Year)	Randomization Process	Deviation from the Intended Interventions	Missing Outcome Data	Measurement of the Outcome	Selection of the Reported Result	Overall Risk of Bias
<b>Injectable Semaglutide</b>						
<b>STEP 9</b>	Low	Low	Low	Low	Low	Low
	Notes:					
<b>SELECT</b>	Low	Low	Low	Low	Low	Low
	Notes:					
<b>STEP-HFpEF</b>	Low	Low	Low	Low	Low	Low
	Notes:					
<b>ESSENCE</b>	Low	Low	Low	Low	Low	Low
	Notes:					
<b>Tirzepatide</b>						
<b>SUMMIT</b>	Low	Low	Low	Low	Low	Low
	Notes:					
<b>SURMOUNT OSA</b>	Low	Low	Some Concerns	Low	Low	Some Concerns
	Notes: More participants had missing data and discontinued the trial in the placebo group for documented reasons (i.e., withdrawal by subject) compared to the semaglutide group.					

## Evaluation of Clinical Trial Diversity

We evaluated the demographic diversity of clinical trials using the ICER-developed Clinical trial Diversity Rating (CDR) Tool.<sup>51</sup> The CDR tool was designed to evaluate the three demographic characteristics described in Table D1.5. Representation for each demographic category was evaluated by quantitatively comparing clinical trial participants with disease-specific prevalence estimates<sup>144-146</sup>, using the metric “Participant to Disease-prevalence Representation Ratio” (PDRR). Next, a representation score between 0 to 3 was assigned based on the PDRR estimate (See Table D1.7 for the PDRR cut points that correspond to each representation score). Finally, based on the total score of the demographic characteristics (e.g., race and ethnicity), the categories “Good,” “Fair,” or “Poor” are used to communicate the overall level of diversity of a clinical trial. The description of the rating categories for each demographic characteristic is provided in Table D1.8.

**Table D1.6. Demographic Characteristics and Categories**

Demographic Characteristics	Categories
1. Race and Ethnicity*	Racial categories: <ul style="list-style-type: none"> <li>• White</li> <li>• Black or African American</li> <li>• Asian</li> <li>• American Indian and Alaskan Native</li> <li>• Native Hawaiian and Other Pacific Islanders</li> </ul> Ethnic Category: <ul style="list-style-type: none"> <li>• Hispanic or Latino</li> </ul>
2. Sex	<ul style="list-style-type: none"> <li>• Female</li> <li>• Male</li> </ul>
3. Age	<ul style="list-style-type: none"> <li>• Older adults (≥65 years)</li> </ul>

\*Multinational trials: For multinational clinical trials, our approach is to evaluate only the subpopulation of patients enrolled from the US on racial and ethnic diversity

**Table D1.7. Representation Score**

PDRR	Score
0	0
>0 and Less Than 0.5	1
0.5 to 0.8	2
≥0.8	3

PDRR: Participant to Disease-prevalence Representation Ratio

**Table D1.8. Rating Categories**

Demographic Characteristics	Demographic Categories	Maximum Score	Rating Categories (Total Score)
<b>Race and Ethnicity*</b>	Asian, Black or African American, White, and Hispanic or Latino	12	Good (11-12) Fair (7-10) Poor ( $\leq 6$ )
<b>Sex</b>	Male and Female	6	Good (6) Fair (5) Poor ( $\leq 4$ )
<b>Age</b>	Older adults ( $\geq 65$ years)	3	Good (3) Fair (2) Poor ( $\leq 1$ )

\*American Indian or Alaskan Native & Native Hawaiian or Other Pacific Islander are not factored into the overall racial and diversity rating. However, information on enrollment and PDRR estimates are reported when reliable prevalence estimates are available.

## Results

**Table D1.9. Diversity Ratings on Race and Ethnicity, Sex, and Age (Older Adults)**

Trial	Race and Ethnicity	Sex	Age (Older Adults)
<b>STEP-1</b>	Fair	Fair	NR
<b>STEP-3</b>	Good	Poor	NR
<b>STEP-4</b>	Fair	Poor	NR
<b>STEP-5</b>	Fair	Poor	NR
<b>STEP-8</b>	Good	Poor	NR
<b>STEP-9</b>	Poor	Poor	Good
<b>STEP-10</b>	Fair	Fair	NR
<b>SURMOUNT-1</b>	Fair	Fair	Poor
<b>SURMOUNT-3</b>	Fair	Fair	NR
<b>SURMOUNT-4</b>	Good	Fair	Fair
<b>SURMOUNT-5</b>	Good	Fair	Poor
<b>SURMOUNT-OSA</b>	Fair	Fair	NR
<b>SELECT</b>	Fair	Fair	Good
<b>SURPASS-CVOT</b>	NR	Fair	NR
<b>STEP-HFpEF</b>	Poor	Good	NR
<b>ESSENCE</b>	Fair	Good	NR
<b>SUMMIT</b>	Fair	Good	NR

NE: Not Estimated, NR: Not Reported. OASIS-4 was excluded due to the lack of availability of a publication describing the relevant categories.

\*The ratings presented above reflect representation based on estimates for the U.S. obesity population. CDR ratings may vary when adjusted for the specific disease prevalence within populations enrolled in individual trials.

Table D1.8. presents the clinical trial diversity ratings on race and ethnicity, sex, and age (older adults) for 18 trials. Given that these are multinational clinical trials and US-specific enrollment data is not publicly available, each trial was rated using the full sample.

**Table D1.10. Race and Ethnicity**

	White	Black/ African American	Asian	Hispanic/ Latino	Total Score	Diversity Rating	AIAN	NHPI
<b>Prevalence/ Incidence</b>	79.06%	16.74%	2.72%	21.23%	-	-	1.06%	0.29%
<b>STEP-1</b>	75.10%	5.70%	13.30%	12.00%	-	-	NR	NR
<b>PDRR</b>	0.95	0.34	4.89	0.57	-	-	0	0
<b>Score</b>	3	1	3	2	9	Fair	NC	NC
<b>STEP-3</b>	76.10%	18.90%	1.80%	19.80%	-	-	0.16%	0.49%
<b>PDRR</b>	0.96	1.13	0.66	0.93	-	-	0.15	1.69
<b>Score</b>	3	3	2	3	11	Good	NC	NC
<b>STEP-4</b>	83.70%	13.00%	2.40%	NR	-	-	NR	NR
<b>PDRR</b>	1.06	0.78	0.88	NC	-	-	0	0
<b>Score</b>	3	2	3	0	8	Fair	NC	NC
<b>STEP-5</b>	93.10%	3.90%	0.66%	12.80%	-	-	0.99%	NR
<b>PDRR</b>	1.18	0.23	0.24	0.60	-	-	0.93	0
<b>Score</b>	3	1	1	2	7	Fair	NC	NC
<b>STEP-8</b>	73.30%	18.90%	3.80%	11.50%	-	-	NR	NR
<b>PDRR</b>	0.93	1.13	1.40	0.54	-	-	0	0
<b>Score</b>	3	3	3	2	11	Good	NC	NC
<b>STEP-9</b>	60.90%	7.60%	13.80%	NR	-	-	11.90%	NR
<b>PDRR</b>	0.77	0.45	5.07	NC	-	-	11.23	0
<b>Score</b>	2	1	3	0	6	Poor	NC	NC
<b>STEP-10</b>	88.00%	4.00%	4.00%	3.40%	-	-	0.48%	NR
<b>PDRR</b>	1.11	0.24	1.47	0.16	-	-	0.45	0
<b>Score</b>	3	1	3	1	8	Fair	NC	NC
<b>SURMOUNT-1</b>	70.60%	7.90%	10.90%	47.80%	-	-	9.09%	0.35%
<b>PDRR</b>	0.89	0.47	4.01	2.25	-	-	8.58	1.21
<b>Score</b>	3	1	3	3	10	Fair	NC	NC
<b>SURMOUNT-3</b>	86.00%	10.90%	0.70%	53.90%	-	-	1.03%	NR
<b>PDRR</b>	1.09	0.65	0.26	2.54	-	-	0.97	0
<b>Score</b>	3	2	1	3	9	Fair	NC	NC
<b>SURMOUNT-4</b>	80.10%	11.20%	7.20%	44.20%	-	-	NR	0.29
<b>PDRR</b>	1.02	0.67	2.65	2.08	-	-	0	1
<b>Score</b>	3	2	3	3	11	Good	NC	NC
<b>SURMOUNT-5</b>	76.10%	19.20%	2.40%	26.10%	-	-	0.80%	NR
<b>PDRR</b>	0.96	1.15	0.88	1.23	-	-	0.75	0

	White	Black/ African American	Asian	Hispanic/ Latino	Total Score	Diversity Rating	AIAN	NHPI
<b>Score</b>	3	3	3	3	12	Good	NC	NC
<b>SURMOUNT-OSA</b>	69.30%	5.10%	17.10%	37.10%	-	-	7.89%	NR
<b>PDRR</b>	0.88	0.30	6.29	1.75	-	-	7.44	0
<b>Score</b>	3	1	3	3	10	Fair	NC	NC
<b>SELECT</b>	84.00%	3.80%	8.20%	NR	-	-	NR	NR
<b>PDRR</b>	1.06	0.23	3.01	NC	-	-	0	0
<b>Score</b>	3	1	3	0	7	Fair	NC	NC
<b>SURPASS-CVOT</b>	NR	NR	NR	NR	NR	NR	NR	NR
<b>PDRR</b>	0	0	0	0	0	0	0	0
<b>Score</b>	NC	NC	NC	NC	NC	NC	NC	NC
<b>STEP-HFpEF</b>	95.80%	4.00%	0%	6.80%	-	-	NR	NR
<b>PDRR</b>	1.21	0.24	0.00	0.32	-	-	0	0
<b>Score</b>	3	1	0	1	5	Poor	NC	NC
<b>ESSENCE</b>	67.50%	0.63%	27.00%	18.30%	-	-	NR	NR
<b>PDRR</b>	0.86	0.04	9.93	0.86	-	-	0	0
<b>Score</b>	3	1	3	3	10	Fair	NC	NC
<b>SUMMIT</b>	70.00%	4.90%	17.90%	NR	-	-	6.84%*	
<b>PDRR</b>	0.89	0.29	6.58	NC	-	-	NC	NC
<b>Score</b>	3	1	3	0	7	Fair	NC	NC

AIAN: American Indian or Alaskan Native, NR: Not Reported, NC: Not Calculated, NE: Not Estimated, NHPI: Native Hawaiian or Pacific Islander, PDRR: Participant to Disease-prevalence Representation Ratio

\*Not calculate because reported as "Native American, Alaska Native, or Pacific Islander"

OASIS-4 was excluded due to the lack of a publication or presentation describing the relevant categories.

**Table D1.11. Sex and Age**

	Sex				Age		
	Male	Female	Score	Rating	Older Adults (≥65 years)	Score	Rating
<b>Prevalence/ Incidence</b>	48.35%	51.65%	-	-	16.56%	-	-
<b>STEP-1</b>	25.90%	74.10%	-	-	NR	-	-
<b>PDRR</b>	0.54	1.43	-	-	NC	-	-
<b>Score</b>	2	3	5	Fair	NC	NC	NC
<b>STEP-3</b>	19.00%	81.00%	-	-	NR	-	-
<b>PDRR</b>	0.39	1.57	-	-	NC	-	-
<b>Score</b>	1	3	4	Poor	NC	NC	NC
<b>STEP-4</b>	21.00%	79.00%	-	-	NR	-	-
<b>PDRR</b>	0.43	1.53	-	-	NC	-	-
<b>Score</b>	1	3	4	Poor	NC	NC	NC
<b>STEP-5</b>	22.40%	77.60%	-	-	NR	-	-
<b>PDRR</b>	0.46	1.50	-	-	NC	-	-
<b>Score</b>	1	3	4	Poor	NC	NC	NC
<b>STEP-8</b>	21.60%	78.40%	-	-	NR	-	-
<b>PDRR</b>	0.45	1.52	-	-	NC	-	-
<b>Score</b>	1	3	4	Poor	NC	NC	NC
<b>STEP-9</b>	18.40%	81.60%	-	-	18.90%	-	-
<b>PDRR</b>	0.38	1.58	-	-	1.14	-	-
<b>Score</b>	1	3	4	Poor	3	3	Good
<b>STEP-10</b>	29.00%	71.00%	-	-	NR	-	-
<b>PDRR</b>	0.60	1.37	-	-	NC	-	-
<b>Score</b>	2	3	5	Fair	NC	NC	NC
<b>SURMOUNT</b>	32.50%	67.50%	-	-	6.00%	-	-
<b>PDRR</b>	0.67	1.31	-	-	0.36	-	-
<b>Score</b>	2	3	5	Fair	1	1	Poor
<b>SURMOUNT-3</b>	37.10%	62.90%	-	-	NR	-	-
<b>PDRR</b>	0.77	1.22	-	-	NC	-	-
<b>Score</b>	2	3	5	Fair	NC	NC	NC
<b>SURMOUNT-4</b>	29.40%	70.60%	-	-	10.00%	-	-
<b>PDRR</b>	0.61	1.37	-	-	0.60	-	-
<b>Score</b>	2	3	5	Fair	2	2	Fair
<b>SURMOUNT-5</b>	35.30%	64.70%	-	-	7.90%	-	-
<b>PDRR</b>	0.73	1.25	-	-	0.48	-	-
<b>Score</b>	2	3	5	Fair	1	1	Poor
<b>SURMOUNT-OSA</b>	69.70%	30.30%	-	-	NR	-	-
<b>PDRR</b>	1.44	0.59	-	-	NC	-	-

	Sex				Age		
	Male	Female	Score	Rating	Older Adults (≥65 years)	Score	Rating
Score	2	3	5	Fair	NC	NC	NC
SELECT	72.30%	27.70%	-	-	38.20%	-	-
PDRR	1.50	0.54	-	-	2.31	-	-
Score	3	2	5	Fair	3	3	Good
SURPASS-CVOT	71.10%	28.90%	-	-	NR	-	-
PDRR	1.47	0.56	-	-	NC	-	-
Score	3	2	5	Fair	NC	NC	NC
STEP-HFpEF	43.90%	56.10%	-	-	NR	-	-
PDRR	0.91	1.09	-	-	NC	-	-
Score	3	3	6	Good	NC	NC	NC
ESSENCE	42.90%	57.10%	-	-	NR	-	-
PDRR	0.89	1.11	-	-	NC	-	-
Score	3	3	6	Good	NC	NC	NC
SUMMIT	46.20%	53.80%	-	-	NR	-	-
PDRR	0.96	1.04	-	-	NC	-	-
Score	3	3	6	Good	NC	NC	NC

NC: Not Calculated, PDRR: Participant to Disease-prevalence Representation Ratio; OASIS-4 was excluded due to lack of a publication or presentation describing the relevant data.

## Assessment of Level of Certainty in Evidence

We used the [ICER Evidence Rating Matrix](#) to evaluate the level of certainty in the available evidence of a net health benefit among each of the interventions of focus.<sup>147,148</sup>

## Assessment of Bias

As part of our quality assessment, we evaluated the evidence base for the presence of potential publication bias. Given the emerging nature of the evidence base for these treatments, we scanned the ClinicalTrials.gov site to identify studies completed more than two years ago. Search terms include: “Obesity”, “Semaglutide”, and “Tirzepatide”. We scanned the site to identify studies which would have met our inclusion criteria and for which no findings have been published and did not find any evidence of publication bias.

## Data Synthesis and Statistical Analyses

Data on relevant outcomes were summarized in evidence tables (see Section D3) and synthesized quantitatively and qualitatively in the body of the review. We evaluated the feasibility of conducting a quantitative synthesis by exploring the differences in study populations, study design, analytic methods, and outcomes.

### ***Meta-Analyses Methods***

We conducted random-effects pairwise meta-analyses to compare injectable semaglutide with placebo across multiple pre-specified efficacy and safety outcomes. The assessed efficacy outcomes included percent change in body weight loss from baseline, percent change in SBP from baseline, and percent change in HbA1C from baseline. Safety outcomes included all-cause discontinuations, discontinuations due to AEs, and severe GI side effects. For continuous outcomes (percent body weight loss, SBP, and HbA1C), we used restricted maximum-likelihood estimator (REML) to address heterogeneity and the classical inverse variance formula to calculate the variance of the pooled estimate. Results for continuous outcomes were presented as mean difference (MD) with 95% confidence intervals. For binary outcomes (discontinuations and GI side effects), we used Paule-Mandel estimator (PM) to address heterogeneity and classical inverse variance formula to calculate the variance of the pooled estimate. Results for binary outcomes were presented as rate ratios (RR) with 95% confidence intervals. All statistical analyses were performed using R Statistical Software (version 4.2.1) and data packages tidyverse, meta, and dmetar. Results of the meta-analyses are reported in the main report and supplemental section D.

### ***Feasibility of Conducting Network Meta-Analysis (NMA)***

We examined the feasibility of conducting indirect comparisons or an NMA because direct evidence for the cardiovascular outcomes of tirzepatide versus placebo for patients with obesity and diabetes was not available. Tirzepatide was compared against dulaglutide in the SURPASS CVOT trial while dulaglutide was compared against placebo in the REWIND trial. We examined whether there were notable differences in study populations, study design, intervention type, outcome definition and measurement, and analytic methods, as well as quality of these two trials. Both trials were deemed sufficiently similar in terms of population, design, intervention type, outcome definitions or measurement, and analytic methods. However, only topline data from the SURPASS CVOT trial were available. As such, due to data limitations, we were not able to conduct the NMA at the time of this draft report.

All data analyses were validated by an independent member of the research team. The validator reviewed and confirmed the data analysis methods, data format, and analysis code. The validator re-ran the analysis, validated the results, and confirmed the appropriateness of reported data.

## D2. Additional Clinical Effectiveness Results

### Additional Evidence Base

The main report includes primary sources of data and key evidence to inform our review of injectable semaglutide, oral semaglutide and tirzepatide for the treatment of obesity. In this supplement, we describe details about additional trials that are either briefly mentioned or not included in the main report.

For injectable semaglutide, we provide additional details about the STEP trials. Here, we also discussed four Phase III trials for injectable semaglutide, evaluating outcomes related to weight regain (STEP 4) and obesity-related complications such as knee osteoarthritis (STEP 9), HFpEF (STEP-HFpEF) and metabolic-dysfunction associated hepatitis (ESSENCE). No additional trials were identified for oral semaglutide at a dose 25 mg. For tirzepatide, here we provided details about three Phase III trials that assessed weight regain (SURMOUNT 4), OSA (SURMOUNT-OSA), and cardiovascular outcomes (SUMMIT). Although both ESSENCE and SUMMIT trials included participants with obesity irrespective of their diabetes status, subgroup analyses on participants without diabetes were available.

#### *Injectable Semaglutide*

The study design and baseline characteristics for STEP 1, STEP 3, STEP 5, STEP 8, and STEP 10 are briefly described in the main report. Additional exclusion criteria for all STEP trials to highlight included self-reported change in body weight >5kg or obesity medication within 90 days before screening, previous or planned bariatric surgery during the trial, history of major depressive disorder within 2 years before screening, history of suicidal attempt, diagnosis of other severe psychiatric disorders, uncontrolled thyroid disease, and history of acute pancreatitis within 180 days before screening.<sup>22-26</sup> STEP 1, STEP 3, and STEP 5 had co-primary endpoints of percentage change in body weight from baseline to end of trial and achievement of  $\geq 5\%$  body weight loss.<sup>22-24</sup> The primary endpoint for STEP 8 was percent change in body weight from randomization to week 68.<sup>26</sup> STEP 10 had a co-primary endpoint of change from baseline in percent body weight at week 52 and proportion of participants achieving normoglycemia (HbA1C <6%).<sup>25</sup> See Supplement Table D2.4. for additional details about study design. Baseline characteristics of these trials are presented in Supplement Tables D2.1 and D2.5.

**Table D2.1. Overview of Key Trials of Injectable Semaglutide versus Placebo**

Trials	STEP 1 <sup>22</sup>		STEP 3 <sup>23</sup>		STEP 5 <sup>24</sup>		STEP 8 <sup>26</sup>		STEP 10 <sup>25</sup>		
	SEM	PBO	SEM	PBO	SEM	PBO	SEM	PBO	SEM	PBO	
Study Arms											
Sample Size	1306	655	407	204	152	152	126	85	138	69	
Mean Age, Years (SD)	46 (13)	47 (12)	46 (13)	46 (13)	47 (12)	47 (10)	48 (14)	51 (12)	53 (11)	53 (11)	
Female, %	73%	76%	77%	88%	81%	74%	81%	78%	72%	68%	
Race and Ethnicity, %	White	75%	76%	75%	78%	93%	93%	75%	71%	90%	86%
	Black	6%	6%	20%	18%	5%	3%	20%	22%	4%	4%
	Asian	14%	12%	1%	3%	1%	0%	3%	4%	3%	7%
	Hispanic	12%	13%	18%	23%	12%	14%	12%	8%	4%	1%
Baseline Weight (SD), kg	105 (22)	105 (22)	107 (23)	104 (23)	106 (21)	107 (23)	103 (25)	109 (23)	112 (22)	111 (24)	
Baseline BMI (SD), kg/m <sup>2</sup>	38 (7)	38 (7)	38 (7)	38 (7)	39 (7)	39 (7)	37 (7)	39 (7)	40 (7)	40 (8)	
Mean HbA1C (SD), %	5.7 (0.3)	5.7 (0.3)	5.7 (0.3)	5.8 (0.3)	5.7 (0.3)	5.7 (0.4)	5.5 (0.3)	5.6 (0.4)	5.9 (0.3)	5.9 (0..3)	
Mean Systolic Blood Pressure (SD), mmHg	126 (14)	127 (14)	124 (15)	124 (15)	126 (14)	125 (15)	125 (14)	123 (14)	131 (15)	129 (15)	
Mean eGFR (SD), mL/min/1.73m <sup>2</sup>	96 (19)	96 (18)	97 (21)	97 (21)	96 (17)	93 (18)	96 (21)	92 (20)	NR	NR	
At Least One Comorbidity, %	75%	75%	76%	76%	NR	NR	75%	81%	80%	81%	

BMI: body mass index, eGFR: estimated glomerular filtration rate, HbA1C: hemoglobin A1C, kg: kilogram, m: meter, mmHg: millimeter of mercury, mL: milliliter, min: minute, NR: not reported, PBO: placebo, SD: standard deviation, SEM: semaglutide

### SELECT

The SELECT trial, a large Phase III RCT, examined the effect of injectable semaglutide 2.4 mg on CV outcomes in patients with obesity and without diabetes. A total of 17,604 patients were randomized 1:1 to injectable semaglutide or placebo as an adjunct to standard of care. Participants were eligible to enroll in the trial if they were  $\geq 45$  years old, had a BMI of  $\geq 27$ , and had established CV disease defined as a previous myocardial infarction (MI), stroke, or symptomatic peripheral arterial disease (PAD). Participants were excluded if they had a diagnosis of diabetes or were treated with glucose-lowering or GLP-1 medications in the last 90 days.<sup>18</sup> See Supplement Table D2.4.

Baseline characteristics were similar across the arms. The mean age of trial participants was 62 years. Participants were mostly male (72%) and White (84%), with a mean BMI of 33. About 76% of the trial participants experienced a previous MI, and 23% had a stroke. The mean study follow-up period was 40 months.<sup>18</sup> See Supplement Table D2.9.

#### STEP 4

The objective of the STEP 4 trial was to study the effects of continuing versus withdrawing semaglutide on weight loss maintenance. Participants enrolled in the STEP 4 trial underwent a 20-week dose escalation period receiving semaglutide weekly and then were randomized to either semaglutide 2.4 mg plus lifestyle intervention or placebo plus lifestyle intervention for 52 additional weeks (total 68 weeks). The inclusion and exclusion criteria were similar to the other STEP trials.<sup>149</sup> See Supplement Table D2.4.

Prior to the run-in period, the baseline weight and BMI for all trial participants (N = 803) were 107.2 kg and 38.4. These decreased to 96 kg and 34, respectively, at the time of randomization. The mean age for trial participants was 47 years and a majority of them were female (79%) and White (86%). Over 70% of the trial participants had at least one comorbid condition. Overall, baseline characteristics were comparable between those who continued injectable semaglutide and those who switched to placebo after the run-in period.<sup>149</sup> See Supplement Table D2.13.

#### STEP 9

STEP-9 studied the effects of injectable semaglutide on adults with obesity and moderate to severe knee osteoarthritis (OA). Trial design included a 16-week dose escalation period, a 52-week on-treatment follow-up, and a 7-week off-treatment follow-up period. Adult participants were eligible if they had a BMI of  $\geq 30$ , a clinical diagnosis of knee OA with moderate radiographic changes in the target knee, and had completed a 72-hour washout period of analgesics. Participants with HbA1C  $\geq 6.5\%$ , joint replacement in target knee, arthroscopy or injections in target knee in the last 3 months, previous or planned obesity related surgery, and uncontrolled thyroid disease were excluded from the trial. The co-primary endpoints were percent change in body weight and changes in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score from baseline.<sup>27</sup> See Supplement Table D2.4.

Participants (271 in the semaglutide arm and 136 in the placebo arm) were around 56 years of age, female (82%), predominantly White (61%) and American Indian or Alaska Native (12%), and had a mean BMI of 40. The baseline WOMAC pain score was 71 (SD 16). Approximately half of the adult participants had hypertension and 31% had dyslipidemia.<sup>27</sup> Additional baseline characteristics are reported in Supplement Table D2.12.

#### STEP-HFpEF

The STEP-Heart Failure with Preserved Ejection Fraction (STEP-HFpEF) trial assessed cardiovascular outcomes in addition to weight loss in a population with existing HFpEF. Trial enrollees were randomized 1:1 to semaglutide 2.4 mg or placebo as an add-on to standard of care for 52 weeks. Adults  $\geq 18$  years of age were included if they had a BMI of  $\geq 30$ , left ventricular ejection fraction  $\geq 45\%$ , New York Heart Association (NYHA) class II-IV, a Kansas City Cardiomyopathy Questionnaire

clinical summary score (KCCQ-CSS) of <90 points, and were able to perform the six minute walk distance of at least 100 meters. Participants were also required to have one of the following: elevated left ventricular filling pressure, elevated natriuretic peptide level plus echocardiographic abnormalities, or hospitalization for heart failure in the last 12 months plus ongoing treatment with diuretics or echocardiographic abnormalities. Participants with prior myocardial infarction, stroke, unstable angina pectoris, hospitalization for heart failure, or transient ischemic attack during the last 30 days were excluded. The co-primary endpoints were change in the KCCQ-CSS and percent change from baseline in body weight at week 52.<sup>29</sup> See Supplement Table D2.4.

The STEP-HFpEF trial participants (N=529) were mostly older adults (69 years of age), female (56%), predominantly White (96%), with a mean BMI of 37 and a median KCCQ-CSS score of 59 points. Approximately two-thirds of the trial participants were classified as NYHA functional class II; the remaining were class III or IV. The most common comorbidities among trial participants were hypertension (82%) and atrial fibrillation (52%).<sup>29</sup> See Supplement Table D2.11.

### ESSENCE Trial

The ESSENCE trial randomized a total of 1197 participants 2:1 to receive injectable semaglutide 2.4 mg or placebo in addition to standard care for MASH or related conditions. Adult participants were enrolled if they had histologically documented steatohepatitis and liver fibrosis of stage 2 or 3 and a nonalcoholic fatty liver disease activity score (NAS) of  $\geq 4$ . Participants with HbA1C  $\geq 9.5\%$ , chronic liver disease other than metabolic dysfunction-associated steatotic liver disease (MASLD), relevant alcohol consumption or dependence, aspartate aminotransferase (AST)  $>5$  times the upper limit of normal (ULN), or alanine aminotransferase (ALT)  $>5$  ULN were excluded from the trial. The trial follow-up period was designed in two parts, with the first part ending at week 72 and the second part continuing until week 240. The 72-week endpoints were the resolution of steatohepatitis with no worsening of liver fibrosis and a reduction in liver fibrosis with no worsening of steatohepatitis. The 240-week primary endpoint was cirrhosis-free survival.<sup>28</sup> See Supplement Table D2.2.

Baseline characteristics were presented for the first 800 patients enrolled in the ESSENCE trial and were similar across the arms. Participants were around 56 years of age, with a mean BMI was 35. Although most participants were White (68%), the trial enrolled a substantial proportion of Asian participants (28%). Approximately 56% of the participants had type 2 diabetes.<sup>28</sup> See Supplement Table D2.11.

### **Oral Semaglutide**

#### OASIS 4

The trial had co-primary endpoints of percent change in body weight and proportion of participants with  $\geq 5\%$  body weight loss.<sup>39</sup> The mean age for all participants was 48 years and around 80% were

female, with a mean BMI of 38. The trial participants were predominantly White (92%), with Black participants (7%) representing most of the remaining sample. The mean HbA1C was 5.7% and the mean systolic blood pressure was 131 mmHg.<sup>39</sup> See Supplement Table D2.6.

## ***Tirzepatide***

### *SURMOUNT 1 and SURMOUNT 3*

The co-primary endpoints for both SURMOUNT 1 and SURMOUNT 3 trials were percent change in body weight and proportion of participants achieving  $\geq 5\%$  body weight loss.<sup>42,43</sup> Participants in the SURMOUNT 1 and SURMOUNT 3 trials had largely similar baseline characteristics. Participants enrolled in SURMOUNT 1 had slightly higher baseline BMI (38) than participants in the SURMOUNT 3 trial (36).<sup>42,43</sup> See Supplement Tables D2.2 and D2.7.

**Table. D2.2. Overview of Key Trials of Tirzepatide versus Placebo**

Trials		SURMOUNT 1 42		SURMOUNT 3 43	
		TZP	PBO	TZP	PBO
Study Arms					
Sample Size		630	643	287	292
Mean Age (SD), Years		45 (12)	44 (13)	45 (13)	46 (12)
Female, %		68%	68%	63%	63%
Race and Ethnicity, %	White	70%	70%	86%	86%
	Black	8%	9%	11%	11%
	Asian	11%	11%	1%	1%
	Hispanic	48%	48%	53%	55%
Baseline Weight (SD), kg		106 (23)	105 (21)	103 (22)	101 (21)
Baseline BMI (SD), kg/m <sup>2</sup>		38 (7)	38 (7)	36 (6)	36 (6)
Mean HbA1C (SD), %		5.6 (0.4)	5.6 (0.4)	5.3 (0.4)	5.4 (0.4)
Mean Systolic Blood Pressure (SD), mmHg		123 (13)	123 (13)	121 (13)	121 (12)
Mean eGFR (SD), mL/min/1.73m <sup>2</sup>		98 (18)	98 (18)	96 (17)	97 (17)
At least One Comorbidity, %		61%	62%	67%	66%

BMI: body mass index, eGFR: estimated glomerular filtration rate, HbA1C: hemoglobin A1C, kg: kilogram, m: meter, mL: milliliter, min: minute, mmHg: millimeter of mercury, PBO: placebo, SD: standard deviation, TZP: tirzepatide

### *SURMOUNT 5*

The primary endpoint for the SURMOUNT 5 trial was percent change from baseline in body weight at week 72.<sup>44</sup> Overall, baseline characteristics were similar across the arms. The trial participants were around 45 years of age and mostly female (65%). Although the majority of participants were White (76%), the trial enrolled a substantial proportion of Blacks (19%) and Hispanics (26%). Participants had a baseline BMI of 39 and a mean HbA1C of 5.6%. At baseline, the mean systolic blood pressure was 126 mm Hg and the mean eGFR was 105 mL/min/1.73 m<sup>2</sup>. Over three-quarters of trial participants had at least one comorbid condition. Common obesity-related complications

included hypertension (40%), dyslipidemia (24%), impaired glucose metabolism (19%), anxiety (18%), and OSA (15%).<sup>44</sup> See Supplement Table D2.8.

#### SURPASS CVOT

The SURPASS CVOT evaluated the CV impacts of tirzepatide 15 mg compared to dulaglutide 1.5 mg in adults with T2D and atherosclerotic cardiovascular disease (ASCVD). Participants could enroll if they were  $\geq 40$  years old, had HbA1C between 7% and 10.5%, BMI  $\geq 25$ , and ASCVD. Key exclusion criteria included CV event or intervention in the 60 days prior to screening, hospitalization for heart failure in the two months prior to screening or chronic New York Heart Association (NYHA) functional classification IV heart failure, liver disease, end-stage kidney disease (ESKD) or on chronic dialysis, history of acute or chronic pancreatitis, planned coronary, carotid, or peripheral artery revascularization, or treatment with GLP-1 RA within the last three months.<sup>45</sup>

Baseline characteristics were not available by treatment arm for this currently unpublished trial. Overall, participants were mostly male (71%), had a mean age of 64 years, and a mean BMI of 33. About two-thirds of participants had a history of MI (47%) or stroke (19%).<sup>45</sup>

#### SURMOUNT 4

SURMOUNT 4 studied the effect of continued treatment with or withdrawal of tirzepatide on body weight. The trial included a 36-week, open-label lead-in period followed by a 52-week, double-blind period. Participants were treated with tirzepatide at maximum tolerated dose in the lead-in period and later randomized to either tirzepatide or placebo at week 36. The inclusion and exclusion criteria were similar to other SURMOUNT trials discussed in the main report. The primary endpoint was percent change in body weight from randomization to week 88, with a key secondary endpoint focusing on weight maintenance and regain.<sup>150</sup> See Supplement Table D2.4.

In total, 783 participants were enrolled to initiate tirzepatide and 670 of them later randomized to either tirzepatide or placebo. The baseline weight and BMI for all trial participants were 107.3 kg and 38 prior to the lead-in period, then decreased to 85 kg and 30, respectively, by the time of randomization. Systolic blood pressure also decreased from 126 mm Hg to 115 mm Hg and HbA1C slightly reduced from 5.54% to 5.04%. Baseline characteristics were comparable at randomization.<sup>150</sup> See Supplement Table D2.13 for additional details.

#### SURMOUNT OSA

SURMOUNT-OSA consisted of two identical Phase III trials that evaluated the maximum tolerated dose of tirzepatide (10 mg or 15 mg) plus lifestyle intervention versus placebo plus lifestyle intervention in adults with obesity (BMI  $\geq 30$ ) and moderate to severe obstructive sleep apnea (OSA). Trial 1 enrolled participants who were unable or unwilling to use positive airway pressure (PAP) therapy, while trial 2 recruited participants using PAP therapy for  $\geq 3$  months and planned to

continue the therapy during the trial. Participants with type 1 or type 2 diabetes were excluded from the trial. Additional exclusion criteria included a change in body weight >5 kg in the last 3 months, planned surgery for sleep apnea or obesity, diagnosis of central or mixed sleep apnea, or major craniofacial abnormalities. The primary endpoint was the change in apnea-hypopnea index (AHI) from baseline at week 52.<sup>20</sup> See Supplement Table D2.4.

The investigators randomized a total of 234 participants in trial 1 and 235 participants in trial 2. Overall, baseline characteristics were similar across arms and trials. Trial 1 enrolled participants with a mean age of 48 years, most were male (67%), and White (66%). The mean BMI was 39 and the mean AHI was 52 events per hour. In trial 2, participants had a mean age of 52 years, were mostly male (72%) and White (73%). The mean BMI was 39 and the mean AHI was 50 events per hour. There were numerical differences in the sleep apnea-specific hypoxic burden between groups in both trials.<sup>20</sup> See Table 3.4 and Supplement Table D2.10.

### SUMMIT

The SUMMIT trial examined the effects of tirzepatide in a HFpEF population. Participants were randomized 1:1 to receive tirzepatide or placebo in addition to usual therapy. Participants were eligible for the trial if they were ≥40 years, had chronic heart failure (NYHA class II-IV), a left ventricular ejection fraction ≥50%, and a BMI of ≥30. Participants were also required to have one of the following: elevated NT-proBNP, evidence of left atrial enlargement, or evidence of elevated left ventricular filling pressure. Additional inclusion criteria included a KCCQ-CSS of ≤80, a six-minute walk distance of between 100 and 425 meters, heart failure decompensation in the last 12 months, and an eGFR <70 ml/min/1.73 m<sup>2</sup>. Participants with prior myocardial infarction, stroke, unstable angina pectoris, coronary artery bypass surgery or other major cardiovascular surgery, or transient ischemic attack during the last 90 days, or stage 5 chronic kidney disease were excluded. The co-primary endpoints were time to first event of cardiovascular death or worsening heart failure events and change in the KCCQ-CSS at week 52.<sup>47</sup> See Supplement Table D2.4.

In total, 731 patients (364 in the tirzepatide group and 367 in the placebo group) with obesity and HFpEF were randomized. At baseline, the mean age for participants was 65 years; 54% of them were women and 70% were White. The mean BMI was 38 and the mean KCCQ-CSS was 54 points. Approximately 48% of the trial participants had type 2 diabetes and 47% of the participants had a hospitalization or urgent care visit for worsening heart failure in the last 12 months.<sup>47</sup> See Supplement Table D2.11.

### **Observational Studies**

#### Direct Comparison (Semaglutide vs Tirzepatide)

Rodriguez et al 2024 used electronic health record (EHR) data linked to dispensing information to assess weight loss and rates of gastrointestinal adverse events. Adults were included if they had a

diagnosis code for overweight or obese in the year before their index date, defined as initiation of tirzepatide 5 mg or semaglutide 0.5 mg labeled for diabetes. The primary outcome was percent change in weight loss from baseline. Patients initiating tirzepatide were younger, mostly female, White, and had a lower prevalence of T2D compared to those initiating semaglutide. Propensity scores were used to balance treatment groups, with a sample size of 9,193 for tirzepatide and 9,192 for semaglutide after matching.<sup>32</sup> See Supplement Table D2.3.

Baser et al 2024 utilized a large cohort from the Kythera database, which included three anti-obesity medication groups (semaglutide, tirzepatide, and liraglutide) and one AOM non-user group. A subgroup analysis with 23,933 patients in the semaglutide and 12,854 patients in the tirzepatide group was available. Patients were required to have a clinical diagnosis of obesity before index date (i.e., first prescription claim) and continuous medical and pharmacy benefits data for the last 12 months. Participants in the tirzepatide group were slightly older and comorbidities were more common than semaglutide group. The primary outcome was incidence of OA.<sup>31</sup> See Supplement Table D2.3.

Anson et al 2024 conducted another large study using the TriNetX database with two adult cohorts: one with T2D (N=8,446) and another without T2D (N=13,846). The study incorporated a new user design where patients were included and followed for at least 12 months. After matching, the mean age for all patients without T2D was 48 years and 73% were female. The primary outcome was incidence of T2D.<sup>30</sup> See Supplement Table D2.3.

Huang et al 2024 was a retrospective study that included 8,840 propensity score matched pairs of tirzepatide and semaglutide users from the TriNetX US database. Patients were excluded if they had a history of T1D or T2D, HIV, ESKD, or any study medication use in the last six months. The outcomes of interest were ocular health outcomes, including incidence of cataracts, oculomotor binocular dysfunction, visual issues and blindness, visual disturbances, dry eye disease, and ametropic accommodative dysfunction.<sup>33</sup> See Supplement Table D2.3.

### *Injectable Semaglutide*

Ruseva et al 2025 used Komodo Health Database and included 4,424 individuals treated with injectable semaglutide 2.4 mg for the management of obesity. The study endpoints included changes in body weight, BMI, and other cardiometabolic biomarkers (i.e., SBP, HbA1C, LDL etc.) with a follow-up period of 68 weeks, mimicking the clinical trials.<sup>38</sup> Baser et al 2024 identified 1,360 individuals with obesity diagnosis receiving semaglutide and compared them with 39,891 obese individuals not taking semaglutide to assess the risk of osteoarthritis.<sup>35</sup> Wang et al 2023 investigated the risk of suicidal ideation associated with semaglutide compared with non-GLP1 medications.<sup>36</sup> Able et al 2024 identified total of 3,094 non-diabetic obese men using semaglutide were matched with non-user controls from TriNetX database to assess the risk of erectile dysfunction.<sup>34</sup> Gleason et al 2024 measured adherence and persistence to GLP-1 treatments for

obesity using data from integrated pharmacy and medical claims. Their cohort comprised 4,066 patients with obesity using different GLP-1 products, excluding those with a diagnosis of diabetes. Persistence and adherence data relevant to only Wegovy® and Rybelsus® (off-label use) were extracted from this study.<sup>37</sup> See Supplement Table D2.3.

### Tirzepatide

Hankosky et al 2024 first evaluated persistence, changes in body weight, and BMI among 20,998 non-diabetic, anti-obesity medication-eligible individuals using the Optum's Market Clarity Database.<sup>48</sup> Subsequently, Hankosky et al 2025 published a study of 4,177 individuals from the Healthcare Integrated Research Database assessing persistence, utilization patterns, and changes in body weight.<sup>49</sup> Hunter Gibble et al 2024 investigated the real-world use of tirzepatide (i.e., adherence and persistence) among anti-obesity medication-eligible cohort of patients (N=10,193) using the Verdigm database.<sup>50</sup> Additionally, a separate large-scale, propensity score-matched study by Wu et al 2025 evaluated the impacts of tirzepatide compared with lifestyle interventions on all-cause mortality, major adverse cardiovascular events (MACE), and major adverse kidney events (MAKE) in 42,300 individuals with OSA and obesity.<sup>151</sup> See Supplement Table D2.3.

**Table D2.3. Summary of Included Observational Studies**

Author, Year	Comparators	Database	N	Outcome(s) Assessed
<b>Semaglutide</b>				
Ruseva, 2025	Semaglutide	Komodo Health	4,424	Body weight, BMI, Cardiometabolic outcomes
Baser, 2024	Semaglutide	Kythera Medicare	1,360	Risk of osteoarthritis
	Non-user		39,891	
Wang, 2023	Semaglutide	TriNetX	52,783	Risk of suicidal ideation
	Other AOM		52,783	
Able, 2024	Semaglutide	TriNetX	3,094	Risk of erectile dysfunction
	Non-user		3,094	
Gleason, 2024	Injectable Semaglutide	Integrated medical and pharmacy claims	419	Adherence and Persistence
	Oral Semaglutide		285	
<b>Tirzepatide</b>				
Hankosky, 2023	Tirzepatide	Optum’s Market Clarity	20,998	Persistence and Weight loss
Hankosky, 2024	Tirzepatide	Healthcare Integrated Research	4,177	Persistence and Weight loss
Hunter-Gibble, 2024	Tirzepatide	Veradigm’s Network EHR and claims	10,193	Adherence and Persistence
Wu, 2025	Tirzepatide	TriNetX	21,150	All-cause mortality, MACE, and MAKE
	Placebo		21,150	
<b>Direct Comparison (Tirzepatide vs. Semaglutide)</b>				
Rodriguez, 2024	Tirzepatide	Truveta	4,420	Weight loss and GI side effects
	Semaglutide		4,402	
Baser, 2024	Tirzepatide	Kythera	12,854	Incidence of OA
	Semaglutide		23,933	
Anson, 2024	Tirzepatide	TriNetX	6,923	Incidence of T2D
	Semaglutide		6,923	
Huang, 2024	Tirzepatide	TriNetX	8,840	Ocular outcomes
	Semaglutide		8,840	

AOM: anti-obesity medication, BMI: body mass index, EHR: electronic health record, GI: gastrointestinal, MACE: major adverse cardiovascular events, MAKE: major adverse kidney events, OA: osteoarthritis, T2D: type 2 diabetes

## Additional Clinical Benefits

### *Injectable Semaglutide*

#### Additional Meta-Analyses of STEP Trials

In a pooled meta-analysis of STEP 1, STEP 3, and STEP 8 trials, participants treated with semaglutide had statistically significantly greater reductions in mean SBP (change from baseline -5.96, 95% CI: -8.96 to -2.95;  $I^2=70%$ ) and mean HbA1C (change from baseline -0.31; 95% CI: -0.40 to -0.22;  $I^2=86%$ ) than those treated with placebo.<sup>22,23,26</sup> STEP 5 and STEP 10 trials were excluded from the meta-analysis due to study design differences; however, results from these trials also showed similar reductions in these outcomes.

#### STEP 1

A post-hoc analysis of the STEP 1 trial reported that participants achieving greater weight loss showed greater physical functioning improvements in these two instruments.<sup>152</sup>

The STEP 1 trial assessed body composition using dual energy X-ray absorptiometry (DEXA) in a subset of participants. Participants in the DEXA subpopulation (N = 140) were slightly older (51 years) and had lower baseline body weight (98 kg) and BMI (35) compared to the overall study population. Baseline body compositions were comparable between injectable semaglutide and placebo. Body composition data at week 68 showed that there was greater reduction in total fat mass (7 kg, percent point change -3%), regional visceral fat mass (-0.3 kg, percent point change -2%), and total lean body mass (-3 kg, percent point change -3%) with injectable semaglutide compared with placebo.<sup>22</sup> See Supplement Table D2.42.

In the STEP 1 trial extension, which included 327 participants, both treatment groups experienced weight regain one year after the withdrawal of semaglutide. The semaglutide arm regained a mean of 11.6% of weight from week 68 to 120, while the placebo arm regained a mean of 1.9% from week 68 to 120. Data also showed increases in BMI and cardiometabolic risk factors including SBP, HbA1C, and LDL cholesterol, in both treatment groups from week 68 to week 120; thus returning to the baseline values. Other STEP trials also included off-treatment follow-up periods ranging from 7 to 28 weeks, but did not measure weight regain.<sup>62</sup>

#### STEP 5

Data from the STEP 5 trial suggested a statistically significant difference between injectable semaglutide 2.4 mg and placebo on percent weight change from baseline (mean difference -8.51%; 95% CI: -8.75% to -8.27%) after 104 weeks.<sup>24</sup>

In an exploratory analysis, the STEP 5 trial assessed the intensity and type of food cravings using the 19-item Control of Eating Questionnaire (CoEQ). This questionnaire included four domains with 17 items related to craving control, positive mood, craving for savory, and craving for sweet, each scored on a 0 to 10 scale, and two questions related to hunger and fullness. Among 174 participants completing the questionnaire, the percent mean body weight change from baseline to week 104 was -14.8% in the injectable semaglutide group compared to -2.4% in the placebo group (mean difference -12.4; 95% CI: -16.2 to -8.5). Semaglutide treatment improved all domain scores compared to placebo over the follow-up period, but only craving control and craving for savory domain scores showed statistically significant differences at week 104. Treatment with injectable semaglutide also led to improvement in scores for hunger and fullness, but were only statistically significant for short-term follow-up (week 20).<sup>153</sup>

#### STEP 4

The STEP 4 trial showed that participants who continued injectable semaglutide after the 20-week run in period lost an additional mean of 7.9% of body weight at week 68; in contrast, those who were assigned to placebo gained a mean of 6.9% from week 20 to week 68, suggesting substantial weight regain upon discontinuation of injectable semaglutide.<sup>149</sup> See Supplement Table D2.31.

#### STEP 9

The STEP 9 trial co-primary endpoints were mean body weight change from baseline and mean WOMAC pain score change from baseline to week 68. reported a -13.7% mean body weight change from baseline in the semaglutide group compared to only -3.2% changes in the placebo group (mean difference -10.5; 95% CI: -12.3 to -8.6). Injectable semaglutide demonstrated a greater reduction in the WOMAC pain score compared to the placebo group at week 68 (-41.7 points vs. -27.5 points), with a mean difference of -14.1 points (95% CI: -20 to -8.3). Secondary endpoint data also suggest a significantly greater improvement in the WOMAC physical function score in the semaglutide arm (-41.5 points) compared to the placebo arm (-26.7 points). In an exploratory analysis of STEP 9, participants with obesity and knee OA receiving injectable semaglutide achieved a greater mean improvement in six-minute walk distance from baseline to week 68 than those receiving placebo (56.8 m vs. 14.2 m, mean difference 42.6; 95% CI: 25.6 to 59.7).<sup>27</sup> See Supplement Table D2.30.

## SELECT

In another prespecified analysis, semaglutide demonstrated a lower risk (HR 0.80; 95% CI: 0.73 to 0.87) of first MACE-5 events, defined as CV death, non-fatal MI, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina.<sup>154</sup> At week 208, the mean percent body weight change from baseline for injectable semaglutide and placebo were -10.2 and -1.5, with a mean difference of -8.7 (95% CI: -9.4 to -7.9;  $p < 0.0001$ ).<sup>81</sup> The SELECT trial comparing injectable semaglutide versus placebo assessed EQ-5D-5L index score (0-1) and VAS score (0-100) for measures of HRQoL, with higher scores indicating better patient-reported health status. The mean difference for EQ-5D-5L index score was 0.01 (95% CI: 0.01 to 0.02) and for VAS score was 1.60 (95% CI: 1.16 to 2.04). Both scores were statistically significant and favored injectable semaglutide 2.4 mg over placebo in adults with obesity and preexisting CVD. Additionally, participants receiving injectable semaglutide had statistically significantly greater reductions in changes from baseline SBP (mean difference -3.31), HbA1C (mean difference -0.32), and LDL cholesterol (mean difference -2.18) at week 104 compared to placebo.<sup>18</sup> See Supplement Table D2.27.

## STEP HFpEF

The STEP-HFpEF trial co-primary endpoints were percent body weight change from baseline and KCCQ-CSS score change from baseline to week 52. There was a greater body weight change from baseline in the injectable semaglutide arm (-13.3%) compared to placebo arm (-2.6%), with a mean difference of -10.7% (95% CI: -11.9 to -9.4;  $p < 0.001$ ) at week 52. Semaglutide demonstrated a greater improvement in KCCQ-CSS score from baseline at week 52 compared to placebo (16.6 vs. 8.7, mean difference 7.8; 95% CI: 4.8 to 10.9;  $p < 0.001$ ). Approximately 63% of the semaglutide participants achieved at least 10% increase in KCCQ-CSS score in the semaglutide group compared to 49% in the placebo group (OR 2.1; 95% CI: 1.4 to 3.1). The STEP-HFpEF trial also assessed six-minute walk test as a confirmatory secondary endpoint and semaglutide arm showed an advantage over placebo (mean difference 20.3; 95% CI: 8.6 to 32.1) at week 52.<sup>29</sup> See Supplement Table D2.29.

## ESSENCE

The ESSENCE trial was conducted in two parts. Results related to part one coprimary endpoints were presented in the main report. At week 72, participants receiving injectable semaglutide irrespective of their diabetes status lost -10.5% of baseline body weight compared to -2% in placebo (mean difference -8.5; 95% CI: -9.6 to -7.4;  $p < 0.001$ ).<sup>28</sup> Part 2 of the trial will assess cirrhosis-free survival over 204 weeks, with results expected in 2029. See Supplement Table D2.29.

## ***Tirzepatide***

### *SURMOUNT 1 and SURMOUNT 3*

The SURMOUNT 1 trial also reported 3-year efficacy and safety data evaluating tirzepatide in participants with prediabetes status. At week 176, the mean difference between tirzepatide 15 mg and placebo was -18.4 (95% CI: -22.2 to -14.7), similar to the percent weight loss at one-year post-titration. Additionally, around 87% of trial participants receiving tirzepatide 15 mg achieved at least a 5% weight loss from baseline compared to 30% in the placebo group.<sup>59</sup> SURMOUNT-1 trial showed that higher percentages of weight reductions in the tirzepatide group were associated with greater improvements in these HRQoL assessments.<sup>54</sup>

A total of 160 participants had body composition data from DEXA at both baseline and week 72 in the SURMOUNT 1 trial. Data were pooled for tirzepatide 5 mg, 10 mg, and 15 mg. The mean difference in percent total fat mass changes from baseline was -25.7 (95% CI: -31.4 to -20) and in percent total lean mass changes from baseline was -8.3 (95% CI: -10.6 to -6.1) at week 72. There was a notable reduction in the fat-to-lean mass ratio with tirzepatide (0.93 at baseline to 0.70 at week 72) than placebo (from 0.95 to 0.88).<sup>155</sup>

Both SURMOUNT 1 and SURMOUNT 3 trials reported a mean percent change in urine albumin-creatinine ratio (UACR) from baseline of -9.3% to -12.3% with tirzepatide versus -3.2% to -8.8% with placebo at week 72, indicating a potential protective effects of tirzepatide on renal function.<sup>42,43</sup>

### *SURPASS CVOT*

An analysis reported by the manufacturer using patient-level propensity-matched data from the SURPASS-CVOT and REWIND trials reportedly calculated reductions in MACE (HR 0.72; 95% CI: 0.55 to 0.94) and all-cause mortality (HR 0.61; 95% CI: 0.45 to 0.82) for tirzepatide compared with placebo<sup>46</sup>; however, we do not yet have sufficient data to conduct a network meta-analysis to confirm these findings.

### *SURMOUNT 4*

In the SURMOUNT 4 trial, participants were treated with tirzepatide for 36 weeks before randomization to either continue tirzepatide or switch to placebo. At week 88, the group continuing on tirzepatide had a mean change in body weight from week 36 of -5.5% compared to a mean change of +14% in the group randomized to placebo. Key secondary endpoints showed that approximately 90% of participants treated with tirzepatide maintained  $\geq 80\%$  of their initial weight loss compared with only 16% in the placebo group. Additionally, the risk of returning to  $>95\%$  of baseline body weight was reduced by 98% (HR 0.02; 95% CI: 0.01 to 0.06) in the tirzepatide group.<sup>150</sup> See Supplement Table D2.31.

### SURMOUNT OSA

Around 61-72% participants in the tirzepatide group achieved at least a 50% reduction in AHI at week 52 compared to only 19-23% participants in the placebo group. Around -17.7% to -19.6% changes in body weight from baseline were observed with semaglutide compared to -1.6% to -2.3% changes with the placebo group in both trials. Injectable semaglutide also led to reductions in SBP at week 48 compared to those with placebo.<sup>20</sup> See Supplement Table D2.28.

### SUMMIT

The composite primary endpoint of death from cardiovascular causes or a worsening heart-failure event, stratified by diabetes status, occurred in 11% non-diabetic participants in the tirzepatide group compared to 15% participants in the placebo group (HR 0.66; 95% CI: 0.37 to 1.18). There was a significant improvement in the KCCQ-CSS score changes from baseline with tirzepatide compared to placebo at week 52 weeks (mean difference 7.5; 95% CI: 2.7 to 12.3). Although data related to the non-diabetic subgroup were not available, tirzepatide demonstrated greater weight reductions (-13.9%) compared to placebo (-2.2%) at week 52 in the overall population, with a mean difference of -11.6 (95% CI: -12.9 to -10.4;  $p < 0.001$ ).<sup>47</sup> See Supplement Table D2.29.

## Additional Harms

### *Injectable Semaglutide*

A pooled meta-analysis of STEP 1, STEP 3, STEP 4, and STEP 8 trials found that statistically significantly fewer participants (14%) receiving injectable semaglutide discontinued the trial for any reason compared with those receiving placebo (19%), with an RR of 0.75 (95% CI: 0.61 to 0.91;  $I^2$  17%). However, discontinuations due to adverse events were significantly more common in the semaglutide arm (RR 1.89; 95% CI: 1.31 to 2.74;  $I^2$  0%) compared to placebo. The pooled findings showed a higher proportion (4%) of participants receiving injectable semaglutide experienced severe GI side effects; although this was not statistically significant compared with placebo (1%).<sup>22,23,26,149</sup>

There were higher rates of serious adverse events in the placebo arm (12%) versus the semaglutide arm (8%) in the STEP 5 trial, thought to be due to chance events (e.g., COVID-19 infection, jaw and rib fractures, cancer) felt to be unrelated to the intervention.<sup>24</sup> In total, there were four deaths in the semaglutide arms compared to only one death in the placebo arms across STEP 1, STEP 5, and STEP 10 trials, with no deaths reported in STEP 3 and STEP 8 trials. Except for STEP 8, gallbladder-related disorders were more frequent in the semaglutide group compared to placebo. Rates of CV disorders were higher in the placebo arm than in the semaglutide arm across trials. Acute pancreatitis and acute renal failure rates were rarely observed in either arm.<sup>22,23,25,26</sup> See Supplement Table D2.32.

Harms data from the STEP 4, STEP 9, STEP-HFpEF, SELECT, and ESSENCE trials showed similar patterns to other STEP trials mentioned in the main section of this report. See Supplement Tables D2.34 and D2.36-38. In all these trials, around 49-86% of participants treated with injectable semaglutide and 48-80% of the participants treated with placebo experienced at least one treatment-emergent adverse event. Serious adverse events were generally comparable between injectable semaglutide (8-33%) and placebo (6-36%), except in the STEP-HFpEF trial, where participants in the semaglutide group reported fewer serious events (13% vs. 27%). Rates of gastrointestinal side effects were more common with those who continued injectable semaglutide than those switched to placebo in the STEP 4 trial; other trials did not report comprehensive GI side effects. There were more cardiovascular side effects in those who switched to placebo (11%) compared to those who continued semaglutide (5%).<sup>27-29,149,156</sup> See Supplement Tables D2.36, D2.38, and D2.39.

### *Tirzepatide*

Harms data from SURMOUNT 1 and SURMOUNT 3 trials are mostly presented in the main section of this report. Additionally, four deaths occurred in the placebo group compared to one in the tirzepatide group in the SURMOUNT 1 trial, whereas SURMOUNT 3 reported one death in each arm.

The harms profile in SURMOUNT 4, SURMOUNT OSA, and SUMMIT trials aligned with previous tirzepatide studies.<sup>20,47,150</sup> The SURMOUNT 4 trial reported two deaths and none of them were deemed related to the treatment.<sup>150</sup> No deaths occurred in the two SURMOUNT OSA trials.<sup>20</sup> The SUMMIT trial reported 19 deaths (5%) in the tirzepatide group compared to 15 (4%) in the placebo group; though death from any cause was not statistically different across arms.<sup>47</sup> Across these trials, around 60-86% of participants treated with tirzepatide experienced at least one treatment-emergent adverse event compared to 56-77% of participants treated with placebo. Rates of serious adverse events were similar between groups (3-26%). Gastrointestinal side effects were more frequent with tirzepatide than placebo.<sup>20,47,150</sup> A notable difference was seen in the SUMMIT trial among participants with obesity and HFpEF, where more than double participants in the placebo group (8%) experienced cardiac failure compared to the tirzepatide group (4%).<sup>47</sup> See Supplement Tables D2.37, D2.38, and D2.40.

## **Additional Evidence from Observational Studies**

### ***Injectable Semaglutide***

Ruseva et al. conducted a retrospective cohort study of 4,414 patients who were obese or overweight with  $\geq 1$  comorbidities and using injectable semaglutide 2.4 mg. Data were coming from a large US integrated claims and medical record database. They found a 14.8% reduction in body weight from baseline after 68 weeks of treatment. Those using semaglutide also achieved statistically significant reductions in cardiometabolic risk measures including BMI, SBP, HbA1C, and LDL cholesterol at week 52.<sup>38</sup> In observational studies, semaglutide demonstrated lower risks of suicidal ideation (HR 0.27; 95% CI: 0.20 to 0.36) and osteoarthritis (HR: 0.84;  $p = 0.01$ ), but had an increased risk of erectile dysfunction (RR 4.5; 95% CI: 2.3 to 9.0).<sup>34-36</sup>

### ***Tirzepatide***

The percent mean change in body weight from baseline was 11.9-12.9% at 6-month post-index period.<sup>48,49</sup> The proportions of patients achieving categorical weight loss thresholds of  $\geq 5\%$ ,  $\geq 10\%$ ,  $\geq 15\%$ , and  $\geq 20\%$  were 86-89%, 62-69%, 31-37%, and 11-15%, respectively.<sup>48,49</sup>

Wu et al 2025 included 21,150 patients with obesity and OSA who were prescribed tirzepatide. Against a 1:1 propensity score-matched control group, those treated with tirzepatide had a lower risk of all-cause mortality (HR 0.44; 95% CI: 0.34 to 0.58;  $p < 0.001$ ), MACE (HR 0.73, 0.62, 0.86;  $p < 0.001$ ), and major adverse kidney event (HR 0.43; 95% CI: 0.34 to 0.53;  $p < 0.001$ ) compared to the control group.<sup>151</sup>

### ***Direct Comparison (Tirzepatide versus Semaglutide)***

Rodriguez et al 2024 conducted an observational study comparing tirzepatide 5 mg with semaglutide 0.5 mg. In the one-third of the cohort that did not have diabetes, the mean percent

body weight changes from baseline for tirzepatide and semaglutide were 18.1% and 10.1% at 12 months after treatment initiation, respectively, with a treatment difference of -8% (95% CI: -6.7 to -9.2). The odds of achieving  $\geq 5\%$ ,  $\geq 10\%$ , and  $\geq 15\%$  weight loss were 2-3 times higher in the tirzepatide group than in the semaglutide group.<sup>32</sup> Huang et al 2024 compared 8,840 matched pairs of tirzepatide and semaglutide users from TriNetX US network data to assess ocular outcomes. Over two years of follow-up, tirzepatide users demonstrated a lower risk of cataracts (HR 0.41; 95% CI: 0.19 to 0.85) and age-related cataracts (HR 0.34; 95% CI: 0.15 to 0.76) compared to semaglutide users.<sup>33</sup>

Similar rates of GI adverse events were observed between tirzepatide and semaglutide in the observational study conducted by Rodriguez et al, although data specific to the non-diabetic population were not reported.<sup>32</sup>

Baser et al 2024 reported a lower risk of osteoarthritis with Zepbound (HR 0.57; 95% CI: 0.50 to 0.65;  $p < 0.0001$ ) compared with Wegovy.<sup>31</sup> Anson et al 2024 included both cohorts with and without pre-existing T2D, with a mean follow up close to one year. Participants receiving tirzepatide had a lower risk (HR 0.73; 95% CI: 0.58 to 0.92 ;  $p < 0.001$ ) of developing T2D compared to those receiving semaglutide over one year in the cohort without pre-existing T2D. There was a greater reduction in body weight changes from baseline with tirzepatide (-7.7 kg) compared to semaglutide (-4.8 kg). Similar reduction in HbA1C was also observed with tirzepatide (-0.24%) compared to semaglutide (-0.1%).<sup>30</sup>

## D2. Evidence Tables

Table D2.4. Evidence Tables

Trial Name/NCT	Design	Treatment Arms	Inclusion Criteria	Exclusion Criteria	Primary Outcome
<b>Semaglutide</b>					
<b>STEP 1</b> <b>NCT03548935</b>	Phase III, randomized, double-blinded, placebo controlled, multicenter study  N=1961  Population: Adults with obesity or overweight with at least one weight-related comorbidity	-Semaglutide s.c. 2.4 mg once weekly -Placebo	-BMI $\geq 30$ or $\geq 27$ with presence of comorbidity (hypertension, dyslipidemia, sleep apnea, CVD) -History of at least one self-reported unsuccessful dietary effort to lose body weight	- HbA1C $\geq 48$ mmol/mol - Change of $\geq 5$ kg in body weight within 90 days	Change in Body Weight (%) [week 68]
<b>STEP 3</b> <b>NCT03611582</b>	Phase III, randomized, double-blinded, placebo controlled, multicenter study  N=611  Population: Adults with obesity or overweight with at least one weight-related comorbidity	-Semaglutide s.c. 2.4 mg once weekly -Placebo  -Participant in both arms will also receive intensive behavioral therapy	-BMI $\geq 30$ or $\geq 27$ with presence of comorbidity (hypertension, dyslipidemia, sleep apnea, CVD) -History of at least one self-reported unsuccessful dietary effort to lose body weight	- HbA1C $\geq 48$ mmol/mol - Change of $\geq 5$ kg in body weight within 90 days	Change in Body Weight (%) [week 68]

Trial Name/NCT	Design	Treatment Arms	Inclusion Criteria	Exclusion Criteria	Primary Outcome
<p><b>STEP 4</b> <b>NCT03548987</b></p>	<p>Phase III, randomized, double-blinded, placebo controlled, multicenter, withdrawal study</p> <p>N=902</p> <p>Population: Adults with obesity or overweight with at least one weight-related comorbidity</p>	<p>-Semaglutide s.c. 2.4 mg once weekly</p> <p>-Placebo</p> <p>-For 20 week run in period all participants will receive open-label semaglutide</p>	<p>-BMI <math>\geq 30</math> or <math>\geq 27</math> with presence of comorbidity (hypertension, dyslipidemia, sleep apnea, CVD)</p> <p>-History of at least one self-reported unsuccessful dietary effort to lose body weight</p>	<p>- HbA1C <math>\geq 48</math> mmol/mol</p> <p>- Change of <math>\geq 5</math> kg in body weight within 90 days</p>	<p>Change in Body Weight (%) [week 20 - week 68]</p>
<p><b>STEP 5</b> <b>NCT03693430</b></p>	<p>Phase III, randomized, double-blinded, placebo controlled, multicenter study</p> <p>N=304</p> <p>Population: Adults with obesity or overweight with at least one weight-related comorbidity</p>	<p>-Semaglutide s.c. 2.4 mg once weekly</p> <p>-Placebo</p>	<p>-BMI <math>\geq 30</math> or <math>\geq 27</math> with presence of comorbidity (hypertension, dyslipidemia, sleep apnea, CVD)</p> <p>-History of at least one self-reported unsuccessful dietary effort to lose body weight</p>	<p>- HbA1C <math>\geq 48</math> mmol/mol</p> <p>- Change of <math>\geq 5</math> kg in body weight within 90 days</p>	<p>Change in Body Weight (%) [week 104]</p>

Trial Name/NCT	Design	Treatment Arms	Inclusion Criteria	Exclusion Criteria	Primary Outcome
<b>STEP 8</b> <b>NCT04074161</b>	Phase III, randomized, open-label, multicenter study  N=338  Population: Adults with obesity or overweight with at least one weight-related comorbidity	-Semaglutide s.c. 2.4 mg once weekly -Liraglutide s.c. 3 mg once daily -Placebo	-BMI $\geq 30$ or $\geq 27$ with presence of comorbidity (hypertension, dyslipidemia, sleep apnea, CVD) -History of at least one self-reported unsuccessful dietary effort to lose body weight	- HbA1C $\geq 48$ mmol/mol - Change of $\geq 5$ kg in body weight within 90 days	Change in Body Weight (%) [week 68]
<b>STEP 9</b> <b>NCT05064735</b>	Phase III, randomized, double-blinded, placebo controlled, multicenter study  N=407  Population: Adults with obesity and knee osteoarthritis	-Semaglutide s.c. 2.4 mg once weekly -Placebo	-BMI $\geq 30$ -Clinical diagnosis of knee OA -Pain due to knee OA	-Joint replacement in target knee -Arthroscopy or injections into target knee within last 3 months prior to enrolment	Change in WOMAC pain score [week 68]

Trial Name/NCT	Design	Treatment Arms	Inclusion Criteria	Exclusion Criteria	Primary Outcome
<b>STEP 10</b> <b>NCT05040971</b>	Phase III, randomized, double-blinded, placebo controlled, multicenter study  N=207  Population: Adults with obesity and prediabetes	-Semaglutide s.c. 2.4 mg once weekly -Placebo	-BMI $\geq 30$ -HbA1c $\geq 6.0$ and $\leq 6.4$ percent OR -FPG $\geq 5.5$ and $\leq 6.9$ mmol/L	-History of type 1 or type 2 diabetes -Prior treatment with glucose-lowering agent -HbA1c $\geq 6.5$ percent -FPG $\geq 7.0$ mmol/L	Change in Body Weight (%) [week 52]
<b>SELECT</b> <b>NCT03574597</b>	Phase III, randomized, double-blinded, placebo controlled, multicenter study  N=17604  Population: Adults with obesity or overweight and preexisting cardiovascular disease	-Semaglutide s.c. 2.4 mg once weekly -Placebo	- $\geq 45$ years age -BMI $\geq 27$ -Established cardiovascular disease	-Cardiovascular event within the past 60 days -HbA1C $\geq 48$ mmol/mol -History of type 1 or type 2 diabetes	First occurrence of a composite outcome measure consisting of: CV death, non-fatal MI, or non-fatal stroke [240 weeks]

Trial Name/NCT	Design	Treatment Arms	Inclusion Criteria	Exclusion Criteria	Primary Outcome
<b>ESSENCE</b> <b>NCT04822181</b>	Phase III, randomized, double-blinded, placebo controlled, multicenter study  N=1205  Population: Adults with Non-cirrhotic non-alcoholic steatohepatitis	-Semaglutide s.c. 2.4 mg once weekly -Placebo	-Histological evidence of NASH -evidence of fibrosis stage 2 or stage 3 according to the NASH CRN -NAS $\geq 4$ with a score of $\geq 1$ in steatosis, lobular inflammation and hepatocyte ballooning	-Documented causes of chronic liver disease other than non-alcoholic fatty liver disease	Resolution of steatohepatitis and no worsening of liver fibrosis [72 weeks]
<b>STEP HFpEF</b> <b>NCT04788511</b>	Phase III, randomized, double-blinded, placebo controlled, multicenter study  N=529  Population: Adults with obesity-related heart failure with preserved ejection fraction	-Semaglutide s.c. 2.4 mg once weekly -Placebo	-BMI $\geq 27$ -NYHA class II-IV -LVEF $\geq 45\%$	-HbA1c $\geq 6.5$ percentage -Change of $\geq 5$ kg in body weight within 90 days	Change in KCCQ [52 weeks]

Trial Name/NCT	Design	Treatment Arms	Inclusion Criteria	Exclusion Criteria	Primary Outcome
<b>OASIS 4</b> <b>NCT05564117</b>	Phase III, randomized, double-blinded, placebo controlled, multicenter study  N=307  Population: Adults with obesity or overweight with at least one weight-related comorbidity	-Semaglutide oral 25mg daily -Placebo	-BMI $\geq 30$ or $\geq 27$ with presence of comorbidity (hypertension, dyslipidemia, sleep apnea, CVD) -History of at least one self-reported unsuccessful dietary effort to lose body weight	-HbA1c $\geq 6.5$ percentage -Change of $\geq 5$ kg in body weight within 90 days	Change in Body Weight (%) [week 64]
<b>Tirzepatide</b>					
<b>SURMOUNT-1</b> <b>NCT04184622</b>	Phase III, randomized, double-blinded, placebo controlled, multicenter study  N=2539  Population: Adults with obesity or overweight with at least one weight-related comorbidity	-Tirzepatide s.c. 5mg once -weekly -Tirzepatide s.c. 10mg once weekly -Tirzepatide s.c. 15mg once weekly -Placebo	-BMI $\geq 30$ or $\geq 27$ with presence of comorbidity (hypertension, dyslipidemia, sleep apnea, CVD) -History of at least one self-reported unsuccessful dietary effort to lose body weight	-Diabetes mellitus -Change of $\geq 5$ kg in body weight within 3 months	Change in Body Weight (%) [week 72]

Trial Name/NCT	Design	Treatment Arms	Inclusion Criteria	Exclusion Criteria	Primary Outcome
<b>SURMOUNT-3 NCT04657016</b>	Phase III, randomized, double-blinded, placebo controlled, multicenter study  N=579  Population: Adults with obesity or overweight with at least one weight-related comorbidity who successfully lost ≥5% of baseline weight during a 12-week lead-in period with intensive lifestyle intervention.	-Tirzepatide s.c. maximum tolerated dose (10 or 15 mg) once weekly -Placebo	-BMI ≥30 or ≥27 with presence of comorbidity (hypertension, dyslipidemia, sleep apnea, CVD) -History of at least one self-reported unsuccessful dietary effort to lose body weight	-Diabetes mellitus -Change of ≥5 kg in body weight within 3 months	Change in Body Weight (%) [week 72]

Trial Name/NCT	Design	Treatment Arms	Inclusion Criteria	Exclusion Criteria	Primary Outcome
<p><b>SURMOUNT-4</b> <b>NCT04660643</b></p>	<p>Phase III, randomized, double-blinded, placebo controlled, multicenter, withdrawal study</p> <p>N=783</p> <p>Population: Adults with obesity or overweight with at least one weight-related comorbidity</p>	<p>-Tirzepatide s.c. maximum tolerated dose (10 or 15 mg) once weekly</p> <p>-Placebo</p> <p>-For 36-week run in period all participants will receive open-label tirzepatide</p>	<p>-BMI <math>\geq 30</math> or <math>\geq 27</math> with presence of comorbidity (hypertension, dyslipidemia, sleep apnea, CVD)</p> <p>-History of at least one self-reported unsuccessful dietary effort to lose body weight</p>	<p>-Diabetes mellitus</p> <p>-Change of <math>\geq 5</math> kg in body weight within 3 months</p>	<p>Change in Body Weight (%) [week 88]</p>
<p><b>SURMOUNT-5</b> <b>NCT05822830</b></p>	<p>Phase III, randomized, open-label, multicenter study</p> <p>N=751</p> <p>Population: Adults with obesity or overweight with at least one weight-related comorbidity</p>	<p>-Tirzepatide s.c. maximum tolerated dose (10 or 15 mg) once weekly</p> <p>-Semaglutide s.c. maximum tolerated dose (1.7 or 2.4 mg) once weekly</p>	<p>-BMI <math>\geq 30</math> or <math>\geq 27</math> with presence of comorbidity (hypertension, dyslipidemia, sleep apnea, CVD)</p> <p>-History of at least one self-reported unsuccessful dietary effort to lose body weight</p>	<p>-Diabetes mellitus</p> <p>-Change of <math>\geq 5</math> kg in body weight within 3 months</p>	<p>Change in Body Weight (%) [week 72]</p>

Trial Name/NCT	Design	Treatment Arms	Inclusion Criteria	Exclusion Criteria	Primary Outcome
<b>SURPASS-CVOT</b> <b>NCT04255433</b>	Phase III, randomized, double-blind, active comparator, multicenter study  N=13299  Population: Adults with type 2 diabetes and increased cardiovascular risk	-Tirzepatide s.c. maximum tolerated dose (5, 10, or 15 mg) -Dulaglutide s.c. 1.5 mg	-BMI $\geq 25$ -Diagnosis of type 2 diabetes -Established cardiovascular disease	-Hospitalized for congestive heart failure 2 months prior to screening -NYHA Classification IV	Time to first occurrence of death from CV causes, myocardial Infarction, or Stroke (MACE-3) [up to 54 months]
<b>SURMOUNT-OSA</b> <b>NCT05412004</b>	Phase III, randomized, double-blind, placebo controlled, multicenter study  N=469  Population: Adults with obstructive sleep apnea and obesity	-Tirzepatide s.c. maximum tolerated dose (10 or 15 mg) once weekly -Placebo	-AHI $\geq 15$ on PSG -BMI $\geq 30$ -History of at least one self-reported unsuccessful dietary effort to lose body weight	-Have type 1 diabetes mellitus or type 2 diabetes mellitus -Change of $\geq 5$ kg in body weight within 3 months	Change from Baseline in Apnea-Hypopnea Index [week 52]

Trial Name/NCT	Design	Treatment Arms	Inclusion Criteria	Exclusion Criteria	Primary Outcome
<b>SUMMIT NCT04847557</b>	Phase III, randomized, double-blinded, placebo controlled, multicenter study  N=731  Population: Adults with heart failure with preserved ejection fraction and obesity	-Tirzepatide s.c. maximum tolerated dose (10 or 15 mg) once weekly -Placebo	- NYHA class II-IV and LVEF $\geq$ 50% - BMI $\geq$ 30 - 6MWD 100-425m - KCCQ CSS $\leq$ 80	- HbA1c $\geq$ 9.5% or uncontrolled diabetes	Change from Baseline in KCCQ [week 52]

6MWD: 6 minute walk distance, AHI: apnea-hypopnea index, BMI: body mass index, CV: cardiovascular, CVD: cardiovascular disease, HbA1C: hemoglobin A1C, HFpEF: heart failure with preserved ejection fraction, KCCQ: Kansas city cardiomyopathy questionnaire, kg: kilogram, LVEF: left ventricular ejection fraction, mg: milligram, MI: myocardial infarction, NASH: non-alcoholic steatohepatitis, NYHA: New York heart association, PSG: polysomnography, s.c.: subcutaneous, WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index

Source: [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov)

**Table D2.5. Baseline Characteristics of Key Trials of Injectable Semaglutide<sup>22,23,25,26,119,157</sup>**

Trial		STEP-1		STEP-3		STEP-5		STEP-8		STEP-10	
Arms		SEM	PBO	SEM	PBO	SEM	PBO	SEM	PBO	SEM	PBO
Sample Size		1306	655	407	204	152	152	126	85	138	69
Mean Waist Circumference, cm ± SD		114.6±14.8	114.8±14.4	113.6±15.1	111.8±16.2	115.8±14.3	115.7±15.5	111.8±16.3	115.4±15.1	120.1±14.8	119.9±14.7
Mean Glycated Hemoglobin, % ± SD		5.7±0.3	5.7±0.3	5.7±0.3	5.8±0.3	NR	NR	NR	NR	NR	NR
Mean Diastolic Blood Pressure, mm Hg ± SD		80±10	80±10	80±10	81±10	80±9	80±10	81±9	79±9	NR	NR
Mean Pulse, beats/min ± SD		72±10	72±10	71±10	71±10	73±11	72±9	71±9	72±10	NR	NR
Mean Fasting Plasma Glucose ± SD		95.4±10.7	94.7±10.5	93.9±9.4	94.0±9.8	5.3±0.5	5.3±0.6	96.1±10.2	97.6±12.2	105.1±9.8	107.7±12.4
Mean Fasting Serum Insulin, Geometric Mean pmol/L (CV)		12.9 (58.6)	12.8 (61.2)	90.1 (59.5)	92.6 (61.0)	87.6 (51.4)	88.1 (62.6)	12.4 (60.1)	12.1 (67.0)	NR	NR
C-Reactive Protein, Geometric Mean (CV)		3.87 (151.1)	3.87 (135.5)	4.52 (142.1)	4.35 (129.9)	4.8 (129.9)	3.8 (128.8)	3.9 (124.1)	4.1 (187.1)	NR	NR
Lipid Levels, Mean mg/dl (CV)	Total Cholesterol	189.6 (20.5)	192.1 (19.4)	185.4 (19.8)	188.7 (20.6)	4.9* (20.9)	4.8* (18.3)	184.9 (21.0)	182.2 (22.8)	4.8* (19.8)	4.7* (18.7)
	HDL Cholesterol	49.4 (25.6)	49.5 (25.0)	107.7 (30.3)	111.8 (31.2)	1.2* (25.2)	1.2* (22.5)	51.9 (24.1)	50.7 (27.7)	1.2* (26.0)	1.2* (22.7)
	LDL Cholesterol	110.3 (31.6)	112.5 (29.8)	51.6 (24.0)	50.9 (22.6)	2.9* (30.1)	2.9* (25.7)	106.4 (32.5)	105.2 (32.9)	2.7* (31.6)	2.7* (32.1)
	VLDL Cholesterol	24.5 (45.8)	24.9 (46.5)	21.0 (49.7)	21.7 (44.5)	0.6* (46.5)	0.6* (47.4)	21.4 (47.2)	21.1 (49.2)	0.7* (44.4)	0.7* (43.2)
	Free Fatty Acids	12.3 (57.9)	12.7 (53.8)	11.9 (59.4)	11.1 (64.8)	0.4* (57.2)	0.4* (63.3)	10.5 (72.0)	10.6 (56.5)	NR	NR
	Triglycerid-es	126.2 (47.4)	127.9 (49.0)	107.9 (50.3)	110.9 (44.4)	1.3* (46.6)	1.2* (47.4)	110.1 (49.1)	108.2 (49.2)	1.6* (46.4)	1.5* (44.5)

Trial		STEP-1		STEP-3		STEP-5		STEP-8		STEP-10	
Arms		SEM	PBO	SEM	PBO	SEM	PBO	SEM	PBO	SEM	PBO
Sample Size		1306	655	407	204	152	152	126	85	138	69
Coexisting Conditions, n (%)	Dyslipidemia	499 (38.2)	226 (34.5)	145 (35.6)	67 (32.8)	58 (38.2)	49 (32.2)	60 (47.6)	36 (42.4)	63 (46%)	22 (32%)
	Hypertension	472 (36.1)	234 (35.7)	145 (35.6)	67 (32.8)	56 (36.8)	62 (40.8)	48 (38.1)	39 (45.9)	64 (46%)	32 (46%)
	Knee OA	173 (13.2)	102 (15.6)	76 (18.7)	31 (15.2)	21 (13.8)	25 (16.4)	23 (18.3)	22 (25.9)	18 (13%)	8 (12%)
	Obstructive Sleep Apnea	159 (12.2)	71 (10.8)	58 (14.3)	19 (9.3)	27 (17.8)	24 (15.8)	24 (19.0)	19 (22.4)	14 (10%)	8 (12%)
	Asthma or COPD	147 (11.3)	80 (12.2)	67 (16.5)	25 (12.3)	15 (9.9)	17 (11.2)	18 (14.3)	13 (15.3)	NR	NR
	Nonalcoholic Fatty Liver Disease	101 (7.7)	62 (9.5)	23 (5.7)	12 (5.9)	16 (10.5)	15 (9.9)	5 (4.0)	7 (8.2)	NR	NR
	Polycystic Ovarian Syndrome	62/955 (6.5)	34/498 (6.8)	17 (5.4)	10 (5.6)	10/123 (8.1)	5/113 (4.4)	5 (4.9)	1 (1.5)	NR	NR
	Coronary Artery Disease	32 (2.5)	17 (2.6)	6 (1.5)	4 (2.0)	2 (1.3)	3 (2.0)	4 (3.2)	4 (4.7)	NR	NR
No. of Coexisting Conditions at Screening, n (%)	None	328 (25.1)	163 (24.9)	99 (24.3)	49 (24.0)	NR	NR	32 (25.4)	16 (18.8)	NR	NR
	1	337 (25.8)	187 (28.5)	93 (22.9)	53 (26.0)	NR	NR	31 (24.6)	17 (20.0)	NR	NR
	2	298 (22.8)	135 (20.6)	96 (23.6)	43 (21.1)	NR	NR	25 (19.8)	21 (24.7)	NR	NR
	3	183 (14.0)	96 (14.7)	62 (15.2)	38 (18.6)	NR	NR	17 (13.5)	9 (10.6)	NR	NR
	4	96 (7.4)	43 (6.6)	31 (7.6)	14 (6.9)	NR	NR	10 (7.9)	9 (10.6)	NR	NR
	≥5	64 (4.9)	31 (4.7)	26 (6.4)	7 (3.4)	NR	NR	11 (8.7)	13 (15.3)	NR	NR

Trial		STEP-1		STEP-3		STEP-5		STEP-8		STEP-10	
Arms		SEM	PBO	SEM	PBO	SEM	PBO	SEM	PBO	SEM	PBO
Sample Size		1306	655	407	204	152	152	126	85	138	69
SF-36, Mean ± SD	Physical Functioning Score	51.0±6.9	50.8±7.9	51.9±6.7	52.1±6.8	NR	NR	NR	NR	NR	NR
	Physical Component Summary Score	51.1±7.3	51.1±7.9	51.6±6.9	51.7±7.3	NR	NR	NR	NR	NR	NR
	Mental Component Summary Score	55.4±5.7	55.5±5.9	55.7±5.3	55.4±6.1	NR	NR	NR	NR	NR	NR
IWQOL-Lite-CT, Mean ± SD	Physical Function Score	65.4±24.0	64.0±24.4	NR	NR	NR	NR	NR	NR	NR	NR
	Total Score	63.6±21.2	63.3±20.9	NR	NR	NR	NR	NR	NR	NR	NR

cm: centimeter, COPD: chronic obstructive pulmonary disease, CV: coefficient of variation, HDL: high-density lipoprotein, IWQOL-Lite-CT: The Impact of Weight on Quality of Life–Lite Clinical Trials Version, LDL: low-density lipoprotein, min: minute, mg/dl: milligrams per deciliter, mm Hg: millimeters of mercury, mmol/L: millimoles per liter, No.: number, NR: not reported, OA: osteoarthritis, PBO: placebo SEM: semaglutide, SD: standard deviation, SF-36: Short Form 36, VLDL: very low-density lipoprotein

\*Units are mmol/L not mg/dl

**Table D2.6. Baseline Characteristics of Oral Semaglutide<sup>39</sup>**

Study Name		OASIS-4	
		SEM	PBO
Arms		SEM	PBO
N		205	102
Mean Age, Years		48	47
Female, %		75.6	85.3
Race or Ethnic Group, %	White	92.7	89.2
	Asian	0.5	1
	Black or African American	6.3	8.8
	Other	0.5	1
BMI, Mean kg/m <sup>2</sup>		37.5	37.8
Mean Waist Circumference, cm		114.0	113.6
Mean Blood Pressure, mm Hg	Systolic	131.3	131.0
	Diastolic	83.0	83.2
Fasting Plasma Glucose, Mean		95.4	95.7
Mean HbA1C, %		5.7	5.7
Glycemic Status, %	Normoglycemia	51.2	52
	Prediabetes	47.3	46.1
	Diabetes*	1.5	2

BMI: body mass index, cm: centimeter, kg/m<sup>2</sup>: kilogram per square meter, mmHg: millimeters of mercury, PBO: placebo SEM: semaglutide

\*Participants did not have diabetes at screening but did at randomization.

**Table D2.7. Baseline Characteristics of Key Trials of tirzepatide<sup>42,43,55</sup>**

Study Name		SURMOUNT-1		SURMOUNT-3	
Arms		TZP	PBO	TZP	PBO
N		630	643	287	292
Duration of Obesity, Years ± SD		14.8±10.75	14.0±10.71	15.4±11.6	14.8±10.8
Body-Mass Index category, n (%)	<30	40 (6.3)	24 (3.7)	37 (12.9)	50 (17.1)
	≥30 to <35	199 (31.6)	227 (35.3)	100 (34.8)	107 (36.6)
	≥35 to <40	179 (28.4)	180 (28.0)	95 (33.1)	79 (27.1)
	≥40	212 (33.7)	212 (33.0)	55 (19.2)	56 (19.2)
Waist Circumference, cm ± SD		114.4±15.59	114.0±14.92	109.3±15.2	109.6±15.1
Diastolic Blood Pressure, mm Hg ± SD		79.3±8.23	79.6±7.95	79.1±8.9	78.1±9.2
Pulse, Beats/min ± SD		72.5±9.95	72.9±9.27	72.0±10.8	70.4±10.3
Lipid Levels, Geometric Mean mg/dl (Coefficient of Variation, %)	Total Cholesterol	187.4 (19.9)	186.4 (20.3)	185.2 (37.2)	185.3 (38.2)
	HDL Cholesterol	47.5 (25.5)	46.5 (26.9)	48.4 (12.7)	49.3 (12.9)
	LDL Cholesterol	109.5 (30.0)	108.4 (30.5)	112.5 (32.5)	112.3 (32.3)
	Free Fatty Acid	0.46 (47.5)	0.47 (44)	NR	NR
	Triglycerides	127.9 (47.5)	130.5 (49.2)	121.4 (55.7)	118.6 (53.3)
Prediabetes, n (%)		253 (40.2)	270 (42.0)	NR	NR
Glycated hemoglobin % ± SD		5.6±0.41	5.6±0.38	5.3 (0.4)	5.4 (0.4)
Fasting Glucose, mg/dl ± SD		95.3±10.3	95.7±9.5	92.6 (11.3)	91.3 (9.4)
Fasting Insulin, mIU/liter ± SD		14.4±9.3	14.3±9.9	70.7 (59)	62.9 (44.4)
SF-36 Physical Function Score ± SD		49.6±7.8	49.7±7.7	51.7 (6.7)	51.7 (6.8)
IWQoL-Lite-CT Physical Function Composite Score ± SD		NR	NR	73.4±21.3	71.4±22
Obesity Related Complications, n (%)	Hypertension	207 (32.9)	199 (30.9)	95 (33.1)	104 (35.6)
	Dyslipidemia	182 (28.9)	186 (28.9)	71 (24.7)	81 (27.7)
	ASCVD	21 (3.3)	21 (3.3)	5 (1.7)	6 (2.1)
	PCOS	6 (1.4)	13 (3)	8 (4.4)	8 (4.4)
	OSA	46 (7.3)	59 (9.2)	25 (8.7)	34 (11.6)
	OA	77 (12.2)	76 (11.8)	43 (15)	48 (16.4)

Study Name		SURMOUNT-1		SURMOUNT-3	
Arms		TZP	PBO	TZP	PBO
N		630	643	287	292
	Anxiety	94 (14.9)	108 (16.8)	61 (21.3)	55 (18.8)
	Depression				
	NAFLD				
	Asthma or COPD				
	Gout				
No. of Weight Related Complications, n (%)	0	249 (39.5)	245 (38.1)	96 (33.4)	100 (34.2)
	1	284 (45.1)	280 (43.6)	102 (35.5)	81 (27.7)
	2			48 (16.7)	54 (18.5)
	3	86 (13.7)	103 (16.1)	22 (7.7)	36 (12.3)
	4			14 (4.9)	14 (4.8)
	5+			5 (1.7)	7 (2.4)
SF36-v2, Mean Score (SD)	Mental Component Score	NR	NR	53.9 (0.4)	54 (0.5)
	Physical Component Score	NR	NR	52.7 (0.4)	52.7 (0.5)
Domain Scores, Mean (SD)	Physical Functioning	NR	NR	51.8 (0.4)	51.6 (0.5)
	Role Physical	NR	NR	53.1 (0.4)	52.8 (0.5)
	Bodily Pain	NR	NR	52.7 (0.5)	52.6 (0.6)
	General Health	NR	NR	54.3 (0.5)	54.8 (0.5)
	Vitality	NR	NR	56.2 (0.5)	56.2 (0.5)
	Social Functioning	NR	NR	53.3 (0.4)	53.4 (0.4)
	Role Emotional	NR	NR	51.7 (0.5)	51.4 (0.5)
	Mental Health	NR	NR	54.1 (0.5)	54.2 (0.5)

ASCVD: atherosclerotic cardiovascular disease, cm: centimeter, COPD: chronic obstructive pulmonary disease, HDL: high-density lipoprotein, IWQOL-Lite-CT: The Impact of Weight on Quality of Life–Lite Clinical Trials Version, LDL: low-density lipoprotein, mg/dl: milligrams per deciliter, mIU/liter: milli-international units per liter, mm Hg: millimeters of mercury, NAFLD: non-alcoholic fatty liver disease, OA: osteoarthritis, OSA: obstructive sleep apnea, PBO: placebo, PCOS: polycystic ovary syndrome, SD: standard deviation, SF-36: Short Form 36, TZP: tirzepatide

**Table D2.8. Baseline Characteristics of Direct Comparison Trial<sup>44</sup>**

Study Name		SURMOUNT-5	
Arms		TZP	SEM
N		374	376
Age, Years ± SD		45 (12.9)	44.4 (12.7)
Female, n (%)		242 (64.7)	243 (64.6)
Race or Ethnic Group, n (%)	American Indian or Alaska Native	6 (1.6)	0
	Asian	11 (2.9)	7 (1.9)
	Black or African American	77 (20.6)	67 (17.8)
	White	276 (73.8)	295 (78.5)
	Multiple	4 (1.1)	7 (1.9)
	Hispanic or Latino	93 (24.9)	103 (27.4)
Duration of Obesity, Years ± SD		16.4 (11.6)	14.7 (11)
Body Weight, kg ± SD		112.7 (24.8)	113.4 (26.3)
Mean Body-Mass Index ± SD		39.4 (7.4)	39.4 (7.7)
Body-Mass Index Category, n (%)	<35	115 (30.7)	118 (31.4)
	≥35	259 (69.3)	258 (68.6)
Waist Circumference, cm ± SD		117.7 (16.1)	118.8 (17.6)
Blood Pressure, mm Hg ± SD	Systolic	125.6 (13.56)	125.8 (12.48)
	Diastolic	81.1 (8.48)	81.6 (8.04)
	Pulse, Beats per min	72 (9.54)	72.7 (10.02)
Lipid Levels, Geometric Mean mg/dl (Coefficient of Variation, %)	Total cholesterol	188.7 (37.4)	190.9 (35.3)
	HDL Cholesterol	49.4 (13.1)	49.9 (13.5)
	LDL Cholesterol	113.5 (31.7)	114.6 (30.7)
	Triglycerides	127 (66.2)	133.5 (105.1)
Estimated GFR, ml/min/1.73 m <sup>2</sup>		104.6 (17.43)	106 (16.88)
Prediabetes, n (%)		215 (57.5)	210 (55.9)
Glycated Hemoglobin % ± SD		5.6 (0.35)	5.6 (0.38)
Fasting Glucose, mg/dl ± SD		94.4 (10.43)	94.9 (9.83)
Obesity Related Complications	Hypertension	156 (41.7)	141 (37.5)

Study Name		SURMOUNT-5	
Arms		TZP	SEM
N		374	376
	Dyslipidemia	86 (23)	96 (25.5)
	Impaired Glucose	77 (20.6)	66 (17.6)
	Back Pain	49 (13.1)	48 (12.8)
	Gallbladder Disease	36 (9.6)	45 (12)
	OSA	55 (14.7)	55 (14.6)
	OA	32 (8.6)	35 (9.3)
	Anxiety	70 (18.7)	67 (17.8)
	Depression	45 (12)	46 (12.2)
	NAFLD	11 (2.9)	7 (1.9)
	Asthma or COPD	42 (11.2)	31 (8.2)
	Gout	11 (2.9)	7 (1.9)
Number of Weight Related Complications	0	102 (27.3)	79 (21)
	1	85 (22.7)	108 (28.7)
	2	73 (19.5)	74 (19.7)
	3	40 (10.7)	58 (15.4)
	4	26 (7)	24 (6.4)
	5+	48 (12.8)	33 (8.8)

COPD: chronic obstructive pulmonary disease, GFR: glomerular filtration rate, HDL: high-density lipoprotein, kg: kilogram, LDL: low-density lipoprotein mg/dl: milligrams per deciliter, NAFLD: non-alcoholic fatty liver disease, OA: osteoarthritis, OSA: obstructive sleep apnea, SD: standard deviation, SEM: semaglutide, TZP: tirzepatide

**Table D2.9. Baseline Characteristics of Key Cardiovascular Trials<sup>18</sup>**

Study Name		SELECT	
Arms		SEM	PBO
N		8803	8801
BMI category, n (%)	<30	2555 (29)	2469 (28.1)
	≥30 to <35	3693 (42)	3781 (43)
	≥35 to <40	1687 (19.2)	1659 (18.9)
	≥40	868 (9.9)	892 (10.1)
Mean Waist Circumference, cm (SD)		111.3 (13.1)	111.4 (13.1)
Glycated Hemoglobin, % (SD)		5.78 (0.34)	5.78 (0.33)
Mean Diastolic Blood Pressure, mm Hg (SD)		79.4 (10)	79.2 (9.9)
Mean Pulse, beats/min (SD)		68.9 (10.6)	68.6 (10.7)
Lipid Levels, Geometric mean mg/dl (CV)	Total Cholesterol	153 (131, 182)	153 (131, 183)
	HDL Cholesterol	44 (37, 52)	44 (37, 52)
	LDL Cholesterol	78 (61, 102)	78 (61, 102)
	Triglycerides	134 (99, 188)	135 (100, 190)
Glycemic status, n (%)	Normoglycemia	2925 (33.2)	2980 (33.9)
	Prediabetes	5877 (66.8)	5819 (66.1)
Median High-Sensitivity CRP Level (IQR), mg/liter		1.87 (0.89, 4.18)	1.80 (0.86, 4.06)
EQ-5D-5L Index Score		0.88 (0.15)	0.88 (0.15)
EQ-5D-5L VAS Score		77.15 (15.63)	77.15 (15.73)

BMI: body mass index, cm: centimeter, CV: coefficient of variation, HDL: high-density lipoprotein, IQR: interquartile range, LDL: low-density lipoprotein, mg: milligram, PBO: placebo, SD: standard deviation, SEM: semaglutide

**Table D2.10. Baseline Characteristics of Obstructive Sleep Apnea Trial<sup>20</sup>**

Study Name		SURMOUNT-OSA			
Arms		TZP	PBO	TZP	PBO
N		114	120	120	115
Body-Mass Index Category, n (%)	<35	33 (28.9)	44 (36.7)	33 (27.7)	33 (28.9)
	≥35 to <40	39 (34.2)	35 (29.2)	47 (39.5)	41 (36)
	≥40	42 (36.8)	41 (34.2)	39 (32.8)	40 (35.1)
Waist Circumference, cm ± SD		122.6 (16.6)	119.8 (14.8)	120.7 (13.1)	121 (14)
Diastolic Blood Pressure, mm Hg ± SD		83.7 (8.9)	84 (8.6)	832.2 (8.2)	80.5 (8.6)
Prediabetes, n (%)		74 (64.9)	78 (65)	69 (57.5)	64 (55.7)
Glycated Hemoglobin % ± SD		5.69 (0.37)	5.64 (0.35)	5.62 (0.37)	5.65 (0.44)
Apnea-Hypopnea Index Events		52.9 (30.5)	50.1 (31.5)	46.1 (22.4)	53.1 (30.2)
OSA Severity	No Apnea	0	1 (0.8)	NR	NR
	Mild: AHI <15 Events/hr	1 (0.9)	2 (1.7)	0	2 (1.8)
	Moderate: AHI ≥15 Events	39 (34.2)	43 (36.1)	35 (29.4)	37 (32.5)
	Severe: AHI ≥30 Events/hr	74 (64.9)	73 (61.3)	84 (70.6)	75 (65.8)

Study Name	SURMOUNT-OSA			
Arms	TZP	PBO	TZP	PBO
N	114	120	120	115
Missing Data	0	1 (0.8)	1 (0.8)	1 (0.9)
PROMIS Sleep-Related Impairment T Score	53.2 (7.5)	54.3 (8.5)	55.3 (8.4)	55 (9.5)
PROMIS Sleep-Related Disturbance T Score	53.8 (6)	53.5 (7.4)	56 (7.6)	55.7 (7.6)
ESS Score	10.3 (5.3)	10.8 (5.2)	10.8 (4.6)	9.5 (4.4)
Sleep Apnea-specific Hypoxic Burden, min/hr	153.6 (102.7)	137.8 (104.1)	132.2 (83.4)	142.1 (112.5)
hsCRP Concentration, mg/liter	3.5 (120)	3.6 (124.6)	3.0 (124.3)	2.7 (127.5)

AHI: apnea-hypopnea index, cm: centimeter, ESS: Epworth Sleepiness Scale, hsCRP: high-sensitivity C-reactive protein, mm Hg: millimeters of mercury, OSA: obstructive sleep apnea, PROMIS: Patient-Reported Outcomes Measurement Information System, SD: standard deviation

**Table D2.11. Baseline Characteristics of Additional Clinical Trials<sup>28,29,47</sup>**

Trials		ESSENCE		STEP-HFpEF		SUMMIT	
Study Arms		SEM	PBO	SEM	PBO	TZP	PBO
Sample Size		534	266	263	266	364	367
Mean Age, Years		56 (11)	55 (12)	70	69	66 (11)	65 (11)
Female, %		59%	54%	57%	56%	55%	53%
Race and Ethnicity, %	White	68%	67%	97%	95%	70%	70%
	Black	1%	1%	3%	5%	6%	4%
	Asian	27%	28%	NR	NR	16%	20%
	Hispanic	18%	19%	6%	8%	54%	56%
Baseline Weight, kg		95 (25)	98 (25)	105	105	103 (22)	103 (23)
Baseline BMI, kg/m <sup>2</sup>		34 (7)	35 (7)	37	37	38 (6)	38 (7)
Mean HbA1C, %		NR	NR	NR	NR	48%	49%
Type 2 Diabetes, %		55%	57%	0%	0%	48%	49%
Mean Systolic Blood Pressure		NR	NR	133	132	128 (13)	128 (14)
Mean eGFR, mL/min/1.73m <sup>2</sup>		NR	NR	NR	NR	65 (24)	64 (24)
Median UACR, mg/g, (IQR)		NR	NR	NR	NR	NR	NR
NYHA Functional Class, n (%)	II	NR	NR	70%	63%	72%	73%
	III or IV	NR	NR	30%	37%	28%	27%
Comorbidities, n (%)	Coronary Artery Disease	NR	NR	20%	17%	31%	29%
	Hypertension	NR	NR	82%	82%	NR	NR

BMI: body mass index, eGFR: estimated glomerular filtration rate, IQR: interquartile range, NYHA: New York Heart Association, PBO: placebo, SEM: semaglutide, TZP: tirzepatide, UACR: urine albumin-to-creatinine ratio

**Table D2.12. Baseline Characteristics of Knee Osteoarthritis Trial<sup>27</sup>**

Study Name		STEP-9	
Arms		SEM	PBO
N		271	136
Mean Age, Years $\pm$ SD		56 $\pm$ 10	56 $\pm$ 10
Female, n (%)		228 (84.1)	104 (76.5)
Race or Ethnic Group, n (%)	White	168 (62.0)	80 (58.8)
	Asian	16 (5.9)	6 (4.4)
	Black or African American	18 (6.6)	13 (9.6)
	Other	32 (11.8)	26 (19.1)
Mean Body Weight, kg $\pm$ SD		108.7 $\pm$ 24.1	108.5 $\pm$ 24.5
BMI, Mean $\pm$ SD		40.5 $\pm$ 7.3	40.0 $\pm$ 7.1
BMI Category, n (%)	<30	0	1 (0.7)
	$\geq$ 30 to <35	67 (24.7)	32 (23.5)
	$\geq$ 35 to <40	84 (31.0)	56 (41.2)
	$\geq$ 40	120 (44.3)	47 (34.6)
Mean Waist Circumference, cm $\pm$ SD		118.3 $\pm$ 15.8	119.7 $\pm$ 15.9
Mean Blood Pressure, mm Hg $\pm$ SD	Systolic	132 $\pm$ 14	131 $\pm$ 15
	Diastolic	82 $\pm$ 10	82 $\pm$ 10
Coexisting Conditions at the Time of Screening, n (%)	Dyslipidemia	80 (29.5)	44 (32.4)
	Hypertension	128 (47.2)	68 (50.0)
	Asthma or COPD	19 (7.0)	19 (14.0)
	Gastroesophageal Reflux Disease	31 (11.4)	15 (11.0)
	Cardiovascular Disease	13 (4.8)	8 (5.9)
WOMAC Pain Score, Mean (SD)		72.8 $\pm$ 15.6	67.2 $\pm$ 16.0

BMI: body mass index, COPD: Chronic obstructive pulmonary disease, kg: kilogram PBO: placebo, SEM: semaglutide, SD: standard deviation, WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index

**Table D2.13. Baseline Characteristics of Treatment Withdrawal Trials<sup>149,150</sup>**

Study Name		STEP-4		SURMOUNT-4	
Arms		SEM	PBO	TZP	PBO
N		535	268	335	335
Mean Age, Years (SD)		47 (12)	46 (12)	49 (13)	48 (12)
Female, n (%)		429 (80.2)	205 (76.5)	236 (70.4)	237 (70.7)
Race or ethnic group, n (%)	White	446 (83.4)	226(84.3)	264 (78.8)	273 (81.5)
	Asian	15(2.8)	4(1.5)	26 (7.8)	22 (6.6)
	Black or African American	69(12.9)	35(13.1)	39 (11.6)	36 (10.7)
	Hispanic or Latino	42(7.9)	21(7.8)	141 (42.1)	155 (46.3)
Mean Body Weight, kg (SD)		96.5 (22.5)	95.4 (22.7)	84.6 (19.8)	85.8 (22.3)
BMI, Mean (SD)		34.5 (6.9)	34.1 (7.1)	30.3 (6)	30.7 (6.8)
BMI, n (%)	<25	7(1.3)	9(3.4)	NR	NR
	≥25 to <30	153(28.6)	69(25.7)	NR	NR
	<30	NR	NR	181 (54)	183 (54.6)
	≥30 to <35	166(31.0)	97(36.2)	88 (26.3)	75 (22.4)
	≥35 to <40	116(21.7)	52(19.4)	41 (12.2)	43 (12.8)
	≥40	93(17.4)	41(15.3)	25 (7.5)	34 (10.1)
Mean Waist Circumference, cm (SD)		105.5 (15.9)	104.7 (16.9)	96.8 (14.1)	98.2 (16)
Glycated Hemoglobin, % (SD)		5.4 (0.3)	5.4 (0.3)	5.07 (0.30)	5.04 (0.31)
Mean Blood Pressure, mm Hg (SD)	Systolic	121 (13)	121 (13)	115 (12)	115 (12)
	Diastolic	78 (9)	78 (9)	75 (9)	76 (9)
	Pulse, beats/min	76 (9)	76 (9)	77 (9)	78 (9)
Fasting Plasma Glucose, mean (SD)		87.9 (7.7)	86.9 (7.6)	85.1 (7.4)	85 (7.8)
Lipid Levels, Geometric Mean mg/dl (Coefficient of Variation)	Total Cholesterol	177.2 (152.9-201.9)*	177.6 (156.0-198.8)*	179.9 (36.8)	180.2 (37.2)
	HDL Cholesterol	44.4(37.8-51.7)*	44.0(36.5-51.0)*	49.1 (11.6)	48.8 (11.5)
	LDL Cholesterol	110.4(91.1-130.9)*	112.5(93.6-130.9)*	111 (32.4)	113.2 (33.6)
	VLDL Cholesterol	18.5(14.3-24.7)*	17.8(13.5-24.7)*	NR	NR
	Free Fatty Acids	12.5(9.0-18.0)*	12.5(8.5-17.9)*	NR	NR
	Triglycerides	95.2(73.9-125.5)*	90.8(69.4-126.4)*	99.1 (45.1)	93 (44.3)
	Estimated GFR, ml/min/1.73 m <sup>2</sup>	94.2 (81.3-106.6)*	95.9 (83.5-108.1)*	96.4 (18.8)	97.9 (17.9)
Coexisting Conditions at the Time of Screening, n (%)	Dyslipidemia	189 (35.3)	99 (36.9)	113 (33.7)	99 (29.6)
	Hypertension	199 (37.2)	99 (36.9)	119 (35.5)	117 (34.9)
	Knee osteoarthritis	72 (13.5)	27 (10.1)	NR	NR
	Obstructive sleep apnea	61 (11.4)	33 (12.3)	40 (11.9)	41 (12.2)
	Asthma or COPD	57 (10.7)	35 (13.1)	34 (10.1)	35 (10.4)
	Nonalcoholic Fatty Liver Disease	37 (6.9)	18 (6.7)	22 (6.6)	26 (7.8)
	Polycystic Ovarian Syndrome	15 (3.5)	10 (4.9)	9 (3.8)	14 (5.9)

Study Name		STEP-4		SURMOUNT-4	
Arms		SEM	PBO	TZP	PBO
N		535	268	335	335
	<b>Coronary artery disease</b>	4 (0.7)	3 (1.1)	NR	NR
<b>No. of Coexisting Conditions at Screening, n (%)</b>	<b>None</b>	144 (26.9)	70 (26.1)	98 (29.3)	107 (31.9)
	<b>1</b>	160 (29.9)	78 (29.1)	99 (29.6)	96 (28.7)
	<b>2</b>	103 (19.3)	68 (25.4)	59 (17.6)	53 (15.8)
	<b>3</b>	77 (14.4)	34 (12.7)	39 (11.6)	37 (11)
	<b>4</b>	38 (7.1)	15 (5.6)	26 (7.8)	26 (7.8)
	<b>≥5</b>	13 (2.4)	3 (1.1)	14 (4.2)	16 (4.8)
<b>SF-36 (SD)</b>	<b>Physical Functioning Score</b>	53.8 (5.7)	54.1 (5.0)	53.4 (5.8)	53.2 (6.5)

BMI: body mass index, cm: centimeter, COPD: chronic obstructive pulmonary disease, HDL: high-density lipoprotein, LDL: low-density lipoprotein, mm Hg: millimeters of mercury, kg: kilogram, SD: standard deviation, VLDL: very low-density lipoprotein  
 \*(interquartile range)

**Table D2.14. Additional Results of Key Weight Loss Trials of Injectable semaglutide<sup>22,23,25,26,119</sup>**

Study Name	Arm	N	Body Weight Change from Baseline		% Unadjusted Weight Loss from Baseline to One Year	≥5% Body-Weight Reduction	
			% (SE)	Difference vs Placebo (95% CI; p value)	Mean (SE)	% of Participants	Odds Ratio (95% CI; p value)
STEP-1	SEM	1306	-14.85	-12.44 (-13.37, -11.51; <0.001)	-15.6	86.4	11.2 (8.9, 14.2; <0.001)
	PBO	655	-2.41		-2.8	31.5	
STEP-3	SEM	407	-16.0	-10.3 (-12.0, -8.6; <0.001)	-16.5	86.6	6.1 (4.0, 9.3; <0.001)
	PBO	204	-5.7		-5.8	47.6	
STEP-5	SEM	152	-15.2 (0.9)	-12.6 (-15.3, -9.8; <0.0001)	-17.4	77.1	5.0 (3.0, 8.4; <0.0001)
	PBO	152	-2.6 (1.1)		-2.7	34.4	
STEP-8	SEM	126	-15.8 (-17.6, -13.9)*	-13.9 (-16.7, -11.0)	-16.4	87.2	NR
	PBO	85	-1.9 (-4.0, 0.2)*		-1.6	29.5	
STEP-10	SEM	138	-13.9 (0.7)†	-11.2 (-13.0, -9.4; <0.0001)	NR	86	15.9 (7.5, 33.6; <0.0001)
	PBO	69	-2.7 (0.6)†		NR	26	

CI: confidence interval, NR: not reported, PBO: placebo, SE: standard error, SEM: semaglutide

\*(95% CI)

†Standard deviation

**Table D2.15. Additional Results of Key Weight Loss Trials of Injectable Semaglutide**  
**Continued**<sup>22,23,25,26,119</sup>

Study Name	Arm	N	≥10% Body-Weight Reduction		≥15% Body-Weight Reduction		≥20% Body-Weight Reduction	
			% of Participants	Odds ratio (95% CI; p value)	% of Participants	Odds Ratio (95% CI; p value)	% of Participants	Odds Ratio (95% CI; p value)
STEP-1	SEM	1306	69.1	14.7 (11.1, 19.4; <0.001)	50.5	19.3 (12.9, 28.8; <0.001)	32	26.9 (14.2, 51)
	PBO	655	12		4.9		1.7	
STEP-3	SEM	407	75.3	7.4 (4.9, 11.0; <0.001)	55.8	7.9 (4.9, 12.6; <0.001)	35.7	13.7 (6.2, 30.3; <0.001)
	PBO	204	27.0		13.2		3.7	
STEP-5	SEM	152	61.8	7.2 (4.0, 13.2; <0.0001)	52.1	9.4 (4.4, 20.0; <0.0001)	36.1	12.8 (3.9, 41.9)
	PBO	152	13.3		7.0		2.3	
STEP-8	SEM	126	70.9	NR	55.6	NR	38.5	NR
	PBO	85	15.4	NR	6.4	NR	2.6	NR
STEP-10	SEM	138	74	32.7 (12.0, 89.1; <0.0001)	48	52.2 (7.1, 383.1; 0.0001)	25	39.6 (2.4, 641.2; 0.0097)
	PBO	69	8		2		0	

CI: confidence interval, NR: not reported, PBO: placebo, SEM: semaglutide

**Table D2.16. Secondary Outcomes of Key Weight Loss Trials of Injectable Semaglutide** <sup>22,23,25,26,119</sup>

Study Name	Arm	N	Waist Circumference, cm		Systolic Blood Pressure, mm Hg	
			Mean Change from Baseline (95% CI)	Difference vs Placebo (95% CI; p value)	Mean Change from Baseline	Difference vs Placebo (95% CI; p value)
STEP-1	SEM	1306	-13.54	-9.42 (-10.30, -8.53; <0.001)	-6.16	-5.10 (-6.34, -3.87; <0.001)
	PBO	655	-4.13		-1.06	
STEP-3	SEM	407	-14.6	-8.3 (-10.1, -6.6; <0.001)	-5.6	-3.9 (-6.4, -1.5; 0.001)
	PBO	204	-6.3		-1.6	
STEP-5	SEM	152	-14.4 (0.9)*	-9.2 (-12.2 to -6.2; <0.0001)	-5.7 (1.1)*	-4.2 (-7.3 to -1.0; 0.0102)
	PBO	152	-5.2 (1.2)*		-1.6 (1.2)*	
STEP-8	SEM	126	-13.2 (-15.0, -11.5)	NR	-5.7 (-8.1, -3.3)	NR
	PBO	85	-2.0 (-4.0, 0.1)	NR	3.2 (0.3, 6.1)	NR
STEP-10	SEM	138	-11.1 (0.8)†	-8.3 (-10.4, 6.2; <0.0001)	-8.8 (1.1)†	-7.8 (-11.3, -4.3; <0.0001)
	PBO	69	-2.8 (0.7)†		-1.0 (1.4)†	

CI: confidence interval, cm: centimeter, mm Hg: millimeters of mercury, NR: not reported, PBO: placebo, SEM: semaglutide

\*Standard error

†Standard deviation

**Table D2.17. Secondary Outcomes of Key Weight Loss Trials of Injectable Semaglutide Continued**<sup>22,23,25,26,119</sup>

Study Name	Arm	N	Body Weight, kg		Body-Mass Index		Glycated Hemoglobin, Percentage Points	
			Mean Change from Baseline	Difference vs Placebo (95% CI; p value)	Mean Change from Baseline	Difference vs Placebo (95% CI; p value)	Mean Change from Baseline	Difference vs Placebo (95% CI; p value)
STEP-1	SEM	1306	-15.3	-12.7 (-13.7, -11.7)	-5.54	-4.61 (-4.96, -4.27)	-0.45	-0.29 (-0.32, -0.26)
	PBO	655	-2.6		-0.92		-0.15	
STEP-3	SEM	407	-16.8	-10.6 (-12.5, -8.8; <0.001)	-6.0	-3.8 (-4.4, -3.1; <0.001)	-0.51	-0.24 (-0.29, -0.19; <0.001)
	PBO	204	-6.2		-2.2		-0.27	
STEP-5	SEM	152	-16.1 (1.0)*	-12.9 (-16.1, -9.8)	-5.9 (0.4)*	-4.3 (-5.7, -2.9)	NR	NR
	PBO	152	-3.2 (1.2)*		-1.6 (0.6)*		NR	
STEP-8	SEM	126	-15.3(-17.3, -13.4)	-13.8 (-16.8, -10.7)	NR	NR	NR	NR
	PBO	85	-1.6 (-3.9, 0.8)		NR		NR	
STEP-10	SEM	138	-15.2 (0.8)†	-12.4 (-14.4, -10.3)	NR	NR	NR	NR
	PBO	69	-2.8 (0.6)†		NR		NR	

CI: confidence interval, kg: kilogram, NR: not reported, PBO: placebo, SEM: semaglutide

\*Standard error

†Standard deviation

**Table D2.18. Secondary Outcomes of Key Weight Loss Trials of Injectable semaglutide Continued<sup>22,23,25,26,119,157</sup>**

Study Name	Arm	N	Fasting Serum Insulin		Fasting Plasma Glucose, mg/dl	
			% Change from Baseline	Difference vs Placebo (95% CI; p value)	Mean Change from Baseline (SE)	Difference vs Placebo (95% CI; p value)
STEP-1	SEM	1306	-26	-21 (-26, -17; <0.0001)	-8.53	-7.87 (-9.04, -6.70; <0.0001)
	PBO	655	-7		-0.48	
STEP-3	SEM	407	-32.3	-20.3 (-30.4, -8.7; 0.001)	-6.73	-6.09 (-8.13, -4.04; <0.001)
	PBO	204	-15.0		-0.65	
STEP-5	SEM	152	-32.7	-27.4 (-39.3, -13.3)	-0.4 (0.05)	-0.5 (-0.7, -0.4)
	PBO	152	-7.2		0.1 (0.06)	
STEP-8	SEM	126	-27.8	NR	-8.3	NR
	PBO	85	-3.5		3.3	
STEP-10	SEM	138	NR	NR	-0.8 (0.1)*	-0.6 (-0.8, -0.4; <0.0001)
	PBO	69	NR		-0.2 (0.1)*	

CI: confidence interval, mg/dl: milligrams per deciliter, NR: not reported, PBO: placebo, SE: standard error, SEM: semaglutide

\*mmol/L (standard deviation)

**Table D2.19. Secondary Outcomes of Key Weight Loss Trials of Injectable Semaglutide Continued** <sup>22,23,25,26,119,157</sup>

Study Name	Arm	N	Diastolic Blood Pressure, mmHg		Total Cholesterol		HDL Cholesterol	
			Mean Change from Baseline (95% CI; p value)	Difference vs Placebo (95% CI; p value)	Mean Change from Baseline (95% CI; p value)	Difference vs Placebo (95% CI; p value)	Ratio to Baseline	Difference vs Placebo (95% CI; p value)
STEP-1	SEM	1306	-2.83	-2.41 (-3.25, -1.57; <0.0001)	0.97†	0.97 (0.95, 0.98)	1.05†	1.04 (1.02, 1.05)
	PBO	655	-0.42		1†		1.01†	
STEP-3	SEM	407	-3.0	-2.2 (-3.9, -0.6; 0.008)	-3.8	-5.8 (-8.4, -3.2; <0.001)	6.5	1.5 (-1.8, 4.9; 0.39)
	PBO	204	-0.8		2.1		5.0	
STEP-5	SEM	152	-4.4 (0.9)*	-3.7 (-6.1, -1.2)	-3.3	-4.6 (-8.4, -0.6)	9.6	1.3 (-3.9, 6.9)
	PBO	152	-0.8 (0.9)*		1.4		8.1	
STEP-8	SEM	126	-5.0 (-7.0, -3.1)	NR	-7.1 (-10.7, -3.3)	NR	-0.3(-3.6, 3.0)	NR
	PBO	85	0.7 (-1.5, 2.9)	NR	-3.3 (-7.9, 1.5)	NR	-0.9 (-4.5, 2.9)	NR
STEP-10	SEM	138	NR	NR	0.9†	0.9 (0.9, 1.0; 0.017)	0.8†	0.9 (0.8, 1.0; 0.0024)
	PBO	69	NR	NR	1.0†		1.0†	

CI: confidence interval, HDL: high-density lipoprotein, mm Hg: millimeters of mercury, NR: not reported, PBO: placebo, SE: standard error, SEM: semaglutide

\*Standard error

†Ratio to baseline

**Table D2.20. Secondary Outcomes of Key Weight Loss Trials of Injectable Semaglutide Continued<sup>22,23,25,26,119,157</sup>**

Study Name	Arm	N	LDL Cholesterol		VLDL Cholesterol		Free Fatty Acids	
			Mean Change from Baseline (95% CI; p value)	Difference vs Placebo (95% CI; p value)	Mean Change from Baseline (95% CI; p value)	Difference vs Placebo (95% CI; p value)	Mean Change from Baseline (95% CI; p value)	Difference vs Placebo (95% CI; p value)
STEP-1	SEM	1306	0.97*	0.96 (0.94, 0.98; 0.0011)	0.78*	0.84 (0.81, 0.87)	0.83*	0.89 (0.83, 0.94)
	PBO	655	1.01*		0.93*		0.93*	
STEP-3	SEM	407	-4.7	-7.1 (-10.9, -3.2; <0.001)	-22.5	-17.0 (-22.8, -10.9; <0.001)	-11.9	-15.3 (-25.0, -4.3; 0.008)
	PBO	204	2.6		-6.6		4.0	
STEP-5	SEM	152	-6.1	-3.4 (-9.1, 2.6)	-18.9	-21.5 (-29.6, -12.4)	0.3	-6.2 (-21.2, 11.6)
	PBO	152	-2.7		3.3		7.0	
STEP-8	SEM	126	-6.5 (-12.4, -0.1)	NR	-20.7(-25.1, -16.0)	NR	-12.6 (-22.1, -2.0)	NR
	PBO	85	-1.1 (-11.4, 10.4)		-4.1 (-12.1, 4.6)		2.6 (-10.5, 17.5)	
STEP-10	SEM	138	0.8*	0.9 (0.8, 1.0; 0.0018)	1*	1.0 (1.0, 1.1; 0.14)	0.9*	0.9 (0.9, 1.01; 0.072)
	PBO	69	1*		1*		1*	

CI: confidence interval, LDL: low-density lipoprotein, NR: not reported, PBO: placebo, SE: standard error, SEM: semaglutide, VLDL: very low-density lipoprotein

\*Ratio to baseline

**Table D2.21. Secondary Outcomes of Key Weight Loss Trials of Injectable Semaglutide Continued<sup>22,23,25,26,119,157</sup>**

Study Name	Arm	N	Triglycerides		C-reactive Protein	
			Mean Change from Baseline (95% CI; p value)	Difference vs Placebo (95% CI; p value)	Mean Change from Baseline (95% CI; p value)	Difference vs Placebo (95% CI; p value)
STEP-1	SEM	1306	0.78*	0.84 (0.81, 0.87; <0.0001)	0.47*	0.56 (0.51, 0.61; <0.0001)
	PBO	655	0.93*		0.85*	
STEP-3	SEM	407	-22.5	-17.0 (-22.8, -10.8; <0.001)	-59.6	-47.6 (-55.0, -39.0; <0.001)
	PBO	204	-6.5		-22.9	
STEP-5	SEM	152	-19.0	-21.9 (-29.8, -13.2)	-56.7	-53.1 (-63.2, -40.0)
	PBO	152	3.7		-7.8	
STEP-8	SEM	126	-20.7 (-25.6, -15.6)	NR	-52.6 (-61.3, -42.0)	NR
	PBO	85	-3.2 (-11.4, 5.8)		-20.1 (-34.7, -2.3)	
STEP-10	SEM	138	NR	NR	NR	NR
	PBO	69	NR		NR	

CI: confidence interval, NR: not reported, PBO: placebo, SEM: semaglutide

\*Ratio to baseline

**Table D2.22. Patient Reported Outcomes of Injectable Semaglutide Trials<sup>22,23,158,159</sup>**

Study Name	Arm	N	STEP-1		STEP-3	
			SEM	PBO	SEM	PBO
			1306	655	407	204
SF-36 Physical Functioning Score		Mean Change from Baseline	2.21	0.41	2.4	1.6
		Difference vs Placebo (95% CI; p value)	1.80 (1.18, 2.42; <0.001)		0.8 (-0.2, 1.9; 0.12)	
Clinically Meaningful SF-36 Physical Functioning Score Improvement (≥3.7 points)		% of Participants	39.8	24.1	36.3	25.5
		Estimated Treatment Difference (95% CI; p value)	15.6 (10.4, 20.8; <0.0001)		10.8 (0.9, 20.7; 0.0318)	
		Mean Change from Baseline	NR	NR	3.0	2.3

Study Name		STEP-1		STEP-3	
Arm		SEM	PBO	SEM	PBO
N		1306	655	407	204
SF-36 Physical Component Summary Score	Difference vs Placebo (95% CI; p value)	NR		0.7 (-0.5, 1.9; 0.27)	
SF-36 Mental Component summary Score	Mean change from baseline	NR	NR	-0.8	-2.9
	Difference vs Placebo (95% CI; p value)	NR		2.1 (0.5, 3.6; 0.011)	
SF-36 Bodily Pain Score	Mean Change from Baseline	NR	NR	0.9	-0.5
	Difference vs Placebo (95% CI; p value)	NR		1.3 (0, 2.7; 0.05)	
SF-36 Role-physical	Estimated Treatment Difference (95% CI; p value)	1.4 (0.7, 2.0; <0.0001)		NR	
SF-36 General Health	Estimated Treatment Difference (95% CI; p value)	2.2 (1.5, 2.9; <0.0001)		NR	
SF-36 Vitality	Estimated Treatment Difference (95% CI; p value)	1.9 (1.1, 2.7; <0.0001)		NR	
SF-36 Social Functioning	Estimated Treatment Difference (95% CI; p value)	1.3 (0.6, 2.0; 0.0002)		NR	
SF-36 Role-emotional	Estimated Treatment Difference (95% CI; p value)	0.7 (-0.1, 1.5; 0.0979)		NR	
SF-36 Mental Health	Estimated Treatment Difference (95% CI; p value)	1.1 (0.4, 1.9; 0.0026)		NR	
IWQOL-Lite-CT Physical Function Score	Mean Change from Baseline	14.67	5.25	NR	NR
	Difference vs Placebo (95% CI; p value)	9.43 (7.50, 11.35; <0.001)		NR	
Clinically Meaningful IWQOL-Lite-CT Physical Function Score Improvement (≥14.6 points)	% of Participants	51.2	32.9	NR	NR
	Odds Ratio (95% CI; p value)	2.72 (2.14, 3.47)		NR	

CI: confidence interval, IWQOL-Lite-CT: The Impact of Weight on Quality of Life–Lite Clinical Trials Version, PBO: placebo, SF-36: Short Form 36, SEM: semaglutide

**Table D2.23. Additional Results of Oral Semaglutide Trial<sup>28</sup>**

Study Name		OASIS-4	
Arms		SEM	PBO
N		205	102
Body Weight Change from Baseline	% (95% CI)	-13.6	-2.2
	Difference vs Placebo (95% CI; p value)	-11.4 (-13.9, -9.0; <0.0001)	
≥5% Body-weight Reduction	% of participants	79.2	31.1
	Odds ratio (95% CI; p value)	7.3 (4.2, 12.8; <0.0001)	
≥10% Body-weight Reduction	% of participants	63	14.4
	Odds ratio (95% CI; p value)	9.1 (4.7, 17.3; <0.0001)	
≥15% Body-weight Reduction	% of participants	50	5.6
	Odds ratio (95% CI; p value)	15.7 (6.2, 40.2; <0.0001)	
≥20% Body-weight Reduction	% of participants	29.7	3.3
	Odds ratio (95% CI; p value)	12.2 (3.7, 40.3; <0.0001)	
Waist Circumference, cm	Mean change from baseline (95% CI)	-12.2	-2.8
	Difference vs Placebo (95% CI; p value)	-9.5 (-12.4, -6.6; <0.0001)	
Systolic Blood Pressure, mm Hg	Mean change from baseline	-6.8	-5.4
	Difference vs Placebo (95% CI; p value)	-1.4 (-4.6, 1.8; 0.3960)	
IWQOL-Lite-CT Physical Function Score	Mean change from baseline	16.2	8.4
	Difference vs Placebo (95% CI; p value)	7.7 (3.3, 12.2; 0.0006)	
Fasting Plasma Glucose, mg/dl	Mean change from baseline	-6.6	0.4
	Difference vs Placebo (95% CI; p value)	-7 (-11.2, -2.8; 0.0012)	
Diastolic Blood Pressure, mm Hg	Mean change from baseline	-2.7	-2.1
	Difference vs Placebo (95% CI; p value)	-0.65 (-2.8, 1.5; 0.5500)	
HDL Cholesterol	Ratio to baseline	3.1	-0.4
	Difference vs Placebo (95% CI; p value)	3.5 (-0.7, 7.9; 0.0999)	
LDL Cholesterol	Ratio to baseline	-4.4	0.2
	Difference vs Placebo (95% CI; p value)	-4.6 (-10.6, 1.7; 0.1511)	
VLDL Cholesterol	Ratio to baseline	-18.2	-8.3
	Difference vs Placebo (95% CI; p value)	-10.8 (-19.2, -1.4; 0.0249)	

Study Name		OASIS-4	
Arms		SEM	PBO
N		205	102
Triglycerides	Ratio to baseline	-18.4	-7.5
	Difference vs Placebo (95% CI; p value)	-11.8 (-20.2, -2.5; 0.0140)	
C-Reactive Protein	Ratio to baseline	-46.4	-4.2
	Difference vs Placebo (95% CI; p value)	-44.0 (-57.8, -25.7; <0.0001)	
HbA1c, %	Mean change from baseline	-0.29	-0.06
	Difference vs Placebo (95% CI; p value)	-0.23 (-0.31, -0.15; <0.0001)	

CI: confidence interval, cm: centimeter, HDL: high-density lipoprotein, IWQOL-Lite-CT: The Impact of Weight on Quality of Life–Lite Clinical Trials Version, LDL: low-density lipoprotein, mm Hg: millimeters of mercury, PBO: placebo, SEM: semaglutide

**Table D2.24. Additional Results of Key Trials of Tirzepatide<sup>42,43,155</sup>**

Study Name		SURMOUNT-1		SURMOUNT-3	
Arms		TZP	PBO	TZP	PBO
N		630	643	287	292
Body Weight Change from Baseline	% (95% CI or SE)	-20.9 (-21.8, -19.9)	-3.1 (-4.3, -1.9)	-18.4 (0.7)	2.5 (1)
	Difference vs Placebo (95% CI; p value)	-17.8 (-19.3, -16.3; <0.001)		-20.8 (-23.2, -18.5)	
≥5% Body-Weight Reduction	%	90.9 (88, 93.8)	34.5 (29.8, 39.2)	87.5 (2.2)	16.5 (3)
	Odds ratio (95% CI; p value)	NR		34.6 (19.2, 62.6)	
≥10% Body-Weight Reduction	%	83.5 (80, 86.9)	18.8 (14.9, 22.7)	76.7 (2.7)	8.9 (2.4)
	Odds ratio (95% CI; p value)			34.7 (17.6, 68.3)	
≥15% Body-weight Reduction	%	70.6 (66.7, 74.5)	8.8 (5.9, 11.7)	65.4 (3)	4.2 (1.8)
	Odds ratio (95% CI; p value)			48.2 (19.2, 121)	
≥20% Body-weight Reduction	%	56.7 (52.6, 60.8)	3.1 (1.1, 5.1)	44.7 (3)	2.2 (1.3)
	Odds ratio (95% CI; p value)			40.4 (12.2, 133.8)	
≥25% Body-weight Reduction	%	36.2 (32.3, 40.1)	1.5 (0.1, 2.9)	28.7 (2.7)	1.2 (0.9)
	Odds ratio (95% CI; p value)	NR		33.70 (8.84, 128.52)	
≥30% Body-weight Reduction	%	NR	NR	NR	NR
	Odds ratio (95% CI; p value)	NR		NR	

Study Name		SURMOUNT-1		SURMOUNT-3	
Arms		TZP	PBO	TZP	PBO
N		630	643	287	292
Proportion of Patients achieving waist circumference ≤88 cm	%	NR	NR	NR	NR
	Odds ratio (95% CI; p value)	18.5 (11.6, 29.5)		NR	
Waist Circumference, cm	Mean change from baseline	-18.5 (-19.3, -17.6)	-4.0 (-5.1, -2.8)	NR	NR
	Difference vs Placebo (95% CI; p value)	-14.5 (-15.9, -13.0)		NR	
Systolic Blood Pressure, mm Hg	Mean change from baseline	-7.6 (-8.5, -6.7)	-1.2 (-2.1, -0.3)	-5.1 (0.7)	4.1 (0.7)
	Difference vs Placebo (95% CI; p value)	NR		-9.2 (-11.2, -7.2)	
Diastolic Blood Pressure, mm Hg	Mean change from baseline	-4.6 (-5.2, -4.0)	-1.0 (-1.7, -0.3)	-3.2 (0.5)	2.3 (0.5)
	Difference vs Placebo (95% CI; p value)	NR		-5.5 (-6.9, -4.1)	
Body Weight, kg	Mean change from baseline	NR	NR	-21.5 (0.7)	3.5 (0.7)
	Difference vs Placebo (95% CI; p value)	NR		-25.0 (-26.9, -23.2)	
Body-mass Index	Mean change from baseline	NR	NR	-7.7 (0.2)	1.2 (0.2)
	Difference vs Placebo (95% CI; p value)	NR		-8.9 (-9.6, -8.3)	
Glycated Hemoglobin, percentage points	Mean change from baseline	NR	NR	-0.5 (0)	0
	Difference vs Placebo (95% CI; p value)	NR		-0.5 (-0.5, -0.4)	
Fasting Plasma Glucose, mg/dl	Mean change from baseline	-10.6 (-11.5, -9.6)	0.9 (-0.1, 1.9)	-8.8 (0.8)	2.4 (0.9)
	Difference vs Placebo (95% CI; p value)			-11.2 (-13.5, -8.8)	
Fasting Serum Insulin	% change from baseline	-49.6 (-52.3, -46.9)	-9.7 (-14.8, -4.6)	-39.1 (2.5)	17.3 (5)
	Difference vs Placebo (95% CI; p value)			-48.1 (-53.7, 41.7)	
Triglycerides	% change from baseline	-31.4 (-33.5, -29.3)	-6.3 (-9.3, -3.3)	-25.8 (1.6)	3 (2.3)
	Difference vs Placebo (95% CI; p value)			-28.0 (-32.3, -23.4)	
Total Cholesterol	% change from baseline	-7.4 (-8.6, -6.2)	-1.1 (-2.5, 0.2)	-3.0 (1)	5.2 (1.1)
	Difference vs Placebo (95% CI; p value)			-7.8 (-10.4, -5.1)	
HDL Cholesterol	% change from baseline	8.2 (6.7, 9.7)	0.2 (-1.2, 1.7)	15.4 (1.2)	3.6 (1.1)
	Difference vs Placebo (95% CI; p value)			11.4 (8.2, 14.7)	
LDL Cholesterol	% change from baseline	-8.6 (-10.5, -6.8)	-0.9 (-3.0, 1.3)	-6.1 (1.4)	6.1 (1.7)
	Difference vs Placebo (95% CI; p value)			-11.5 (-15.3, -7.5)	
VLDL Cholesterol	% change from baseline	-31.7 (-33.8, -29.6)	-5.6 (-8.6, -2.6)	-25.6 (1.6)	3 (2.3)

Study Name		SURMOUNT-1		SURMOUNT-3	
Arms		TZP	PBO	TZP	PBO
N		630	643	287	292
	Difference vs Placebo (95% CI; p value)			-27.8 (-32.1, -23.2)	
Free Fatty Acids	Ratio to baseline	-9.8 (-14.0, -5.6)	6.1 (-0.1, 12.3)	-33.1 (2.2)	-15.0 (3)
	Difference vs Placebo (95% CI; p value)			-21.3 (-28.4, -13.6)	
HbA1c	Mean change from baseline	-0.51 (-0.53, -0.49)	-0.07 (-0.09, -0.05)	NR	NR
Fat Mass (pooled TZP)	Sample Size, N	124	36	NR	NR
	% change from baseline	-33.9	-8.2	NR	NR
	Difference vs Placebo (95% CI; p value)	-25.7 (-31.4, -20.0; p <0.001)		NR	
Lean Mass (pooled TZP)	Sample Size, N	124	36	NR	NR
	% change from baseline	-10.9	-2.6	NR	NR
	Difference vs Placebo (95% CI; p value)	-8.3 (-10.6, -6.1; p<0.001)		NR	
Visceral Fat Mass (pooled TZP)	Sample Size, N	106	29	NR	NR
	% change from baseline	-40.1	-7.3	NR	NR
	Difference vs Placebo (95% CI; p value)	-32.8 (-42.8, -22.8; p <0.001)		NR	

CI: confidence interval, cm: centimeter, HDL: high-density lipoprotein, kg: kilogram, LDL: low-density lipoprotein, mg/dl: milligrams per deciliter, mm Hg: millimeters of mercury, PBO: placebo SE: standard error, TZP: tirzepatide, VLDL: very-low-density lipoprotein

**Table D2.25. Patient Reported Outcomes of Key Trials of Tirzepatide<sup>54,55</sup>**

Study Name		SURMOUNT-1		SURMOUNT-3	
Arms		TZP	PBO	TZP	PBO
N		630	643	231	209
SF-36	Mental component score	NR	NR	53.8 (0.5)	52.8 (0.5)
	Mean change from baseline	0.71 (0.29)	-0.47 (0.30)	NR	NR
	Difference vs Placebo (95% CI; p value)	1.19 (0.37, 2.00); p<0.01		0.9 (-0.4, 2.3); p = 0.182	
	Physical component score	NR	NR	55.8 (0.4)	51.8 (0.4)
	Mean change from baseline	4.18 (0.23)	1.62 (0.25)	NR	NR
	Difference vs Placebo (95% CI; p value)	2.56 (1.89, 3.23); p<0.001		4.0 (2.8, 5.1): p<0.001	
Domain Scores	Physical functioning	4.14 (0.25)	1.76 (0.26)	3.3 (0.4)	-0.6 (0.4)
	Difference vs Placebo (95% CI; p value)	2.38 (1.67, 3.09); p<0.001		3.9 (2.8, 4.9)	

Study Name		SURMOUNT-1		SURMOUNT-3	
Arms		TZP	PBO	TZP	PBO
N		630	643	231	209
	Role Physical	2.76 (0.25)	1.42 (0.26)	54.8 (0.4)	52.3 (0.4)
	Difference vs Placebo (95% CI; p value)	1.34 (0.62, 2.05); p<0.001		2.5 (1.4, 3.6); p<0.001	
	Bodily Pain	2.85 (0.32)	0.44 (0.34)	54.9 (0.5)	51.5 (0.5)
	Difference vs Placebo (95% CI; p value)	2.41 (1.50, 3.32); p<0.001		3.3 (1.9, 4.8); p<0.001	
	General Health	4.20 (0.28)	1.03 (0.29)	56.9 (0.4)	52.8 (0.5)
	Difference vs Placebo (95% CI; p value)	3.16 (2.38, 3.95); p<0.001		4.1 (2.8, 5.3); p<0.001	
	Vitality	3.19 (0.30)	0.21 (0.32)	57.5 (0.5)	55.1 (0.5)
	Difference vs Placebo (95% CI; p value)	2.99 (2.12, 3.86); p<0.001		2.4 (1.0, 3.8); p<0.001	
	Social Functioning	1.15 (0.26)	0.29 (0.28)	54.1 (0.4)	52.5 (0.4)
	Difference vs Placebo (95% CI; p value)	0.86 (0.11, 1.60); p<0.05		1.6 (0.5, 2.7); p=0.005	
	Role Emotional	1.79 (0.30)	0.32 (0.32)	52.5 (0.5)	50.6 (0.5)
	Difference vs Placebo (95% CI; p value)	1.48 (0.62, 2.33); p<0.001		1.9 (0.5, 3.3); p=0.008	
	Mental Health	1.05 (0.30)	-0.23 (0.32)	54.4 (0.5)	53 (0.5)
Difference vs Placebo (95% CI; p value)	1.28 (0.42, 2.15); p<0.01		1.5 (0.1, 2.8); p=0.036		
IWQOL-Lite-CT Total Score	Mean change from baseline	22.6 (0.6)	10.5 (0.7)	18	2.8
	Difference vs Placebo (95% CI; p value)	12.1 (10.3, 13.9); p<0.001		15.2 (12.5, 17.9)	
IWQOL-Lite-CT Physical Function score	Mean change from baseline	21.8 (0.7)	10.1 (0.8)	13.9 (1.1)	1.1 (1.2)
	Difference vs Placebo (95% CI; p value)	11.7 (9.6, 13.8); p<0.001		12.8 (9.7, 16)	
IWQOL-Lite-CT Physical Composite score	Mean change from baseline	20.8 (0.7)	9.7 (0.7)	14.5	0.9
	Difference vs Placebo (95% CI; p value)	11.1 (9.1, 13.1); p<0.001		13.6 (10.6, 16.6)	
IWQOL-Lite-CT Psychosocial Composite Score	Mean change from baseline	23.6 (0.7)	11 (0.7)	19.9	3.8
	Difference vs Placebo (95% CI; p value)	12.7 (10.7, 14.6); p<0.001		16 (13.1, 19)	
EQ-5D-5L Index Score	Mean changes from baseline	0.06 (0.01)	0.02 (0.01)	NR	NR
	Estimated treatment difference (95% CI; p value)	0.05 (0.03, 0.06); p<0.001		NR	
EQ-5D-5L VAS Score	Mean changes from baseline	8.6 (0.5)	2.4 (0.5)	NR	NR

Study Name		SURMOUNT-1		SURMOUNT-3	
Arms		TZP	PBO	TZP	PBO
N		630	643	231	209
	Estimated treatment difference (95% CI; p value)	6.2 (4.8, 7.6); p<0.001		NR	

CI: confidence interval, IWQOL-Lite-CT: The Impact of Weight on Quality of Life–Lite Clinical Trials Version, NR: not reported, PBO: placebo, SF-36: Short Form 36, TZP: tirzepatide

**Table D2.26. Additional Results of Direct Comparison Trial<sup>44</sup>**

Study Name		SURMOUNT-5	
Arms		TZP	SEM
N		374	376
Body Weight Change from Baseline	% (95% CI or SE)	-20.2 (-21.4, -19.1)	-13.7 (-14.9, -12.6)
	Difference vs Semaglutide (95% CI; p value)	-6.5 (-8.1, -4.9)	
≥10% Body-weight Reduction	%	304 (81.6)	227 (60.5)
	Odds ratio (95% CI; p value)	1.3 (1.2, 1.5)	
≥15% Body-weight Reduction	%	241 (64.6)	151 (40.1)
	Odds ratio (95% CI; p value)	1.6 (1.4, 1.9)	
≥20% Body-weight Reduction	%	181 (48.4)	103 (27.3)
	Odds ratio (95% CI; p value)	1.8 (1.5, 2.2)	
≥25% body-weight reduction	%	118 (31.6)	60 (16.1)
	Odds ratio (95% CI; p value)	2.0 (1.5, 2.6)	
≥30% Body-weight Reduction	%	74 (19.7)	26 (6.9)
	Odds ratio (95% CI; p value)	2.8 (1.9, 4.3)	
Waist Circumference, cm	Mean change from baseline	-18.4 (-19.6, -17.2)	-13.0 (-14.3, -11.7)
	Difference vs Semaglutide (95% CI; p value)	-5.4 (-7.1, -3.6)	
Body Weight, kg	Mean change from baseline	-22.8 (-24.1, -21.5)	-15 (-16.3, -13.7)
	Difference vs Semaglutide (95% CI; p value)	-7.9 (-9.7, -6.0)	
Body-Mass Index	Mean change from baseline	-8.0 (-8.5, -7.5)	-5.3 (-5.8, -4.8)

Study Name		SURMOUNT-5	
Arms		TZP	SEM
N		374	376
Difference vs Semaglutide (95% CI; p value)		-2.7 (-3.3, -2.0)	

CI: confidence interval, cm: centimeter, IWQOL-Lite-CT: The Impact of Weight on Quality of Life–Lite Clinical Trials Version, kg: kilogram, SE: standard error, SEM: semaglutide, TZP: tirzepatide

**Table D2.27. Additional Results of Cardiovascular Trials<sup>18,19,154</sup>**

Study Name		SELECT	
Arms		SEM	PBO
N		8803	8801
Body Weight Change from Baseline	% (95% CI)	-9.39 (0.09)	-0.88 (0.08)
	Difference vs Placebo (95% CI; p value)	-8.51 (-8.75, -8.27)	
Waist Circumference, cm	Mean change from baseline (95% CI)	-7.56 (0.09)	-1.03 (0.09)
	Difference vs Placebo (95% CI; p value)	-6.53 (-6.79, -6.27)	
Systolic Blood Pressure, mm Hg	Mean change from baseline	-3.82 (0.16)	-0.51 (0.16)
	Difference vs Placebo (95% CI; p value)	-3.31 (-3.75, -2.88)	
Diastolic Blood Pressure, mm Hg	Mean change from baseline	-1.02 (0.10)	-0.47 (0.10)
	Difference vs Placebo (95% CI; p value)	-0.55 (-0.83, -0.27)	
Total Cholesterol	Ratio to baseline	-4.63%	-1.92%
	Difference vs Placebo (95% CI; p value)	-2.77 (-3.37, -2.16)	
HDL Cholesterol	Ratio to baseline	4.86%	0.59%
	Difference vs Placebo (95% CI; p value)	4.24 (3.70, 4.79)	
LDL Cholesterol	Ratio to baseline	-5.25%	-3.14%
	Difference vs Placebo (95% CI; p value)	-2.18 (-3.22, -1.12)	
Triglycerides	Ratio to baseline	-18.34%	-3.20%
	Difference vs Placebo (95% CI; p value)	-15.64 (-16.68, -14.58)	
Primary Cardiovascular Composite End Point	% of participants	569 (6.5)	701 (8)
	Odds ratio (95% CI; p value)	0.80 (0.72, 0.90); p<0.001	

Study Name		SELECT	
Arms		SEM	PBO
N		8803	8801
Death from Cardiovascular	% of participants	223 (2.5)	262 (3)
	Odds ratio (95% CI; p value)	0.85 (0.71, 1.01); p=0.07	
Heart Failure Composite	% of participants	300 (3.4)	361 (4.1)
	Odds ratio (95% CI; p value)	0.82 (0.71, 0.96)	
Death from any Cause	% of participants	375 (4.3)	458 (5.2)
	Odds ratio (95% CI; p value)	0.81 (0.71, 0.93)	
Cardiovascular Expanded Composite Endpoint	% of participants	873 (9.9)	1074 (12.2)
	Odds ratio (95% CI; p value)	0.80 (0.73, 0.87)	
Cardiovascular Expanded Composite plus Death from any Cause	% of participants	710 (8.1)	877 (10)
	Odds ratio (95% CI; p value)	0.80 (0.72, 0.88)	
Nonfatal MI	% of participants	234 (2.7)	322 (3.7)
	Odds ratio (95% CI; p value)	0.72 (0.61, 0.85)	
Nonfatal Stroke	% of participants	154 (1.7)	165 (1.9)
	Odds ratio (95% CI; p value)	0.93 (0.74, 1.15)	
Hospitalization or Urgent Visit for HF	% of participants	97 (1.1)	122 (1.4)
	Odds ratio (95% CI; p value)	0.79 (0.60, 1.03)	
Coronary Revascularization	% of participants	473 (5.4)	608 (6.9)
	Odds ratio (95% CI; p value)	0.77 (0.68, 0.87)	
Unstable Angina Leading to Hospitalization	% of participants	109 (1.2)	124 (1.4)
	Odds ratio (95% CI; p value)	0.87 (0.67, 1.13)	
Glycated Hemoglobin Level at Least 6.5%	% of participants	306 (3.5)	1059 (12)
	Odds ratio (95% CI; p value)	0.27 (0.24, 0.31)	
Nephropathy Composite end Point	% of participants	155 (1.8)	198 (2.2)
	Odds ratio (95% CI; p value)	0.78 (0.63, 0.96)	
Heart Rate, beats/min	Mean changes from baseline	3.79 (0.11)	0.69 (0.11)
	Estimated treatment difference (95% CI; p value)	3.10 (2.80, 3.39)	
High Sensitivity CRP Level	Mean changes from baseline	-39.12%	-2.08%

Study Name		SELECT	
Arms		SEM	PBO
N		8803	8801
	Estimated treatment difference (95% CI; p value)	-37.82 (-39.70, -35.90)	
EQ-5D-5L Index Score	Mean changes from baseline	0.01 (0)	-0.1 (0)
	Estimated treatment difference (95% CI; p value)	0.01 (0.01, 0.02)	
EQ-5D-5L VAS Score	Mean changes from baseline	2.52 (0.16)	0.92 (0.16)
	Estimated treatment difference (95% CI; p value)	1.60 (1.16, 2.04)	
First MACE-5 Events	Hazard ratio (95% CI; p value)	0.8 (0.73, 0.87; <0.001)	
Total MACE-5 Events	Mean ratio (95% CI; p value)	0.78 (0.70, 0.86; <0.001)	
Non-fatal MIs	Mean ratio (95% CI; p value)	0.69 (0.58, 0.82; <0.001)	
Coronary Revascularization	Mean ratio (95% CI; p value)	0.74 (0.65, 0.84; <0.001)	
Change in eGFR mL min <sup>-1</sup> 1.73 m <sup>-2</sup>	Mean change	-0.86	-1.61
	Estimated treatment difference (95% CI; p value)	0.75 (0.43, 1.06; <0.001)	
Initiation of Chronic Kidney Replacement Therapy	n (%)	4 (<0.1)	6 (0.1)
	Hazard Ratio (95% CI; p value)	0.66 (0.17, 2.32; 0.52)	
Onset of Persistent eGFR <15 ml min <sup>-1</sup> 1.73 m <sup>-2</sup>	n (%)	5 (0.1)	4 (<0.1)
	Hazard Ratio (95% CI; p value)	1.24 (0.33, 5.02; 0.74)	

CI: confidence interval, CM: centimeter, CRP: c-reactive protein, eGFR: estimated glomerular filtration rate, HF: heart failure, HDL: high-density lipoprotein, LDL: low-density lipoprotein, MACE: Major Adverse Cardiovascular Events, MI: Myocardial infarction, mm Hg: millimeters of mercury

**Table D2.28. Obstructive Sleep Apnea Trial Results<sup>20</sup>**

Study Name		SURMOUNT-OSA			
Arms		TZP	PBO	TZP	PBO
N		114	120	120	115
Body-weight Change from Baseline	% (95% CI)	-17.7 (-19.0, -16.3)	-1.6 (-2.9, -0.2)	-19.6 (-21.0, -18.2)	-2.3 (-3.8, -0.9)
	Difference vs Placebo (95% CI; p value)	-16.1 (-18.0, -14.2)		-17.3 (-19.3, -15.3)	
Systolic Blood Pressure, mm Hg	Mean change from baseline	-9.5 (-11.5, -7.5)	-1.8 (-3.9, 0.2)	-7.6 (-9.7, -5.6)	-3.9 (-6.3, -1.6)
	Difference vs Placebo (95% CI; p value)	-7.6 (-10.5, -4.8)		-3.7 (-6.8, -0.7)	
Diastolic Blood Pressure, mm Hg	Mean change from baseline	-4.9 (-6.4, -3.5)	-2.1 (-3.6, -0.6)	-3.3 (-4.7, -1.9)	-2.2 (-3.8, -0.6)
	Difference vs Placebo (95% CI; p value)	-2.8 (-5.0, -0.7)		-1.1 (-3.2, 1.0)	
Change in Apnea Hypopnea Index	Mean change from baseline	-25.3 (-29.3, -21.2)	-5.3 (-9.4, -1.1)	-29.3 (-33.2, -25.4)	-5.5 (-9.9, -1.2)
	Difference vs Placebo (95% CI; p value)	-20.0 (-25.8, -14.2)		-23.8 (-29.6, -17.9)	
Change in Apnea Hypopnea Index	% change from baseline	-50.7 (-62.3, -39.1)	-3.0 (-16.9, 10.9)	-58.7 (-69.1, -48.4)	-2.5 (-16.2, 11.2)
	Difference vs Placebo (95% CI; p value)	-47.7 (-65.8, -29.6)		-56.2 (-73.7, -38.7)	
Reduction of ≥50% in AHI Events	n (%)	70 (61.2)	23 (19)	86 (72.4)	27 (23.3)
	Odds ratio (95% CI; p value)	3.3 (2.1, 5.1)		3.1 (2.1, 4.5)	
Change in hsCRP Concentration	Mean change from baseline	-1.4 (-1.7, -1.1)	-0.7 (-1.1, -0.3)	-1.4 (-1.6, -1.1)	-0.3 (-0.8, 0.1)
	Difference vs Placebo (95% CI; p value)	-0.7 (-1.2, -0.2)		-1.0 (-1.6, -0.5)	
Change in Sleep Apnea Specific Hypoxic Burden	Mean change from baseline	-95.2 (-103.2, -87.2)	-25.1 (-44.3, -5.9)	-103.0 (-110.3, -95.6)	-41.7 (-63.9, -19.5)
	Difference vs Placebo (95% CI; p value)	-70.1 (-90.9, -49.3)		-61.3 (-84.7, -37.9)	
Change in PROMIS Sleep-related Impairment T Score	Mean change from baseline	-6.6 (-8.2, -4.9)	-3.1 (-4.7, -1.6)	-8.2 (-10.0, -6.3)	-3.9 (-5.9, -1.9)
	Difference vs Placebo (95% CI; p value)	-3.4 (-5.7, -1.2)		-4.3 (-7, -1.6)	
Change in PROMIS Sleep Disturbance T Score	Mean change from baseline	-4.5 (-5.8, -3.1)	-2.4 (-3.8, -1.1)	-7.0 (-8.6, -5.4)	-3.1 (-4.8, -1.4)
	Difference vs Placebo (95% CI; p value)	-2.0 (-4.0, -0.1)		-3.9 (-6.2, -1.6)	

CI: confidence interval, hsCRP: high-sensitivity C-reactive protein, OSA: obstructive sleep apnea, PBO: placebo, PROMIS: Patient-Reported Outcomes Measurement Information System, TZP: tirzepatide

**Table D2.29. Results of Additional Trials<sup>28,29,47</sup>**

Study Name		STEP-HFpEF		ESSENCE		SUMMIT	
Arms		SEM	PBO	SEM	PBO	TZP	PBO
N		263	266	534	266	364	367
Body Weight Change from Baseline	% (95% CI)	-13.3	-2.6	-10.5	-2	-13.9 (0.4)	-2.2 (0.5)
	Difference vs Placebo (95% CI; p value)	-10.7 (-11.9, -9.4; <0.001)		-8.5 (-9.6, -7.4; <0.001)		-11.6 (-12.9, -10.4); p < 0.001	
≥10% body-weight Reduction	% of participants	65.9	9.5	NR	NR	NR	NR
	Odds ratio (95% CI; p value)	15.5 (9.4, 25.4)		NR	NR	NR	NR
≥15% body-weight Reduction	% of participants	43.9	2.1	NR	NR	NR	NR
	Odds ratio (95% CI; p value)	30.6 (12.2, 76.6)		NR	NR	NR	NR
≥20% body-weight Reduction	% of participants	23.6	0.4	NR	NR	NR	NR
	Odds ratio (95% CI; p value)	56.0 (7.8, 400.8)		NR	NR	NR	NR
Waist Circumference, cm	Mean change from baseline (95% CI)	-11.7	-2.7	NR	NR	NR	NR
	Difference vs Placebo (95% CI; p value)	-9.1 (-10.6, -7.5)		NR	NR	NR	NR
Systolic Blood Pressure, mm Hg	Mean change from baseline	-4.9	-2.0	-5.39	-1.39	-4.6 (0.8)	0.1 (0.8)
	Difference vs Placebo (95% CI; p value)	-2.9 (-5.8, 0.1)		-4.00 (-5.93, -2.07)		-4.7 (-6.8, -2.5)	
Diastolic Blood Pressure, mm Hg	Mean change from baseline	NR	NR	-1.90	0.24	-1.2	-0.3
	Difference vs Placebo (95% CI; p value)	NR	NR	-2.14 (-3.43, -0.85)		-0.9 (-2.3, 0.5)	
Total Cholesterol	Ratio to baseline	NR	NR	-6.03	-3.19	NR	NR
	Difference vs Placebo (95% CI; p value)	NR	NR	-2.93 (-5.60, -0.19)		NR	NR
HDL Cholesterol	Ratio to baseline	NR	NR	2.62	-1.95	NR	NR
	Difference vs Placebo (95% CI; p value)	NR	NR	4.66 (2.12, 7.26)		NR	NR
LDL Cholesterol	Ratio to baseline	NR	NR	-6.07	-4.11	NR	NR

Study Name		STEP-HFpEF		ESSENCE		SUMMIT	
Arms		SEM	PBO	SEM	PBO	TZP	PBO
N		263	266	534	266	364	367
	Difference vs Placebo (95% CI; p value)	NR	NR	-2.04 (-6.35, 2.46)		NR	NR
Triglycerides	Ratio to baseline	NR	NR	-16.77	-0.27	NR	NR
	Difference vs Placebo (95% CI; p value)	NR	NR	-16.54 (-21.02, -11.81)		NR	NR
C-reactive Protein	Ratio to baseline	-43.5	-7.3	-53.83	-19.83	-38.8 (4.5)	-5.9 (5.3)
	Difference vs Placebo (95% CI; p value)	0.61 (0.51, 0.72; <0.001)*		-42.41 (-49.75, -33.98)		-34.9 (-45.6, -22.2); p < 0.001	
6 -Minute Walk Distance	Mean change, meters	21.5	1.2	NR	NR	26 (3.8)	10.1 (3.9)
	Estimated treatment difference (95% CI)	20.3 (8.6, 32.1; <0.001)		NR	NR	18.3 (9.9, 26.7); p < 0.001	
KCCQ-CSS, Points	Mean change	16.6	8.7	NR	NR	19.5 (1.2)	12.7 (1.3)
	Estimated Difference (95% CI; p value)	7.8 (4.8, 10.9; <0.001)		NR	NR	6.9 (3.3, 10.6)	
Hierarchical Composite End Point	Crude percentage of wins	60.1	34.9	NR	NR	NR	NR
	Odds ratio (95% CI; p value)	1.72 (1.37, 2.15; <0.001)		NR	NR	NR	NR
Mean Change in KCCQ-OSS	Points	16.6	9.1	NR	NR	NR	NR
	Estimated Difference (95% CI; p value)	7.5 (4.4, 10.6)		NR	NR	NR	NR
≥5-point Increase in KCCQ-CSS	% of participants	75.3	63.7	NR	NR	NR	NR
	Odds ratio (95% CI; p value)	1.9 (1.3, 2.8)		NR	NR	NR	NR
≥10-point increase in KCCQ-CSS	% of participants	63.4	48.5	NR	NR	NR	NR
	Odds ratio (95% CI; p value)	2.1 (1.4, 3.1)		NR	NR	NR	NR
≥15-point Increase in KCCQ-CSS	% of participants	123 (50.6)	85 (35.9)	NR	NR	NR	NR
	Odds ratio (95% CI; p value)	2.2 (1.5, 3.2)		NR	NR	NR	NR
Attainment of Anchor-based Threshold for Change in 6MWT	% of participants	42.5	28	NR	NR	NR	NR
	Odds ratio (95% CI; p value)	2.0 (1.4 to 3.0)		NR	NR	NR	NR
Reduction in NT-proBNP Level	Percentage	-20.9	-5.3	NR	NR	NR	NR
	Estimated Treatment Ratio (95% CI; p value)	0.84 (0.71, 0.98)		NR	NR	NR	NR

Study Name		STEP-HFpEF		ESSENCE		SUMMIT	
Arms		SEM	PBO	SEM	PBO	TZP	PBO
N		263	266	534	266	364	367
Adjudicated Heart Failure Event, Time-to-event Analysis	Number of events	1	12	NR	NR	NR	NR
	Hazard Ratio (95% CI; p value)	0.08 (0.00 to 0.42)		NR	NR	NR	NR
Resolution of Steatohepatitis with No Worsening of Liver Fibrosis	% of participants	NR	NR	62.9	34.3	NR	NR
	Estimated treatment difference (95% CI; p value)	NR	NR	28.7 (21.1, 36.2; <0.001)		NR	NR
Reduction in Liver Fibrosis with No Worsening of Steatohepatitis	% of participants	NR	NR	36.8	22.4	NR	NR
	Estimated treatment difference (95% CI; p value)	NR	NR	14.4 (7.5, 21.3; <0.001)		NR	NR
Resolution of Steatohepatitis with Improvement in Liver Fibrosis	% of participants	NR	NR	32.7	16.1	NR	NR
	Estimated treatment difference (95% CI; p value)	NR	NR	16.5 (10.2, 22.8)		NR	NR
Proportion of Participants Achieving Decrease in Enhanced Liver Fibrosis Score of ≥5	% of participants	NR	NR	55.8	25.5	NR	NR
	Estimated treatment difference (95% CI; p value)	NR	NR	30.3 (23.3, 37.4)		NR	NR
Proportion of Participants Achieving Improvement in Liver Fibrosis	% of participants	NR	NR	40	26.9	NR	NR
	Estimated treatment difference (95% CI; p value)	NR	NR	13.1 (5.9, 20.3)		NR	NR
Proportion of Participants Achieving ≥25% Decrease in Liver Stiffness	% of participants	NR	NR	59.5	35.6	NR	NR
	Estimated treatment difference (95% CI; p value)	NR	NR	23.9 (15.5, 32.3)		NR	NR
Proportion of Participants Achieving ≥30% Decrease in Liver Stiffness	% of participants	NR	NR	52	30.3	NR	NR
	Estimated treatment difference (95% CI; p value)	NR	NR	21.7 (13.4, 29.9)		NR	NR
Decrease in Enhanced Liver Fibrosis Score of ≥0.5	% of participants	NR	NR	55.8	25.5		NR
eGFR Change	Mean change from baseline	NR	NR	NR	NR	2.6	-0.3
	Difference vs Placebo (95% CI; p value)	NR	NR	NR	NR	2.9 (0.9, 4.9); p = 0.004	

Study Name		STEP-HFpEF		ESSENCE		SUMMIT	
Arms		SEM	PBO	SEM	PBO	TZP	PBO
N		263	266	534	266	364	367
UACR Change	Mean change from baseline	NR	NR	NR	NR	-14.7	0.4
	Difference vs Placebo (95% CI; p value)	NR	NR	NR	NR	-15.1 (-28, 0.1); p = 0.051	
Adjudicated Worsening Heart-failure Event Resulting in Hospitalization, Intravenous Drugs in an Urgent Care Setting, or Intensification of oral Diuretic Therapy — no. (%)	Mean change from baseline	NR	NR	NR	NR	29 (8)	52 (14.2)
	Difference vs Placebo (95% CI; p value)	NR	NR	NR	NR	0.54 (0.34, 0.85)	
Adjudicated Worsening Heart-failure Event Resulting in Hospitalization, no. (%)	Mean change from baseline	NR	NR	NR	NR	12 (3.3)	26 (7.1)
	Difference vs Placebo (95% CI; p value)	NR	NR	NR	NR	0.44 (0.22, 0.87)	
Adjudicated Worsening Heart-failure Event Resulting in Intravenous Diuretic Therapy in an Urgent Care Setting, no. (%)	Mean change from baseline	NR	NR	NR	NR	5 (1.4)	12 (3.3)
	Difference vs Placebo (95% CI; p value)	NR	NR	NR	NR	0.41 (0.14, 1.16)	
Adjudicated Worsening Heart-failure Event Resulting in Intravenous Diuretic Therapy in an Outpatient Setting, no. (%)	Mean change from baseline	NR	NR	NR	NR	17 (4.7)	21 (5.7)
	Difference vs Placebo (95% CI; p value)	NR	NR	NR	NR	0.80 (0.42, 1.52)	

6MWT: 6 minute walk test, CI: confidence interval, eGFR: Estimated glomerular filtration rate, HDL: high-density lipoprotein, KCCQ: Kansas City Cardiomyopathy Questionnaire, LDL: low-density lipoprotein, no.: number, NT-proBNP: N-terminal pro B-type natriuretic peptide, UACR: Urine albumin-to-creatinine ratio

\*Estimated treatment ratio

†The hierarchical composite end point included death from any cause, the number and timing of heart failure events, differences of at least 15, at least 10, and at least 5 points in the change in the KCCQ-CSS, and a difference of at least 30 m in the change in the 6-minute walk distance.

**Table D2.30. Results of Knee Osteoarthritis Trial<sup>27</sup>**

Study Name		STEP-9	
		SEM	PBO
Arms		271	136
N		271	136
Body Weight Change from Baseline	Percent change	-13.7	-3.2
	Difference vs Placebo (95% CI; p value)	-10.5 (-12.3, -8.6; <0.001)	
≥5% body-weight Reduction	% of participants	85.2	33.6
	Odds ratio (95% CI; p value)	51.6 (41.6, 61.6; <0.001)	
≥10% body-weight Reduction	% of participants	68.1	12.9
	Odds ratio (95% CI; p value)	55.2 (46.1, 64.3; <0.001)	
≥15% body-weight Reduction	% of participants	45.6	4.5
	Odds ratio (95% CI; p value)	41.1 (33.3, 48.8)	
≥20% body-weight Reduction	% of participants	22.3	1.3
	Odds ratio (95% CI; p value)	21.0 (15.2, 26.8)	
Waist Circumference, cm	Mean change from baseline	-13	-6.1
	Difference vs Placebo (95% CI; p value)	-6.9 (-9.1, -4.7; <0.001)	
SF-36 Physical Functioning score	Mean change from baseline	12	6.5
	Difference vs Placebo (95% CI; p value)	5.6 (3.1, 8.0; <0.001)	
Clinically Meaningful SF-36 Physical Functioning Score Improvement (≥3.7 points)	% of participants	58	29.4
	Estimated treatment difference (95% CI; p value)	28.7 (18, 39.3)	
WOMAC Pain Score	Change from baseline	-41.7	-27.5
	Estimated treatment difference (95% CI)	-14.1 (-20, -8.3; <0.001)	
≥30% Reduction in WOMAC Pain Score	% of participants	77.6	57.8
	Estimated treatment difference (95% CI)	19.8 (9.3, 30.4)	
≥50% Reduction in WOMAC Pain Score	% of participants	65.2	35.3
	Estimated treatment difference (95% CI)	29.9 (19.1, 40.6)	
WOMAC Physical Function Score	Change from baseline	-41.5	-26.7
	Estimated treatment difference (95% CI)	14.9 (-20.4, -9.3; <0.001)	

Study Name		STEP-9	
Arms		SEM	PBO
N		271	136
Meaningful Improvement in WOMAC Physical Function Score ( $\geq 41.2$ point reduction)	Proportion of participants (%)	50.4	29
	Estimated treatment difference (95% CI)	21.4 (10.6, 32.2)	
6 -Minute Walk Distance	Mean change, meters	56.8	14.2
	Estimated treatment difference (95% CI)	42.6 (25.6, 59.7)	

CI: confidence interval, SF-36: Short Form 36, WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index

**Table D2.31. Results of Treatment Withdrawal Trials<sup>149,150</sup>**

Study Name		STEP-4		SURMOUNT-4	
Arms		SEM	PBO	TZP	PBO
N		535	268	335	335
Body-weight Change from Baseline	% (95% CI)	-7.9 (-8.6, -7.2)	6.9 (5.8, 7.9)	-5.5 (-6.8, -4.2)	14 (12.8, 15.2)
	Difference vs Placebo (95% CI; p value)	-14.8 (-16.0, -13.5; <0.001)		-19.4 (-21.2, -17.7)	
$\geq 5\%$ Body-weight Reduction	n (%)	NR	NR	326 (97.3)	235 (70.5)
	Odds ratio (95% CI; p value)	NR		20.3 (7.7, 53.3)	
$\geq 10\%$ Body-weight Reduction	n (%)	NR	NR	309 (92.1)	155 (46.2)
	Odds ratio (95% CI; p value)	NR		26.1 (12.6, 54.1)	
$\geq 15\%$ Body-weight Reduction	n (%)	NR	NR	282 (84.1)	87 (25.9)
	Odds ratio (95% CI; p value)	NR		32.6 (16.4, 64.8)	
$\geq 20\%$ Body-weight Reduction	% of participants	NR	NR	233 (69.5)	42 (12.6)
	Odds ratio (95% CI; p value)	NR		46.1 (20.7, 102.9)	
$\geq 25\%$ Body-weight Reduction	n (%)	NR	NR	183 (54.5)	17 (5)
	Odds ratio (95% CI; p value)	NR		61.5 (25.9, 146.1)	
Waist Circumference, cm	Mean change from baseline (95% CI)	-6.4 (-7.1, -5.7)	3.3 (2.3, 4.3)	-4.7 (-5.7, -3.6)	7.8 (6.9, 8.8)
	Difference vs Placebo (95% CI; p value)	-9.7 (-10.9, -8.5; <0.001)		-12.1 (-13.5, -10.6)	

Study Name		STEP-4		SURMOUNT-4	
Arms		SEM	PBO	TZP	PBO
N		535	268	335	335
Systolic Blood Pressure, mm Hg	Mean change from baseline	0.5 (-0.6, 1.6)	4.4 (2.9, 6.0)	NR	NR
	Difference vs Placebo (95% CI; p value)	-3.9 (-5.8, -2.0; < 0.001)		NR	
Clinically Meaningful SF-36 Physical Functioning Score Improvement (≥3.7 points)	% of participants	18	6.6	NR	NR
	Estimated treatment difference (95% CI; p value)	11.4 (6.5, 16.4; <0.0001)		NR	
Clinically Meaningful IWQOL-Lite-CT Physical Function Score Improvement (≥14.6 points)	% of participants	NR	NR	-4.7 (-5.7, -3.6)	11.1 (10.1, 12.2)
	Odds ratio (95% CI; p value)	NR		-15.8 (-17.3, -14.3)	
Body Weight, kg	Mean change from baseline (95% CI)	-7.1 (-7.8, -6.5)	6.1 (5.1, 7.0)	-4.7 (-5.7, -3.6)	11.1 (10.1, 12.2)
	Difference vs Placebo (95% CI; p value)	-13.2 (-14.3, -12.0; <0.001)		-15.8 (-17.3, -14.3)	
Body-mass Index	Mean change from baseline	-2.6 (-2.8, -2.4)	2.2 (1.8, 2.5)	NR	NR
	Difference vs Placebo (95% CI; p value)	-4.7 (-5.2, -4.3; <0.001)		NR	
Participants Maintaining ≥80% of Lead-in Body Weight Lost at Week 72	n (%)	NR	NR	300 (89.5)	55 (16.6)
	Odds ratio (95% CI; p value)	NR		44 (24.9, 77.5)	
Fasting Plasma Glucose, mg/dl	Mean change from baseline	-0.8 (-1.7, 0.1)	6.7 (4.9, 8.6)	NR	NR
	Difference vs Placebo (95% CI; p value)	-7.5 (-9.6, -5.4; <0.001)		NR	
Fasting Serum Insulin	% change from baseline	-20 (-20, -10)	0 (-10, 10)	NR	NR
	Difference vs Placebo (95% CI; p value)	-18 (-27, -8; <0.001)		NR	
Diastolic Blood Pressure, mm Hg	Mean change from baseline	0.3 (-0.4, 1.1)	0.9 (-0.4, 2.1)	NR	NR
	Difference vs Placebo (95% CI; p value)	-0.6 (-2.0, 0.9; 0.46)		NR	
Participants who Gained Weight	n (%)	79 (15.2)	206 (82.4)	NR	NR
	Odds ratio (95% CI; p value)	0.0 (0.0, 0.1; <0.001)		NR	

CI: confidence interval, cm: centimeter, IWQOL-Lite-CF: The Impact of Weight on Quality of Life–Lite Clinical Trials Version, kg: kilogram, mg/dl: milligrams per deciliter, mm Hg: millimeters of mercury, NR: not reported, SF-36: Short Form 36

**Table D2.32. Safety of Key Trials of Injectable Semaglutide<sup>18,22,23,25,119</sup>**

Study Name	STEP-1		STEP-3		STEP-5		STEP-8		STEP-10		
Arms	SEM	PBO	SEM	PBO	SEM	PBO	SEM	PBO	SEM	PBO	
N	1306	655	407	204	152	152	126	85	138	69	
Any Adverse Event, n (%)	1171 (89.7)	566 (86.4)	390 (95.8)	196 (96.1)	146 (96.1)	136 (89.5)	120 (95.2)	81 (95.3)	NR	NR	
Serious AE, n (%)	128 (9.8)	42 (6.4)	37 (9.1)	6 (2.9)	12 (7.9)	18 (11.8)	10 (7.9)	6 (7.1)	12 (9%)	6 (9%)	
Serious GI Disorders, n (%)	(1.4)	(0)	NR	NR	NR	NR	1 (0.8)	1 (1.2)	NR	NR	
Discontinuation due to AE, n (%)	Any	92 (7.0)	20 (3.1)	24 (5.9)	6 (2.9)	9 (5.9)	7 (4.6)	4 (3.2)	3 (3.5)	4 (3%)	0
	GI	59 (4.5)	5 (0.8)	14 (3.4)	0	6 (3.9)	1 (0.7)	NR	NR	NR	NR
Fatal Events, n (%)	1 (0.1)	1 (0.2)	NR	NR	1 (0.7)	0 (0)	0	0	2 (1%)	0	
<b>Most Common Adverse Events, n (%)</b>											
Nausea	577 (44.2)	114 (17.4)	237 (58.2)	45 (22.1)	81 (53.3)	33 (21.7)	77 (61.1)	19 (22.4)	NR	NR	
Diarrhea	412 (31.5)	104 (15.9)	147 (36.1)	45 (22.1)	53 (34.9)	36 (23.7)	35 (27.8)	22 (25.9)	NR	NR	
Vomiting	324 (24.8)	43 (6.6)	111 (27.3)	22 (10.8)	53 (34.9)	36 (23.7)	32 (25.4)	5 (5.9)	NR	NR	
Constipation	306 (23.4)	62 (9.5)	150 (36.9)	50 (24.5)	47 (30.9)	17 (11.2)	49 (38.9)	20 (23.5)	NR	NR	
Nasopharyngitis	281 (21.5)	133 (20.3)	90 (22.1)	49 (24.0)	24 (15.8)	23 (15.1)	10 (7.9)	9 (10.6)	NR	NR	
Headache	198 (15.2)	80 (12.2)	78 (19.2)	20 (9.8)	16 (10.5)	16 (10.5)	20 (15.9)	10 (11.8)	NR	NR	
Dyspepsia	135 (10.3)	23 (3.5)	NR	NR	20 (13.2)	7 (4.6)	11 (8.7)	5 (5.9)	NR	NR	
Abdominal Pain	130 (10.0)	36 (5.5)	54 (13.3)	10 (4.9)	20 (13.2)	4 (2.6)	NR	NR	NR	NR	
Abdominal Pain Upper	NR	NR	NR	NR	22 (14.5)	10 (6.6)	NR	NR	NR	NR	
Upper Respiratory Tract Infection	114 (8.7)	80 (12.2)	85 (20.9)	44 (21.6)	20 (13.2)	23 (15.1)	9 (7.1)	18 (21.2)	NR	NR	
Backpain	NR	NR	54 (13.3)	22 (10.8)	15 (9.9)	19 (12.5)	6 (4.8)	9 (10.6)	NR	NR	
Dizziness	NR	NR	52 (12.8)	11 (5.4)	NR	NR	NR	NR	NR	NR	
Fatigue	NR	NR	52 (12.8)	15 (7.4)	NR	NR	12 (9.5)	4 (4.7)	NR	NR	
Flatulence	NR	NR	47 (11.5)	23 (11.3)	20 (13.2)	10 (6.6)	NR	NR	NR	NR	
Gastroenteritis Viral	NR	NR	42 (10.3)	13 (6.4)	20 (13.2)	4 (2.6)	NR	NR	NR	NR	
Urinary Tract Infection	NR	NR	42 (10.3)	10 (4.9)	NR	NR	NR	NR	NR	NR	
Abdominal Distention	NR	NR	41 (10.1)	20 (9.8)	NR	NR	NR	NR	NR	NR	
Sinusitis	NR	NR	39 (9.6)	26 (12.7)	NR	NR	8 (6.3)	13 (15.3)	NR	NR	

<b>Arthralgia</b>	NR	NR	NR	NR	NR	NR	8 (6.3)	7 (8.2)	NR	NR
<b>Influenza</b>	NR	NR	NR	NR	20 (13.2)	16 (10.5)	5 (4.0)	6 (7.1)	NR	NR
<b>Decreased Appetite</b>	NR	NR	NR	NR	17 (11.2)	6 (3.9)	15(11.9)	3 (3.5)	NR	NR
<b>Eructation</b>	NR	NR	NR	NR	17 (11.2)	1 (0.7)	17 (13.5)	4 (4.7)	NR	NR

AE: adverse event, GI: gastrointestinal, NR: not reported, PBO: placebo, SEM: semaglutide,

**Table D2.33. Safety of Oral Semaglutide Trial<sup>134</sup>**

Study Name		OASIS-4	
		SEM	PBO
		205	102
Any Adverse Event, %		93.1%	85.3%
Serious Adverse Events, %		3.9%	8.8%
Serious Gastrointestinal Disorders, %		0	1%
Adverse Events Leading to Discontinuation, %	Any	6.9%	5.9%
	Gastrointestinal Disorders	3.4%	2.0%
Fatal Events, n (%)		0	0
<b>Most Common Adverse Events, n (%)</b>			
Nervous System Disorder		51 (25)	15 (14.7)
Metabolism and Nutritional Disorders		30 (14.7)	9 (8.8)
Musculoskeletal and Connective Tissue Disorders		30 (14.7)	21 (20.6)
Skin and Subcutaneous Tissue Disorders		27 (13.2)	10 (9.8)
General Disorders and Administration Site Conditions		36 (17.6)	6 (5.9)
Respiratory, Thoracic and Mediastinal Disorders		24 (11.8)	11 (10.8)
Injury, Poisoning and Procedural Complications		23 (11.3)	14 (13.7)
Psychiatric Disorders		18 (8.8)	13 (12.7)
Vascular Disorders		13 (6.4)	6 (5.9)
Cardiac Disorders		3 (1.5)	6 (5.9)
Reproductive System and Breast Disorders		11 (5.4)	2 (2)
Gastrointestinal Disorders		151 (74)	43 (42.2)

PBO: placebo, SEM: semaglutide

**Table D2.34. Safety of Key Trials of Tirzepatide<sup>42,43</sup>**

Study Name		SURMOUNT-1		SURMOUNT-3			
		Arms		TZP	PBO	TZP	PBO
		N		630	643	287	292
<b>Any Adverse Event, n (%)</b>		497 (78.9)	463 (72.0)	250 (87.1)	224 (76.7)		
<b>Serious Adverse Events, n (%)</b>		32 (5.1)	44 (6.8)	17 (5.9)	14 (4.8)		
<b>Serious Gastrointestinal Disorders, n (%)</b>		21 (3.3)	7 (1.1)	16 (5.6)	5 (1.7)		
<b>Adverse Events Leading to Discontinuation, n (%)</b>	<b>Any</b>	39 (6.2)	17 (2.6)	30 (10.5)	6 (2.1)		
	<b>Nausea</b>	12 (1.9)	2 (0.3)	24 (8.4)	4 (1.4)		
	<b>Diarrhea</b>	3 (0.5)	0	3 (1)	0		
	<b>Abdominal Pain</b>	3 (0.5)	0	NR	NR		
	<b>Dyspepsia</b>	NR	NR	3 (1)	0		
	<b>Vomiting</b>	0	0	6 (2.1)	0		
	<b>Constipation</b>	NR	NR	2 (0.7)	0		
<b>Fatal Events/Death, n (%)</b>		1 (0.2)	4 (0.6)	1 (0.3)	1 (0.3)		
<b>Safety Focus Areas, n (%)</b>	<b>Nausea</b>	195 (31)	61 (9.5)	114 (39.7)	41 (14)		
	<b>Diarrhea</b>	145 (23)	47 (7.3)	89 (31)	27 (9.2)		
	<b>Vomiting</b>	77 (12.2)	11 (1.7)	52 (18.1)	4 (1.4)		
	<b>Constipation</b>	74 (11.7)	37 (5.8)	66 (23)	20 (6.8)		
	<b>Nasopharyngitis</b>	NR	NR	NR	NR		
	<b>Headache</b>	41 (6.5)	42 (6.5)	27 (9.4)	22 (7.5)		
	<b>Dyspepsia</b>	71 (11.3)	27 (4.2)	27 (9.4)	9 (3.1)		
	<b>Abdominal Pain</b>	31 (4.9)	21 (3.3)	30 (10.5)	7 (2.4)		
	<b>Upper Respiratory Tract Infection</b>	NR	NR	25 (8.7)	21 (7.2)		
	<b>Backpain</b>	NR	NR	17 (5.9)	15 (5.1)		
	<b>Dizziness</b>	NR	NR	20 (7.0)	6 (2.1)		
	<b>Fatigue</b>	NR	NR	20 (7.0)	9 (3.1)		
	<b>Flatulence</b>	NR	NR	19 (6.6)	8 (2.7)		
	<b>Urinary Tract Infection</b>	NR	NR	11 (3.8)	15 (5.1)		
<b>Sinusitis</b>	NR	NR	6 (2.1)	16 (5.5)			

Study Name		SURMOUNT-1		SURMOUNT-3	
		TZP	PBO	TZP	PBO
Arms		630	643	287	292
N		630	643	287	292
	Arthralgia	NR	NR	7 (2.4)	15 (5.1)
	Influenza	NR	NR	12 (4.2)	25 (8.6)
	Decreased Appetite	54 (8.6)	21 (3.3)	27 (9.4)	12 (4.1)
	Alopecia	36 (5.7)	6 (0.9)	20 (7)	4 (1.4)
	Eructation	35 (5.6)	4 (0.6)	16 (5.6)	3 (1)
	Gallbladder-related Disorders	6 (1)	5 (0.8)	2 (0.7)	0
	Hepatic Disorders	0	0	NR	NR
	Acute Pancreatitis	1 (0.2)	1 (0.2)	1 (0.3)	1 (0.3)
	MACE	0	5 (0.8)	1 (0.3)	1 (0.3)
	Cardiac Disorders	2 (0.3)	1 (0.2)	0	1 (0.3)
	Allergic Reactions or Hypersensitivity	1 (0.2)	0	NR	NR
	Injection-site Reactions	29 (4.6)	2 (0.3)	32 (11.1)	3 (1)
	Malignant Neoplasms/Cancers	5 (0.8)	7 (1.1)	5 (1.7)	3 (1)
	Anxiety	NR	NR	9 (3.1)	19 (6.5)
	Major Depressive Disorder or Suicidal Ideation	2 (0.3)	0	1 (0.3)	0
	Hypoglycemia	10 (1.6)	1 (0.2)	NR	NR
Serious Hepatobiliary Disorders Reported in >1% of participants, n (%)	Cholelithiasis	4 (0.6)	6 (0.9)	NR	NR
	Acute Cholecystitis	1 (0.2)	0	NR	NR
	Cholecystitis	0	0	NR	NR
	Chronic Cholecystitis	3 (0.5)	3 (0.5)	NR	NR

MACE: Major Adverse Cardiovascular Events, PBO: placebo, TZP: tirzepatide

**Table D2.35. Safety of Direct Comparison Trial<sup>44</sup>**

Study Name		SURMOUNT-5	
Arms		TZP	SEM
N		374	376
Any Adverse Event, n (%)		287 (76.7)	297 (79)
Serious Adverse Events, n (%)		18 (4.8)	13 (3.5)
Serious Gastrointestinal Disorders, n (%)		17 (4.5)	14 (3.7)
Adverse Events Leading to Discontinuation, n (%)	Any	23 (6.1)	30 (8)
	GI related	10 (2.7)	21 (5.6)
	Nausea	5 (1.3)	7 (1.9)
	Diarrhea	1 (0.3)	2 (0.5)
	Vomiting	3 (0.8)	4 (1.1)
	Fatigue	1 (0.3)	1 (0.3)
	Cholelithiasis	0	2 (0.5)
	Constipation	1 (0.3)	2 (0.5)
Fatal Events/Death, n (%)		0	0
Safety Focus Areas, n (%)	Nausea	163 (43.6)	167 (44.4)
	Diarrhea	88 (23.5)	88 (23.4)
	Vomiting	56 (15)	80 (21.3)
	Constipation	101 (27)	107 (28.5)
	Nasopharyngitis	17 (4.5)	23 (6.1)
	Headache	27 (7.2)	27 (7.2)
	Dyspepsia	22 (5.9)	28 (7.4)
	Abdominal pain	24 (6.4)	26 (6.9)
	Upper Respiratory Tract Infection	32 (8.6)	43 (11.4)
	Dizziness	24 (6.4)	18 (4.8)
	Fatigue	39 (10.4)	46 (12.2)
	Abdominal Distention	27 (7.2)	24 (6.4)
	Sinusitis	11 (2.9)	21 (5.6)
Decreased Appetite	17 (4.5)	19 (5.1)	

Study Name		SURMOUNT-5	
Arms		TZP	SEM
N		374	376
	Alopecia	31 (8.3)	23 (6.1)
	Eructation	37 (9.9)	29 (7.7)
	GERD	23 (6.1)	40 (10.6)
	Gallbladder-related Disorders	4 (1.1)	5 (1.3)
	Hepatic Disorders	1 (0.3)	0
	Acute Pancreatitis	0	1 (0.3)
	MACE	0	0
	Cardiac Disorders	3 (0.8)	1 (0.3)
	Allergic Reactions or Hypersensitivity	0	0
	Injection-site Reactions	32 (8.6)	1 (0.3)
	Major Depressive Disorder or Suicidal Ideation	0	0
	Acute renal failure	1 (0.3)	0
	Hypoglycemia	0	1 (0.3)
Renal events, n (%)		1 (0.3)	0
COVID-19, n (%)		51 (13.6)	47 (12.5)

GERD: Gastroesophageal Reflux Disease, GI: Gastrointestinal, MACE: Major Adverse Cardiovascular Events, SEM: semaglutide, TZP: tirzepatide

**Table D2.36. Safety of Cardiovascular Trials<sup>18,156,160</sup>**

Study Name		SELECT	
Arms		SEM	PBO
N		8803	8801
Serious adverse events, n (%)		2941 (33.4)	3204 (36.4)
Serious gastrointestinal disorders, n (%)		342 (3.9)	323 (3.7)
AE leading to discontinuation, n (%)	Any	1461 (16.6)	718 (8.2)
	Gastrointestinal disorders	880 (10)	172 (2)
Fatal events, n (%)		375 (4.3)	458 (5.2)

Study Name		SELECT	
Arms		SEM	PBO
N		8803	8801
Safety Focus Areas, n (%)	Gallbladder-related Disorders	246 (2.8)	203 (2.3)
	Acute Pancreatitis	17 (0.2)	24 (0.3)
	Malignant Neoplasms	422 (4.8)	418 (4.7)
	Acute Renal Failure	171 (1.9)	200 (2.3)
	COVID-19	2108 (23.9)	2150 (24.4)
Serious AEs by System Organ Class, n (%)	Gastrointestinal Disorders	342 (3.9)	323 (3.7)
	Infections and Infestations	624 (7.1)	738 (8.4)
	Neoplasms Benign, Malignant, and Unspecified (including cysts and polyps)	405 (4.6)	402 (4.6)
	Cardiac Disorders	1008 (11.5)	11184 (13.5)
	Injury, Poisoning, and Procedural Complications	305 (3.5)	313 (3.6)
	Reproductive System and Breast Disorders	65 (0.7)	43 (0.5)
	Eye Disorders	41 (0.5)	41 (0.5)
	General Disorders and Administration Site Conditions	273 (3.1)	316 (3.6)
	Hepatobiliary Disorders	126 (1.4)	105 (1.2)
	Musculoskeletal and Tissue Disorders	236 (2.7)	254 (2.9)
	Product Issues	11 (0.1)	16 (0.2)
	Nervous System Disorder	444 (5)	496 (5.6)
	Vascular Disorders	231 (0.6)	259 (2.9)
	Medical Procedures	433 (4.9)	548 (6.2)
Serious GI Disorders, %	Inguinal Hernia	0.4	0.3
	Diarrhea	0.3	0.2
	Gastrointestinal Hemorrhage	0.3	0.2
	Vomiting	0.2	0.1
Events Adjudication Committee Confirmed Deaths		375 (4.3)	458 (5.2)
Cardiovascular Death, n (%)		223 (2.5)	262 (3)
Non-cardiovascular Death, n (%)		152 (1.7)	196 (2.2)
	Acute MI	12 (0.1)	15 (0.2)

Study Name		SELECT	
Arms		SEM	PBO
N		8803	8801
Common Causes of CV Death, n (%)	Heart Failure	14 (0.2)	16 (0.2)
	Sudden Cardiac Death	98 (1.1)	109 (1.2)
	Stroke	15 (0.2)	21 (0.2)
Gastrointestinal Death, n (%)		3 (<0.1)	5 (<0.1)

AE: adverse event, CV: cardiovascular, GI: gastrointestinal, MI: myocardial infarction, PBO: placebo, SEM: semaglutide

**Table D2.37. Safety of Obstructive Sleep Apnea Trial<sup>20</sup>**

Study Name		SURMOUNT-OSA			
Arm		TZP	PBO	TZP	PBO
N		114	120	120	115
Any Adverse Event, n (%)		91 (79.8)	92 (76.7)	99 (83.2)	83 (72.8)
Serious Adverse Events, n (%)		9 (7.9)	7 (5.8)	7 (5.9)	12 (10.5)
Serious Gastrointestinal Disorders, n (%)		4 (3.5)	0	4 (3.4)	0
Adverse Events Leading to Discontinuation, n (%)		5 (4.4)	2 (1.7)	4 (3.4)	8 (7)
Fatal Events/Death, n (%)		0	0	0	0
Safety Focus Areas, n (%)	Nausea	29 (25.4)	12 (10)	26 (21.8)	6 (5.3)
	Diarrhea	30 (26.3)	15 (12.5)	26 (21.8)	10 (8.8)
	Vomiting	20 (17.5)	5 (4.2)	11 (9.2)	1 (0.9)
	Constipation	18 (15.8)	3 (2.5)	18 (15.1)	5 (4.4)
	Nasopharyngitis	3 (2.6)	8 (6.7)	15 (12.6)	12 (10.5)
	Dyspepsia	5 (4.4)	2 (1.7)	11 (9.2)	1 (0.9)
	Abdominal Pain	7 (6.1)	4 (3.3)	5 (4.2)	2 (1.8)
	Upper Respiratory Tract Infection	7 (6.1)	10 (8.3)	5 (4.2)	8 (7)
	Gastroenteritis Viral	3 (2.6)	4 (3.3)	8 (6.7)	11 (9.6)
	Arthralgia	3 (2.6)	6 (5)	4 (3.4)	5 (4.4)
	Influenza	4 (3.5)	8 (6.7)	3 (2.5)	3 (2.6)

Study Name		SURMOUNT-OSA			
		TZP	PBO	TZP	PBO
Arm					
N		114	120	120	115
	Eructation	9 (7.9)	0	10 (8.4)	1 (0.9)
	GERD	9 (7.9)	1 (0.8)	6 (5)	0
	Hepatic Disorders	0	0	0	0
	Acute Pancreatitis	0	0	2 (1.7)	0
	MACE	0	0	0	1 (0.9)
	Cardiac Disorders	7 (6.1)	9 (7.5)	6 (5.0)	2 (1.8)
	Allergic Reactions or Hypersensitivity	0	0	0	0
	Injection-site Reactions	8 (7)	1 (0.8)	6 (5)	0
	Major Depressive Disorder or Suicidal Ideation	2 (1.8)	1 (0.8)	0	2 (1.8)
	Hypoglycemia	0	0	0	0
<b>Renal Events, n (%)</b>		0	0	1 (0.8)	0
<b>COVID-19, n (%)</b>		6 (5.3)	10 (8.3)	8 (6.7)	11 (9.6)
<b>Bronchitis</b>		0	0	3 (2.5)	7 (6.1)
<b>Hypertension</b>		1 (0.9)	8 (6.7)	2 (1.7)	2 (1.8)
<b>Upper Abdominal Pain</b>		4 (3.5)	2 (1.7)	7 (5.9)	2 (1.8)

GERD: Gastroesophageal Reflux Disease, MACE: Major Adverse Cardiovascular Events, PBO: placebo TZP: tirzepatide

**Table D2.38. Safety of Additional Clinical Trials<sup>28,29,47</sup>**

Study Name		STEP-HFpEF		ESSENCE		SUMMIT	
Arms		SEM	PBO	SEM	PBO	TZP	PBO
N		263	266	800	395	364	367
<b>Any Adverse Event, n (%)</b>		NR	NR	690 (86.2)	315 (79.7)	313 (86)	279 (76)
<b>Serious Adverse Events, n (%)</b>		35 (13.3)	71 (26.7)	107 (13.4)	53 (13.4)	96 (26.4)	94 (25.6)
<b>AEs Leading to Discontinuation, n (%)</b>	<b>Any</b>	35 (13.3)	14 (5.3)	21 (2.6)	13 (3.3)	23 (6.3)	5 (1.4)
	<b>Gastrointestinal Disorders</b>	25 (9.5)	7 (2.6)	NR	NR	NR	NR
<b>Fatal Events, n (%)</b>		3 (1.1)	4 (1.5)	3 (0.4)	6 (1.5)	NR	NR
<b>Common AEs Reported, n (%)</b>	<b>Nausea</b>	NR	NR	290 (36.2)	52 (13.2)	62 (17)	24 (6.5)
	<b>Diarrhea</b>	NR	NR	215 (26.9)	48 (12.2)	67 (18.4)	23 (6.3)
	<b>Vomiting</b>	NR	NR	149 (18.6)	22 (5.6)	38 (10.4)	8 (2.2)
	<b>Constipation</b>	NR	NR	178 (22.2)	33 (8.4)	54 (14.8)	22 (6)
	<b>Decreased Appetite</b>	NR	NR	112 (14.0)	11 (2.8)	38 (10.4)	6 (1.6)
	<b>Nervous System Disorder</b>	8 (3.0)	7 (2.6)	NR	NR	NR	NR
	<b>Metabolism and Nutrition Disorders</b>	3 (1.1)	4 (1.5)	NR	NR	NR	NR
	<b>Musculoskeletal and Connective Tissue Disorders</b>	4 (1.5)	4 (1.5)	NR	NR	NR	NR
	<b>General Disorders and Administration Site Conditions</b>	1 (0.4)	3 (1.1)	NR	NR	NR	NR
	<b>Respiratory, Thoracic and Mediastinal Disorders</b>	0	10 (3.8)	NR	NR	NR	NR
	<b>Injury, Poisoning and Procedural Complications</b>	4 (1.5)	4 (1.5)	NR	NR	NR	NR
	<b>Cardiac Disorders</b>	7 (2.7)	30 (11.3)	NR	NR	NR	NR
	<b>Renal or Urinary Disorder</b>	6 (2.3)	4 (1.5)	NR	NR	NR	NR
	<b>Coronavirus Disease 2019</b>	NR	NR	134 (16.8)	74 (18.7)	NR	NR
	<b>Gastrointestinal Disorders</b>	7 (2.7)	7 (2.6)	NR	NR	NR	NR
<b>Safety Focus Areas, n (%)</b>	<b>Gastrointestinal Disorders</b>	7 (2.7)	7 (2.6)	NR	NR	NR	NR
	<b>Gallbladder-related Disorders</b>	NR	NR	20 (2.5)	6 (1.5)	NR	NR
	<b>Hepatobiliary Disorders</b>	3 (1.1)	2 (0.8)	NR	NR	NR	NR
	<b>Acute Pancreatitis</b>	0	1 (0.4)	3 (0.4)	2 (0.5)	NR	NR

Study Name		STEP-HFpEF		ESSENCE		SUMMIT	
Arms		SEM	PBO	SEM	PBO	TZP	PBO
N		263	266	800	395	364	367
	<b>Cardiovascular Disorders</b>	18 (6.8)	41 (15.4)	NR	NR	NR	NR
	<b>Malignant Neoplasms</b>	1 (0.4)	3 (1.1)	13 (1.6)	9 (2.3)	NR	NR
	<b>Neoplasms</b>	2 (0.8)	6 (2.3)	NR	NR	NR	NR
	<b>Acute Renal Failure</b>	5 (1.9)	1 (0.4)	NR	NR	5 (1.4)	3 (0.8)
	<b>Infections and Infestations</b>	4 (1.5)	17 (6.4)	NR	NR	NR	NR
	<b>Misuse and Abuse</b>	0	0	NR	NR	NR	NR
	<b>Medical Errors</b>	0	0	NR	NR	NR	NR
	<b>Gallstone Disease</b>	3 (1.1)	3 (1.1)	NR	NR	NR	NR
	<b>COVID-19</b>	39 (14.8)	45 (16.9)	NR	NR	NR	NR
	<b>Dyspepsia</b>	NR	NR	NR	NR	23 (6.3)	8 (2.2)
	<b>Dizziness</b>	NR	NR	NR	NR	34 (9.3)	18 (4.9)
	<b>Urinary Tract Infection</b>	NR	NR	NR	NR	36 (9.9)	22 (6)
<b>Serious Cardiac Disorders Reported in &gt;1% of Participants, n (%)</b>	<b>Cardiac Failure</b>	NR	NR	NR	NR	15 (4.1)	30 (8.2)
	<b>Atrial Fibrillation</b>	NR	NR	NR	NR	7 (1.9)	3 (0.8)
	<b>Acute MI</b>	NR	NR	NR	NR	6 (1.6)	2 (0.5)
	<b>Unstable Angina</b>	NR	NR	NR	NR	3 (0.8)	5 (1.4)

AE: adverse event, NR: not reported, PBO: placebo, SEM: semaglutide

**Table D2.39. Safety of Knee Osteoarthritis Trial<sup>27</sup>**

Study Name		STEP-9	
Arms		SEM	PBO
N		269	135
Serious Adverse Events, n (%)		27 (10.0)	11 (8.1)
AE Leading to Discontinuation, n (%)	Any	18 (6.7)	4 (3.0)
	GI Disorders	6 (2.2)	0
Fatal Events, n (%)		0	0
Safety Focus Areas, n (%)	Gastrointestinal Disorders	4 (1.5)	1 (0.7)
	Gallbladder-related Disorders	3 (1.1)	1 (0.7)
	Acute Pancreatitis	0	0
	Cardiovascular Disorders	3 (1.1)	2 (1.5)
	Malignant Neoplasms	8 (3.0)	2 (1.5)
	Neoplasms	10 (3.7)	6 (4.4)
	Psychiatric Disorders	0	1 (0.7)
	Acute Renal Failure	0	1 (0.7)
	Medical Errors	2 (0.7)	4 (3.0)
	Joint Replacement	2 (0.7)	0
	COVID-19	51 (19.0)	32 (23.7)

AE: adverse event, GI: gastrointestinal

**Table D2.40. Safety of Treatment Withdrawal Trials<sup>149,150</sup>**

Study Name		STEP-4		SURMOUNT-4	
Arms		SEM	PBO	TZP	PBO
N		535	268	335	335
Any Adverse Event, n (%)		435(81.3)	201(75.0)	202 (60.3)	187 (55.8)
Serious Adverse Events, n (%)		41(7.7)	15(5.6)	10 (3)	10 (3)
Serious Gastrointestinal Disorders, n (%)		NR	NR	6 (1.8)	1 (0.3)
AE Leading to Discontinuation, n (%)		13(2.4)	6(2.2)	6 (1.8)	3 (0.9)
Fatal Events, n (%)		1(0.2)	1(0.4)	1 (0.3)	1 (0.3)
Adverse Events Reported in ≥10% of Participants, n (%)	Nausea	75(14.0)	13(4.9)	27 (8.1)	9 (2.7)
	Diarrhea	77(14.4)	19(7.1)	36 (10.7)	16 (4.8)
	Vomiting	55(10.3)	8(3.0)	19 (5.7)	4 (1.2)
	Constipation	62(11.6)	17(6.3)	NR	NR
	Nasopharyngitis	58(10.8)	39(14.6)	NR	NR
	Headache	41(7.7)	10(3.7)	NR	NR
	Abdominal Pain	35(6.5)	8(3.0)	NR	NR
	Upper Respiratory Tract Infection	NR	NR	8 (2.4)	18 (5.4)
	Backpain	28(5.2)	18(6.7)	NR	NR
	Arthralgia	25(4.7)	14(5.2)	NR	NR
	Influenza	39(7.3)	19(7.1)	NR	NR
	Cardiac Disorders	NR	NR	0	0
Safety Focus Areas, n (%)	Gastrointestinal Disorders	224(41.9)	70(26.1)	NR	NR
	Gallbladder-related Disorders	15(2.8)	10(3.7)	0	3 (0.9)
	Hepatic Disorders	11(2.1)	4(1.5)	0	0
	Acute Pancreatitis	0	0	NR	NR
	Cardiovascular Disorders	26(4.9)	30(11.2)	NR	NR
	Allergic Reactions	26(4.9)	11(4.1)	NR	NR
	Injection-site Reactions	14(2.6)	6(2.2)	NR	NR
Malignant Neoplasms	6(1.1)	1(0.4)	0	3 (0.9)	

Study Name		STEP-4		SURMOUNT-4	
Arms		SEM	PBO	TZP	PBO
N		535	268	335	335
	<b>Psychiatric Disorders</b>	46(8.6)	35(13.1)	NR	NR
	<b>Acute Renal Failure</b>	1(0.2)	1(0.4)	NR	NR
	<b>Hypoglycemia</b>	3(0.6)	3(1.1)	2 (0.6)	0

AE: adverse event, NR: not reported

**Table D2.41. Treatment Withdrawal Subgroup<sup>62</sup>**

STEP-1							
	Arm	Outcome	Weight Loss from Baseline to Week 68				
			<5% Subgroup	≥5 – <10% Subgroup	≥10 – <15% Subgroup	≥15 – <20% Subgroup	≥20% Subgroup
Change in Body Weight from Week 68 to Week 120	SEM	N	12	35	37	45	68
		Change, % points ± SD	4.8 ± 6.7	7.3 ± 6.0	10.7 ± 5.1	11.9 ± 7.1	15.4 ± 8.1
	PBO	N	69	16	5	2	1
		Change, % points ± SD	0.8 ± 4.6	4.4 ± 3.1	4.1 ± 4.2	9.8 ± 0.2	10.8 ± NA

NA: not applicable, SD: standard deviation

**Table D2.42. Body Composition Subgroup<sup>22</sup>**

Study Name		STEP-1	
Arm		SEM	PBO
N		95	45
Total Fat Mass, kg	Change from baseline	-10.4	-1.17
	Estimated treatment difference (95% CI)	-9.23 (-12.72, -5.74)	
Total Fat Mass, percentage	Change from baseline	-4.19	-0.19
	Estimated treatment difference (95% CI)	-4.00 (-6.27, -1.73)	
Regional Cisceral Fat Mass, kg	Change from baseline	-0.47	-0.03
	Estimated treatment difference (95% CI)	-0.45 (-0.60, -0.30)	
Regional Visceral Fat Mass, percentage	Change from baseline	-2.65	0.58
	Estimated treatment difference (95% CI)	-3.23 (-5.35, -1.10)	
Total Lean Body Mass, kg	Change from baseline	-6.92	-1.48
	Estimated treatment difference (95% CI)	-5.44 (-7.07, -3.81)	
Total Lean Body Mass, percentage	Change from baseline	3.61	0.11
	Estimated treatment difference (95% CI)	3.50 (1.35, 5.64)	

CI: confidence interval, kg: kilogram

### D3. Ongoing Studies

**Table D3.1. Ongoing Studies**

Trial Name/NCT	Design	Treatment Arms	Inclusion Criteria	Exclusion Criteria	Primary Outcome
<b>SURMOUNT- MAINTAIN NCT06047548</b>	Phase III, randomized, open-label, multicenter study  N=400  Population: Adults with obesity or overweight with weight-related comorbidities	-Tirzepatide s.c. maximum tolerated dose -Placebo	-BMI $\geq 30$ or $\geq 27$ with presence of comorbidity -History of at least one self-reported unsuccessful dietary effort to lose body weight	-Diabetes mellitus -Change of $\geq 5$ kg in body weight within 3 months -Prior of or planned surgical treatment for obesity	Percent maintenance of body weight reduction during the 60-week weight loss period [week 112]

BMI: body mass index, N: number

Source: [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov)

## **D4. Previous Systematic Reviews and Technology Assessments**

We identified 12 systematic literature reviews or meta-analyses evaluating therapies for weight-loss treatment in adults with overweight or obesity, 3 of which are summarized below.

### **Qin, W., et al. (2024) “Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial”<sup>161</sup>**

This systematic review and meta-analysis aimed to explore the safety and efficacy of once-weekly injectable semaglutide 2.4 mg in non-diabetic patients with overweight or obesity. The primary objective was to assess efficacy, measured by the mean change in body weight and the proportion of patients achieving weight loss exceeding 5%, 10%, 15% and 20% following treatment. The authors’ literature search identified six randomized controlled trials involving a total of 3,962 patients that met the inclusion criteria. For the primary outcome, the findings strongly support a significant and clinically meaningful reduction in body weight with semaglutide use. Compared to placebo, semaglutide resulted in an average body weight reduction of 11.80%, equivalent to approximately 12.2 kg. Furthermore, the semaglutide group significantly outperformed the placebo group in terms of the proportion of patients achieving weight loss thresholds of 5%, 10%, 15% and 20%. Regarding safety, both groups reported similar rates of adverse and serious events. However, the semaglutide group experienced significantly higher rates of gastrointestinal adverse events and treatment discontinuation due to adverse events. The authors acknowledge several limitations, including reliance on published study-level data rather than real-world patient data, which may overestimate the therapeutic effects of semaglutide and introduce potential reporting bias. Additionally, the trials predominantly involved White individuals from Western countries. Therefore, further research involving more racially and geographically diverse populations is warranted to confirm the generalizability of these findings.

### **Dutta, D., et al. (2024) “Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis”<sup>162</sup>**

This systematic review and meta-analysis aimed to evaluate the efficacy and safety of tirzepatide as an anti-obesity agent in individuals without diabetes. The primary outcome was the percentage change in weight from baseline. Secondary outcomes included absolute weight change and the proportion of participants achieving weight reductions of  $\geq 5\%$ ,  $\geq 10\%$ ,  $\geq 15\%$ ,  $\geq 20\%$ , and  $\geq 25\%$ . A literature search was conducted for randomized controlled trials published up to November 2023

that assessed tirzepatide for weight loss in non-diabetic populations. Of the 281 articles identified in the search, two randomized controlled trials met the inclusion criteria and were included in the final analysis. These studies collectively enrolled 1,852 participants and had intervention durations of 72 weeks. Participants receiving tirzepatide experienced a mean percentage weight reduction of 19.44%, corresponding to an absolute weight loss of 17.55 kg over 18 months. These outcomes were significantly greater than those observed in the placebo groups. Additionally, a significantly higher proportion of participants in the tirzepatide group achieved weight loss thresholds of  $\geq 5\%$ ,  $\geq 10\%$ ,  $\geq 15\%$ ,  $\geq 20\%$ , and  $\geq 25\%$ . In terms of safety, tirzepatide was associated with a higher incidence of any adverse events, adverse events leading to treatment discontinuation, severe or serious gastrointestinal events and hypoglycaemia. The rate of serious adverse events was comparable between the tirzepatide and placebo groups. A key limitation of this review is the lack of data representing diverse ethnic populations and geographic regions, limiting the generalizability of the findings. Further long-term studies are needed to assess the durability of weight loss and to evaluate outcomes across more diverse populations.

### **Müllertz, A., et al. (2024) “Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety”<sup>163</sup>**

This systematic review and meta-analysis evaluated the efficacy and safety of injectable semaglutide and tirzepatide at obesity-approved doses in individuals with overweight or obesity, without diabetes, treated for at least one year. Primary outcomes included changes in body weight and waist circumference, with additional consideration of body composition. Researchers searched three databases for randomized controlled trials involving semaglutide or tirzepatide in this population, identifying 744 results. Seven studies met inclusion criteria: five from the STEP trials (semaglutide) and two from the SURMOUNT program (tirzepatide). In the STEP trials, semaglutide led to a pooled mean body weight reduction of 12.9% and a waist circumference decrease of 9.7 cm compared to placebo. In the SURMOUNT trials, tirzepatide showed a mean body weight reduction of 19.2% and a waist circumference decrease of 14.6 cm. Two studies assessed body composition using dual-energy X-ray absorptiometry. In STEP-1, semaglutide reduced fat mass by 8.4 kg and lean mass by 5.3 kg, compared to 1.4 kg and 1.8 kg reductions with placebo, respectively. In SURMOUNT-1, pooled tirzepatide reduced fat mass by 33.9% and lean mass by 10.9%, versus 8.2% and 2.6% with placebo. Adverse events were common for both drugs. In STEP trials, 91.0% of semaglutide-treated participants and 88.9% of placebo participants reported at least one event, primarily gastrointestinal (nausea, diarrhea, constipation, vomiting). In the SURMOUNT trials, 81.5% of tirzepatide-treated participants and 73.5% of those on placebo reported adverse events, with gastrointestinal symptoms again being the most frequent. Limitations include the small number of tirzepatide studies, suggesting stronger evidence currently exists for semaglutide. Additionally, details on study design and adherence to lifestyle interventions were often lacking.

# E. Long-Term Cost-Effectiveness: Supplemental Information

## E1. Detailed Methods

Table E1.1. Impact Inventory

Sector	Type of Impact (Add additional domains, as relevant)	Included in This Analysis from [...] Perspective?		Notes on Sources (if quantified), Likely Magnitude & Impact (if not)
		Health Care Sector	Societal	
<b>Formal Health Care Sector</b>				
<b>Health Outcomes</b>	Longevity effects	X	X	
	Health-related quality of life effects	X	X	
	Adverse events	X	X	
<b>Medical Costs</b>	Paid by third-party payers	X	X	
	Paid by patients out-of-pocket	<input type="checkbox"/>	<input type="checkbox"/>	
	Future related medical costs	X	X	
	Future unrelated medical costs	X	X	
<b>Informal Health Care Sector</b>				
<b>Health-Related Costs</b>	Patient time costs	NA	<input type="checkbox"/>	
	Unpaid caregiver-time costs	NA	<input type="checkbox"/>	
	Transportation costs	NA	<input type="checkbox"/>	
<b>Non-Health Care Sector</b>				
<b>Productivity</b>	Labor market earnings lost	NA	X	
	Cost of unpaid lost productivity due to illness	NA	X	
	Cost of uncompensated household production	NA	<input type="checkbox"/>	
<b>Consumption</b>	Future consumption unrelated to health	NA	<input type="checkbox"/>	
<b>Social Services</b>	Cost of social services as part of intervention	NA	<input type="checkbox"/>	
<b>Legal/Criminal Justice</b>	Number of crimes related to intervention	NA	<input type="checkbox"/>	
	Cost of crimes related to intervention	NA	<input type="checkbox"/>	
<b>Education</b>	Impact of intervention on educational achievement of population	NA	<input type="checkbox"/>	
<b>Housing</b>	Cost of home improvements, remediation	NA	<input type="checkbox"/>	
<b>Environment</b>	Production of toxic waste pollution by intervention	NA	<input type="checkbox"/>	
<b>Other</b>	Other impacts (if relevant)	NA	<input type="checkbox"/>	

NA: not applicable

Adapted from Sanders et al<sup>164</sup>

## Description of evLY Calculations

The equal value life year (evLY) considers any extension of life at the same “weight” no matter what treatment is being evaluated or what population is being modeled. Below are the stepwise calculations used to calculate the evLY.

1. First, we attribute a utility of 0.851, the age- and sex-adjusted utility of the general population in the US that are considered healthy.<sup>165</sup>
2. We calculate the evLY for each model cycle.
3. Within a model cycle, if using the intervention results in additional life years versus the primary comparator, we multiply the general population utility of 0.851 with the additional life years gained ( $\Delta$ LY gained) within the cycle.
4. The life years shared between the intervention and the comparator use the conventional utility estimate for those life years within the cycle.
5. The total evLY for a cycle is calculated by summing steps 3 and 4.
6. The evLY for the comparator arm is equivalent to the QALY for each model cycle.
7. The total evLYs are then calculated as the sum of evLYs across all model cycles over the time horizon.

Finally, the evLYs gained is the incremental difference in evLYs between the intervention and the comparator arm.

## Target Population

The population of focus for the economic evaluation included individuals with obesity or with overweight and at least one obesity-related comorbidity, excluding those with already established type 2 diabetes, who are actively seeking medical management for weight loss. As the characteristics of this real-world population may differ from those enrolled in clinical trials, baseline characteristics were drawn from real-world studies of individuals using weight-lowering medications, wherever available, assuming that real-world users of these medications represent the population pursuing medical weight management.

**Table E1.2. Baseline Population Characteristics**

	Value	Source
Mean Age*	46 years	Gleason, 2024; Ruseva, 2025 <sup>37,38</sup>
Percent Female	79%	Rodriguez, 2025 <sup>79</sup>
Mean BMI	37.6 kg/m <sup>2</sup>	Rodriguez, 2025 <sup>79</sup>
Mean SBP for those Without HTN	125 mmHg	Steven J Atlas, 2022 <sup>69</sup>
Mean SBP for those With HTN	135 mmHg	Rodriguez, 2014; Mackenzie, 2022 <sup>87,88</sup>
Percent Smoking	14.6%	CDC <sup>117</sup>
Percent CVD*	6.5%	Ruseva, 2025 <sup>38</sup>
Percent OSA†	40.3%	Esmaeili, 2025; Rodriguez, 2025 <sup>79,108</sup>

BMI: Body mass index; SBP: Systolic blood pressure; HTN: Hypertension; CVD: Cardiovascular disease; OSA: Obstructive sleep apnea

\*Although Ruseva et al. included all individuals initiating semaglutide, including those with diabetes, it was considered appropriate for our purposes since only a small proportion (5.8%) of the population had diabetes at baseline. The mean age and the percentage with CVD were cross-checked against other real-world studies, Gleason et al. and Rodriguez et al., excluding people with diabetes.<sup>37 79</sup>

†Estimated by weighting the prevalence of OSA among individuals with obesity (41.4%) and those who are overweight (26.1%) according to the distribution of obesity and overweight in the real-world user population reported in Rodriguez et al.<sup>79</sup>

## Treatment Strategies

The list of interventions was developed with input from patient organizations, clinicians, manufacturers, and payers. The full list of interventions is as follows: injectable semaglutide (Wegovy®, Novo Nordisk), oral semaglutide (Novo Nordisk), and tirzepatide (Zepbound®, Eli Lilly) added on to lifestyle modification. The comparator for these interventions was lifestyle modification alone (e.g., caloric restriction and increased physical activity).

## E2. Model Inputs and Assumptions

Model assumptions are listed in Table 4.1.

### Clinical Inputs

Key clinical inputs to the model include transition probabilities, mortality, treatment discontinuation, and adverse events.

#### *Transition Probabilities*

The probability of moving between health states was calculated based on the estimated risks of obesity-related outcomes for each treatment group. These risk estimates incorporated multiple inputs—primarily treatment effects on BMI and metabolic risk factors and either indirect or direct treatment effects on obesity-related outcomes.

### Treatment Effects on BMI

The percentage change in body weight from baseline for each treatment was derived from the ICER meta-analysis of ITT populations, as well as the ITT populations of relevant clinical trials (Table E2.1). The weight change observed at the primary endpoints of the clinical trials (68, 64, and 72 weeks for semaglutide, oral semaglutide, and tirzepatide, respectively) was assumed to represent the reduction achieved during the first year after treatment initiation, as these endpoints reflect weight loss over roughly one year following the titration period. The weight change at week 104 was assumed to represent the reduction achieved by the end of the second year after treatment initiation. From year two onward, BMI remained stable, reflecting sustained weight maintenance with continued treatment. Natural age-related weight gain from year two was explored in a sensitivity analysis, with the BMI increase per year ranging from 0% to 0.4% of baseline BMI (0.4% of baseline BMI corresponds to approximately 0.15 BMI units per year), based on the previous ICER model.<sup>69</sup>

**Table E2.1. Treatment Effects on Body Weight**

Parameter	Input	Source
Change in Weight from Baseline by Year 1 (%), LSM	-3.41%	ICER Pooled data*
Change in Weight from Baseline by Year 2 (%), LSM	-2.60%	<sup>80</sup>
Absolute Difference in % Weight Change by Year 1, SC Semaglutide vs. LSM	-13.14%	ICER MA; Table 3.4
Absolute Difference in % Weight Change by Year 2, SC Semaglutide vs. LSM	-14.00%	<sup>80</sup>
Absolute Difference in % Weight Change by Year 1, Oral Semaglutide vs. LSM	-11.90%	<sup>39</sup>
Absolute Difference in % Weight Change by Year 2, Oral Semaglutide vs. LSM†	-12.68%	Author's calculation <sup>42,80</sup>
Absolute Difference in % Weight Change by Year 1, Tirzepatide vs. LSM‡	-18.97%	<sup>42</sup>
Absolute Difference in % Weight Change by Year 2, Tirzepatide vs. LSM‡	-18.97%	Assumed to be the same as Year 1 data

ICER MA: ICER meta-analysis, LSM: Lifestyle modification; SC: Subcutaneous

\*Pooled from STEP 1, STEP 3, STEP 5, STEP 8, OASIS 4, and SURMOUNT 1 using unadjusted data

†Due to the lack of year 2 data for oral semaglutide, the absolute difference in % weight change at Year 1 for oral semaglutide was adjusted by multiplying it by the ratio of the absolute difference in % weight change at Year 2 to that at Year 1 for injectable semaglutide.

‡The estimate was derived from individuals with obesity and prediabetes due to the lack of an unadjusted efficacy estimate for the overall population; The absolute difference in % weight change at Year 2 was assumed to be the same as at Year 1, due to the absence of Year 2-specific data and consistent with the long-term BMI trend observed in Jastreboff et al. <sup>59</sup>

### Treatment Effects on Metabolic Risk Factors:

The metabolic factors used to estimate the risk of obesity-related outcomes included the proportion of patients treated for hypertension (HTN), systolic blood pressure (SBP) among those treated and untreated for HTN, and glycemic control. In the absence of direct treatment effects on

HTN, the prevalence of treated HTN was estimated as a function of BMI, based on relationships reported in the literature and consistent with the approach used in the previous ICER model.<sup>69,86</sup> For SBP, an average of 125 mmHg was assumed for patients without HTN.<sup>69</sup> For those with (treated) HTN, an average SBP of 135 mmHg was used, based on studies of hypertensive patients receiving medication, reflecting suboptimal blood pressure control despite treatment.<sup>87,88</sup> SBP was held constant over time and did not differ by treatment.

Treatment effects on glycemic control were captured through the modeled risk of developing type 2 diabetes. This risk was estimated for each treatment arm using trial data from individuals with obesity and no baseline diabetes (Table E2.2). The annual probability of diabetes was determined based on multiple studies.<sup>56,59,89-91</sup> The primary estimate of approximately 2.3% per year was derived from Kahn et al. and Torgerson et al., both studies of individuals with obesity without baseline diabetes. However, Kahn et al. included participants with a history of CVD, while Torgerson et al., though more aligned with the modeled population, was conducted in Sweden and is dated. Therefore, to ensure consistency and validity, this estimate was compared against three additional studies: two international multicenter studies of individuals with obesity and prediabetes, and a US-based study of outpatients at a tertiary center aged 45–64 without diabetes. To address any remaining parameter uncertainty, we conducted a scenario analysis using the US-based study. Although this study is US-based, we did not use this study for the basecase due to its age, potential changes in diabetes risk over time, and its somewhat high risk estimate relative to other studies.<sup>91</sup> The direct diabetic impact of injectable semaglutide was derived from the SELECT trial population with obesity and a history of CVD, and that of oral semaglutide was assumed to be the same as injectable semaglutide. The direct diabetic impact of tirzepatide was obtained from the prediabetes population in the SURMOUNT-1 trial. For semaglutide, extrapolation from individuals with a history of CVD was considered reasonable because the intervention is expected to improve glycemic control through mechanisms largely independent of CVD, such as enhancing glucose-dependent insulin secretion and slowing gastric emptying.<sup>166</sup> Although these represent the best available evidence, differences in the source populations may bias the estimates. Therefore, we conducted a scenario analysis where the direct diabetic impacts of injectable and oral semaglutide were estimated using tirzepatide's direct diabetic impact, adjusted by the ratio of year-1 BMI effects for injectable and oral semaglutide relative to tirzepatide.

Lipid control was not explicitly modeled, as it was assumed that lipid levels are optimally managed through statin therapy, and improvements in lipid profiles associated with weight loss are implicitly captured within the modeled association between BMI and CVD risk.

**Table E2.2. Treatment Effects on Glycemic Control**

Input	Value	Source
<b>Annual Probability of Type 2 Diabetes for LSM*</b>	2.3%	56 59,89-91
<b>Direct Impact of SC Semaglutide on Diabetes Risk Compared to LSM (HR)</b>	0.27	Kahn, 2024 <sup>56</sup>
<b>Direct Impact of Oral Semaglutide on Diabetes Risk Compared to LSM (HR)</b>	0.27	Assumed to be the same as injectable semaglutide
<b>Direct Impact of Tirzepatide on Diabetes Risk Compared to LSM (HR)</b>	0.07	Jastreboff, 2025 <sup>59</sup>

HR: Hazard ratio; LSM: Lifestyle modification

*Treatment Effects on the Obesity-Related Outcomes:*

In the lifestyle modification arm, the risk of obesity-related outcomes was estimated using established risk equations or known associations with BMI and metabolic risk factors, accounting for patient demographics and the previously described metabolic profile. In the active treatment arms, direct effects of treatments on outcome risks were incorporated where available to capture mechanisms beyond those mediated by BMI or metabolic factors. When direct evidence was unavailable, outcome risks were instead estimated indirectly using established associations with BMI and/or relevant metabolic factors.

In the lifestyle modification arm, annual risk of primary CVD was estimated using the office-based, non-laboratory prediction model from the Framingham Heart Study, consistent with the previous ICER model (Table E2.3).<sup>69,92</sup> Estimates varied by age and BMI and were calculated for specific patient subpopulations stratified by sex, smoking status, HTN treatment status, and diabetes status. For those who developed CVD, subtypes of CVD were tracked following the approach used in the previous ICER report.<sup>69,167</sup> In this approach, overall CVD risk was divided into stroke (23%), MI (22%), and other CVD (55%). The annual probability of developing HF following acute or post-MI events was estimated based on data from Sulo et al.<sup>168</sup> Among patients who have experienced an MI, the annual probability of recurrent MI was 0.08 for males and 0.07 for females, based on Peters et al.<sup>94</sup> The annual probability of recurrent stroke among patients with a prior stroke was 0.12 based on Kolmos et al.<sup>93</sup> In the intervention arms, annual primary CVD risk or recurrent risk of MI and stroke reflected treatments' direct effects on cardiovascular risk observed in clinical trials.<sup>41,74</sup>

**Table E2.3. Risk of CVD**

Input	Value	Source
<b>Annual Probability of Primary CVD for LSM</b>	Estimated based on the risk function from the Framingham Heart Study	D’Agostino Sr, 2008 <sup>92</sup>
<b>Proportion of Incident CVD by Subtype</b>	23% for stroke 22% for MI 55% for other CVD	Steven J Atlas, 2022; Schultz, 2021 <sup>69,167</sup>
<b>Probability of Developing HF from Acute MI*</b>	$[0.0374 * \text{EXP}(0.0241 * \text{age})] * 0.624$	Sulo, 2016 ; Gerber, 2016 <sup>168,169</sup> ; authors’ calculation
<b>Annual Probability of Developing HF Post MI*</b>	$[0.0018 * \text{EXP}(0.046 * \text{age})] * 0.624$	Sulo, 2016 ; Gerber, 2016 <sup>168,169</sup> ; authors’ calculation
<b>Annual Probability of Recurrent MI</b>	8.1% (male) 7.2% (female)	Peters, 2021 <sup>94</sup>
<b>Annual Probability of Recurrent Stroke</b>	12.0%	Kolmos, 2021 <sup>93</sup>
<b>Direct Impact of SC Semaglutide on Cardiovascular Risk Compared to LSM (HR)†</b>	0.80	Lincoff, 2023 <sup>74</sup>
<b>Direct Impact of Oral Semaglutide on Cardiovascular Risk Compared to LSM (HR)†</b>	0.86	41
<b>Direct Impact of Tirzepatide on Cardiovascular Risk Compared to LSM (HR)††</b>	0.80	Assumed to be the same injectable semaglutide; Nicholls, 2024 <sup>45</sup>

CVD: Cardiovascular disease; LSM: Lifestyle modification; HR: Hazard ratio; MI: Myocardial infarction; HF: Heart failure; TBD: To be determined

\*Exponential functions were fitted to the age-specific heart failure risk data. Given that heart failure attributable to a history of MI is predominantly heart failure with reduced ejection fraction (HFrEF), and other types of heart failure (e.g., heart failure with preserved ejection fraction) are already included as part of the other CVD health state, the incidence of post-MI heart failure was adjusted using the proportion of HFrEF among all HF types (563/902; 62.4%) observed in patients with prior MI, as reported by Gerber et al.<sup>169</sup>

†The hazard ratio was applied to both primary CVD risk and the risk of recurrent MI or stroke.

††This value may be revised once the detailed results of the SURPASS-CVOT trial become available.

ESKD incidence rates for each treatment arm were estimated by applying BMI-related hazard ratios to a reference ESKD incidence rate corresponding to a specified BMI level. Age-specific ESKD incidence rates from the US general population, obtained from the United States Renal Data System (USRDS), served as the reference and were assumed to reflect the risk for individuals with a BMI of 30, given that the mean BMI in the US is approximately 30 and nearly half of the population has a BMI above this threshold.<sup>98-100</sup> BMI-related hazard ratios were derived from a study that examined the association between BMI categories and ESKD risk in the US general population aged 45 and older, excluding key intermediate variables such as hypertension and diabetes from adjustment to capture the full effect through relevant causal pathways.<sup>101</sup> Although a larger US-based study was available, we used it in a scenario analysis rather than the base case, as it is dated and clinical

experts have noted that improvements in the management of obesity-related conditions may have altered the observed associations.<sup>118</sup>

**Table E2.4. Risk of ESKD**

Input	Value	Source
<b>Annual Incidence of ESKD in the Reference Population (a BMI of 30)*</b>	115 per 1,000,000 (age 18-44 years) 593 per 1,000,000 (age 45-64 years) 1219 per 1,000,000 (age 65-74 years) 1581 per 1,000,000 (age 75+ years)	NIH NIDDK USRDS, 2023; Albertus, 2016; Brownstein, 2024 <sup>98-100</sup>
<b>Hazard Ratio of ESKD Incidence Based on BMI†</b>	BMI 25-29.9 vs. <25: 1.08 BMI 30-34.9 vs. <25: 1.29 BMI 35-39.9 vs. <25: 1.50 BMI 40 or higher vs. <25: 1.71	Panwar 2015 <sup>170</sup>

ESKD: End stage kidney disease; BMI: Body mass index

\*The incidence of ESKD in 2021 among the US general population was used as a proxy for the annual incidence of ESKD at a BMI of 30, based on the average BMI of the US population in 2021 (30.23). Consequently, the US general incidence already reflects an elevated risk of ESKD compared with individuals with normal BMI (<25), corresponding to the BMI 30–34.9 group.

†Hazard ratios for each BMI category were estimated by fitting a linear model to digitized data on the association between BMI and hazard ratios for BMI values greater than 25.<sup>170</sup>

The risk of cirrhosis and knee and hip replacements was modeled similarly, using US general population incidence rates as a proxy for risk at a BMI of 30 (approximating the US average BMI), with risks adjusted based on key risk factors including BMI. The incidence of cirrhosis among the US general population was obtained from a study that reported the annual incidence of cirrhosis in 204 countries based on the Global Health Data Exchange.<sup>102</sup> We used the annual incidence estimated for high-income North America in 2019. This incidence rate was adjusted based on BMI categories using a UK-based study that examined the effect of BMI on cirrhosis-related hospitalizations and deaths.<sup>103</sup> Although the UK study may be less generalizable than a US-based study, it was chosen for its recency and more detailed BMI stratification. The reported relative risks were compared with those from a US-based study, confirming their comparability.<sup>171</sup>

The incidence of total hip and knee replacements among the US general population was obtained from a study that used the US National Inpatient Sample (NIS) and Census Bureau data to project the total annual counts for total hip and knee replacements in the US from 2020 to 2040.<sup>104</sup> The age-specific annual probabilities of undergoing knee and hip replacements were estimated by dividing the projected total annual counts in the US in 2020 by the population size of each age group in 2020.<sup>106</sup> The annual probabilities of knee and hip replacements were adjusted using a US-based study that estimated odds ratios stratified by sex and BMI categories.<sup>107</sup>

**Table E2.5. Risk of Cirrhosis**

<b>Input</b>	<b>Value</b>	<b>Source</b>
<b>Annual Incidence of Cirrhosis in the Reference Population (a BMI of 30)*</b>	25.6 per 100,000	Lan, 2023; Brownstein, 2024 <sup>100,102</sup>
<b>Relative Risk of Cirrhosis Incidence Based on BMI†</b>	BMI 25-27.49 vs. <25: 1.05 BMI 27.5-29.9 vs. <25: 1.11 BMI 30-34.9 vs. <25: 1.49 BMI 35 or higher vs. <25: 1.77	Liu, 2010 <sup>103</sup>

BMI: Body mass index

\*The incidence of cirrhosis in high-income North America was used as a proxy for the annual incidence of cirrhosis in the US general population. The average BMI of the US general population is approximately 30 based on Rader et al.<sup>100</sup> Consequently, the US general incidence already reflects an elevated risk of cirrhosis compared with individuals with normal BMI (<25), corresponding to the BMI 30–34.9 group.

†The reported relative risks were compared with those from a US-based study, confirming their comparability.<sup>171</sup>

**Table E2.6. Risk of Knee and Hip Replacements**

Input	Value	Source
<b>Annual Probability of Knee replacement in the Reference Population (a BMI of 30)*</b>	0.01% (<45 years old) 0.44% (45-64 years old) 1.53% (65-84 years old) 0.46% (85 years or older)	Singh, 2019; Zoe Caplan, 2023; United States Census Bureau, 2023 <sup>104-106</sup>
<b>Annual Probability of Hip Replacement in the Reference Population (a BMI of 30)*</b>	0.01% (<45 years old) 0.21% (45-64 years old) 0.65% (65-84 years old) 0.38% (85 years or older)	Singh, 2019; Zoe Caplan, 2023; United States Census Bureau, 2023 <sup>104-106</sup>
<b>Odds Ratio for Knee Replacement Risk Based on Sex and BMI</b>	Varies by sex and BMI categories (See Table 2.9)	Wendelboe, 2003 <sup>107</sup>
<b>Odds Ratio for Hip Replacement Risk Based on Sex and BMI</b>	Varies by sex and BMI categories (See Table 2.9)	Wendelboe, 2003 <sup>107</sup>

BMI: Body mass index

\*Estimated by dividing the total annual counts of knee or hip replacements in the US in 2020 by the population size of each age group in 2020

**Table E2.7. Odds Ratio for the Risk of Knee and Hip Replacements Based on BMI**

BMI	Odds Ratio for Knee Replacement Risk		Odds Ratio for Hip Replacement Risk	
	Male	Female	Male	Female
<b>20-22.49</b>	Reference	Reference	Reference	Reference
<b>22.50-24.99</b>	1.43	1.16	1.09	1.20
<b>25.00-27.49</b>	2.14	2.07	1.33	1.22
<b>27.50-29.99</b>	2.98	4.62	1.73	1.72
<b>30.00-32.49</b>	3.61	6.42	2.54	1.61
<b>32.50-34.99</b>	5.88	7.52	3.30	2.18
<b>35.00-37.49</b>	8.62	11.88	6.65	2.38
<b>37.50-39.99</b>	16.40	17.69*	9.37	3.32*
<b>40.00 or Higher</b>	17.24*	19.05	10.49*	4.47
<b>Source</b>	Wendelboe, 2003 <sup>107</sup>			

BMI: Body mass index

\*Instead of the odds ratios reported in Wendelboe et al., we used imputed values derived from an exponential curve fitted to the remaining data. The original odds ratios deviated from the overall trend and appeared counterintuitive, likely due to small sample sizes and the resulting wide uncertainty around the point estimates.

The proportion of patients with OSA among the modeled population at baseline BMI (37.6) was estimated at 40.3%, as described previously.<sup>79,108</sup> To estimate the proportion of patients with OSA in each treatment arm over time, the baseline prevalence was adjusted using odds ratios from a study that examined BMI subgroups and OSA prevalence associations via individual patient data meta-analysis.<sup>108</sup>

**Table E2.8. Prevalence of OSA**

Input	Value	Source
Prevalence of OSA in the Reference Population (a BMI of 37.6)*	40.3%	Esmaeili, 2025; Rodriguez, 2025, <sup>79,108</sup> authors' calculation
Odds Ratio for the Prevalence of OSA Based on BMI†	1.16 per 1 unit of BMI increase	Esmaeili, 2025; <sup>108</sup> authors' calculation

BMI: Body mass index; OSA: Obstructive sleep apnea

\*Estimated by weighting the prevalence of OSA among individuals with obesity (41.4%) and those who are overweight (26.1%) according to the distribution of obesity and overweight in the real-world user population reported in Rodriguez 2025. The mean BMI among the real-world user population is 37.6 based on Rodriguez 2025.

†Estimated under the assumption of a log-linear relationship between BMI and odds ratio, using data reported in Esmaeli et al: odds ratio for the prevalence OSA of 1.89 (BMI 25-30 vs. <25) and 4.53 (BMI ≥30 VS. <25).<sup>108</sup>

### ***Discontinuation***

The discontinuation rate reflected all-cause discontinuation observed in the trials among the ITT population. Discontinuation impacted only drug costs, as treatment efficacy estimates from the ITT population already account for the effects of discontinuation. All treatment discontinuations were assumed to occur within the first two years of treatment initiation, consistent with the trial follow-up period. Year 1 all-cause discontinuation was obtained from the ICER meta-analysis of ITT populations and from ITT analyses of relevant trials (Table E2.9). All-cause discontinuation by year 2 for lifestyle modification was obtained from Garvey et al.<sup>80</sup> For the interventions, the percentage discontinued by year 2 was assumed equal to year 1 for the following reasons: Although year 2 discontinuation data for injectable semaglutide are available from the STEP 5 trial, the cumulative discontinuation reported at week 104 (13.2%) was lower than the year 1 estimate from the ICER meta-analysis, which is implausible. No year 2 discontinuation data are available for oral semaglutide or tirzepatide. Individuals remaining on treatment after two years are assumed to continue for life.

**Table E2.9. Treatment Discontinuation\***

Parameter	Input	Source
% Discontinued treatment by Year 1, LSM	19.46%	ICER MA
% Discontinued treatment by Year 2, LSM	27.00%	<sup>80</sup>
% Discontinued treatment by Year 1, SC Semaglutide	14.60%	ICER MA
% Discontinued treatment by Year 2, SC Semaglutide	14.60%	Assumed to be the same as Year 1
% Discontinued treatment by Year 1, Oral Semaglutide	14.21%	<sup>39</sup>
% Discontinued treatment by Year 2, Oral Semaglutide	14.21%	Assumed to be the same as Year 1
% Discontinued treatment by Year 1, Tirzepatide	11.09%	<sup>42</sup>
% Discontinued treatment by Year 2, Tirzepatide	11.09%	Assumed to be the same as Year 1

\*Patients are assumed to continue lifestyle modification after discontinuing the intervention.

### **Mortality**

The impact of weight loss on mortality was modeled through its effect on lowering the risk of obesity-related outcomes. Age- and sex-specific mortality rates from the general US population were used as a proxy for individuals with obesity who do not have any of the modeled obesity-related conditions.<sup>109</sup> The hazard ratio (HR) for mortality associated with each obesity-related outcome was sourced from the literature and applied to baseline mortality rates for the US general population to estimate mortality for cohorts with obesity-related outcomes. We used HRs that are adjusted for other conditions wherever possible to avoid double-counting. For health states involving multiple obesity-related outcomes, HRs were combined multiplicatively, consistent with approaches used in other economic models.<sup>69,83,84</sup> In addition to health state-specific mortality, acute mortality was modeled separately for acute MI and stroke. No excess mortality was assumed for OSA or hip/knee replacements, as mortality directly attributable to these conditions is expected to be low and is implicitly captured through associated comorbidities modeled separately.

**Table E2.10. Mortality Inputs**

Input	Value	Source
Mortality HR: Post MI	1.58	Majed, 2015; Steven J Atlas, 2022 <sup>69,172</sup>
Mortality HR: Post Stroke	3.13	Majed, 2015; Steven J Atlas, 2022 <sup>69,172</sup>
Mortality HR: Other CVD	1.59	Pande, 2011; Steven J Atlas, 2022 <sup>69,173</sup>
Mortality HR: HF Post MI	2.55	Gerber, 2016 <sup>169</sup>
Mortality HR: T2D	1.16	Raghavan, 2019 <sup>174</sup>
Mortality HR: ESKD	5.21	Lee, 2023 <sup>175</sup>
Mortality HR: Cirrhosis	3.79	Simon, 2021 <sup>176</sup>
Probability of Death from Acute MI*	6.43%	OECD, 2023 <sup>177</sup>
Probability of Death from Acute Stroke*	6.69%	OECD, 2023 <sup>177</sup>

CVD: Cardiovascular disease; T2D: Type 2 diabetes, ESKD: End-stage kidney disease; HR: Hazard ratio; MI: myocardial infarction; HF: heart failure.

\*Thirty-day mortality following hospital admission for MI or stroke in the US was estimated using the estimates from the US unlinked data, adjusted by the ratio of thirty-day mortality from unlinked versus linked data observed across the OECD28 countries.

### **Adverse Events**

Severe gastrointestinal (GI) adverse events (AEs) were modeled in the analysis. The proportion of patients experiencing severe AEs was informed by ICER meta-analysis and relevant clinical trials (Table E2.11). Disutility associated with these events, along with one-time health care costs for their management, was applied during the first year of the model to reflect their short-term impact on quality of life and costs.

Acute pancreatitis, while potentially impactful, was not modeled separately from other GI AEs because it occurred in only a very small proportion of patients and at similar rates between treatment arms.<sup>178</sup>

**Table E2.11. Adverse Events**

Parameter	Input	Source
% Experiencing severe GI AEs, LSM	1.31%	ICER MA
% Experiencing severe GI AEs, SC Semaglutide	3.20%	ICER MA
% Experiencing severe GI AEs, Oral Semaglutide	0.66%	<sup>39</sup>
% Experiencing severe GI AEs, Tirzepatide	4.01%	<sup>42</sup>

GI: Gastrointestinal; AE: Adverse events; MA: Meta analysis

### **Heterogeneity and Subgroups**

The cost-effectiveness of treatment may vary by baseline obesity status (e.g., overweight, obesity, and severe obesity), as individuals with higher initial BMI tend to achieve greater absolute weight loss or may experience differential treatment effects. To assess how this variation affects outcomes, we performed a scenario analysis for patient groups stratified by the following baseline BMI: BMI

<30, BMI ≥30, BMI ≥35, and BMI ≥40. Based on data availability, each subgroup was characterized by the baseline characteristics listed in Table E2.12 below, as well as by different direct treatment effects on CVD risk.

**Table E2.12. Subgroup-Specific Characteristics**

Parameter	BMI <30	BMI ≥30	BMI ≥35	BMI ≥40	Source
Mean Age	51.9	46.1	45.4	43.5	Manufacturer's data submission (STEP1 data)
Percent Female	63.2%	74.8%	76.2%	79.4%	Manufacturer's data submission (STEP1 data)
Mean BMI	28.8	38.4	41.6	46.0	Manufacturer's data submission (STEP1 data)
Percent Smoker	12%	11.6%	11.4%	12.1%	Manufacturer's data submission (STEP1 data)
HR for CVD: Injectable Semaglutide*	0.74	0.82	0.91	0.86	Lincoff, 2023 <sup>74</sup>
HR for CVD: Oral Semaglutide	0.74	0.82	0.91	0.86	Assume to be the same as injectable semaglutide
HR for CVD: Tirzepatide†	0.74	0.82	0.91	0.86	Assume to be the same as injectable semaglutide

BMI: Body Mass Index; HR: Hazard ratio; CVD: Cardiovascular disease; TBD: To be determined

\*HRs were reported for BMI groups of 30–35, 35–40, 40–45, and 45 or higher in the SELECT trial. These HRs were combined to estimate hazard ratios for broader BMI categories—over 30, over 35, and over 40—using the approach described by Van Doorn et al.<sup>179</sup>

†These values may be revised once the detailed results of the SURPASS-CVOT trial become available.<sup>45</sup>

## Health State Utilities

The impact of weight loss on quality of life was modeled in two ways: through its effect on reducing the risk of obesity-related outcomes that diminish quality of life, and through additional quality-of-life gains directly associated with reductions in BMI, independent of obesity-related outcomes.

Age-specific utility values from the US general population were used to approximate baseline utilities for individuals with normal BMI and no obesity-related conditions.<sup>110 69</sup> Disutilities linked to specific health states or events, along with those directly attributable to BMI changes, were applied to capture the impact of weight loss on quality of life. For health states with multiple obesity-related outcomes, disutilities were combined multiplicatively using disutility multipliers, consistent with methods used in previous economic models and NICE DSU recommendations.<sup>69,82-85</sup> This approach assumes that each additional chronic condition reduces remaining quality of life proportionally rather than absolutely. To estimate utility multipliers, we relied on studies that reported either utility decrements or average utility values for individuals with the condition. These values were used to derive multipliers under the assumption that the baseline utility for a healthy individual without the condition is approximately 0.85.<sup>110</sup> Short-term disutilities from acute events were applied additively, assuming that their temporary impact is likely independent and occurs on top of the baseline impairment associated with chronic conditions. These approaches are consistent with methodologies used in previous economic models of obesity.<sup>69,180</sup>

Age-specific utility values and multipliers for CVD and T2D were derived from Sullivan et al., an ‘off-the-shelf’ catalogue of nationally representative EQ-5D index scores for chronic conditions, adjusted for socio-demographic factors.<sup>110</sup> The utility value for ESKD was obtained from a study using the EQ-5D-5L to estimate quality of life among dialysis patients with ESKD.<sup>181</sup> Utility multipliers for cirrhosis were derived from a previous economic evaluation in Non-Alcoholic Steatohepatitis (NASH) that reported utilities for compensated and decompensated cirrhosis.<sup>182</sup> To estimate overall quality of life for cirrhosis, utility values for compensated and decompensated cirrhosis were weighted according to their population-level distribution as reported by Flamm et al.<sup>183</sup> For OSA, the disutility associated with excessive daytime sleepiness (EDS) was obtained and applied to the proportion of individuals experiencing EDS.<sup>72,184</sup> For those without EDS, the utility decrement associated with OSA, adjusted for EDS, was applied. This approach was used because EDS represents the primary symptomatic manifestation of OSA that significantly impacts patients' quality of life, but not all patients with OSA are expected to experience EDS.

The utility decrement associated with BMI, independent of the modeled obesity-related outcomes, was based on a study that examined the relationship between BMI and EQ-5D–measured quality of life in the general population of England.<sup>111</sup> The analysis was adjusted for socio-demographic characteristics and a broad set of comorbidities, including heart and circulatory disease, diabetes, cancer, mental disorder, musculoskeletal disease, and respiratory disorders. The adjustments in the study do not perfectly align with the specific obesity-related outcomes included in our model, which may result in over- or underestimation of BMI's impact independent of the modeled obesity-related outcomes. However, this study was considered the most appropriate available given the absence of studies that fully match our model design, its clear documentation of included variables, and its incorporation of a broader set of comorbidities compared to previously used studies.<sup>69,82,185,186</sup> Due

to the uncertainty surrounding this estimate, it was tested across a wide range in sensitivity analyses.

**Table E2.13. Quality of Life**

Input	Value	Source
Age-Specific Utility	0.9442-0.0007*age	Steven J Atlas, 2022; Sullivan 2006 <sup>69,110</sup>
Utility Decrement per 1 kg/m <sup>2</sup> Increase in BMI*	0.007	Luah, 2024 <sup>111</sup>
Utility Multiplier: Post MI	0.95	Steven J Atlas, 2022; Sullivan 2006 <sup>69,110</sup>
Utility Multiplier: Post Stroke	0.94	Steven J Atlas, 2022; Sullivan 2006 <sup>69,110</sup>
Utility Multiplier: Other CVD	0.96	Steven J Atlas, 2022; Sullivan 2006 <sup>69,110</sup>
Utility Multiplier: HF post MI	0.93	Steven J Atlas, 2022; Sullivan 2006 <sup>69,110</sup>
Utility Multiplier: T2D	0.96	Steven J Atlas, 2022; Sullivan 2006 <sup>69,110</sup>
Utility Multiplier: ESKD	0.80	Yang, 2015 <sup>181</sup>
Utility Multiplier: Cirrhosis	0.73	ICER, 2023; Flamm, 2024 <sup>182,183</sup>
Utility Multiplier: OSA†	0.92 (with EDS) 0.97 (without EDS)	Cambron-Mellott, 2022 ; Malhotra, 2024 <sup>72,184</sup>
Disutility: Acute Stroke‡	0.19	Steven J Atlas, 2022; Matza, 2015 <sup>69,187</sup>
Disutility: Acute MI‡	0.15	Steven J Atlas, 2022; Matza, 2015 <sup>69,187</sup>
Disutility: Knee Replacement§	0.17 (male) 0.20 (female)	NICE, 2023; NICE, 2021 <sup>83,84</sup>
Disutility: Hip Replacement§	0.17 (male) 0.20 (female)	NICE, 2023; NICE, 2021 <sup>83,84</sup>
Disutility: Severe GI AEs#	0.05	NICE, 2019 <sup>188</sup>

AE: Adverse events; BMI: Body mass index; CVD: Cardiovascular disease; T2D: Type2 diabetes; ESKD: End-stage kidney disease; MI: myocardial infarction; HF: heart failure; OSA: Obstructive sleep apnea; EDS: Excessive Daytime Sleepiness

\*The coefficient was derived by fitting a linear function to digitized data representing the relationship between BMI and quality of life for individuals with a BMI of 25 or higher.

†The disutility associated with EDS was estimated as a weighted average of disutilities for mild (ESS 11–12), moderate (ESS 13–15), and severe EDS (ESS 16–24), using the severity distribution of EDS among individuals with OSA. This average disutility was applied to the proportion of patients with EDS, while a separate disutility value for OSA without EDS was applied to the remaining population. The proportion of patients with EDS and its severity distribution were derived from baseline ESS scores reported in the SURMOUNT-OSA trial, assuming a normal distribution (no EDS: 66%, mild EDS: 7%, moderate EDS: 12%, and severe EDS: 15%).

‡The disutility was applied over a 6-month period, consistent with the previous ICER model for obesity.<sup>69</sup>

Estimated by calculating the difference in quality of life between the acute and chronic health states.

§The disutility was applied for a duration of 1.5 years to capture the disutility leading up to knee or hip replacement.

#The disutility was applied for a duration of 1 week consistent with previous models in obesity<sup>84,188</sup>

## Drug Utilization

The following inputs were used to model drug utilization and associated costs:

- Duration of treatment
- Schedule of doses for each drug in each regimen

**Table E2.14. Treatment Regimen Recommended Dosage**

Generic Name	Semaglutide (SC)	Oral Semaglutide	Tirzepatide	Lifestyle Modification*
<b>Brand Name</b>	Wegovy®	n/a	Zepbound®	n/a
<b>Manufacturer</b>	Novo Nordisk	Novo Nordisk	Eli Lilly	n/a
<b>Route of Administration</b>	Subcutaneous injection	Oral	Subcutaneous injection	N/A
<b>Dosing</b>	Initiate at 0.25 mg once weekly for the first four weeks, with the dose increased every four weeks to reach the maintenance dose of 2.4 mg by week 16	Initiate at 3 mg once per day for the first four weeks, with dose increased every four weeks to reach the maintenance dose of 25 mg by week 16	Initiate at 2.5 mg once weekly for the first four weeks, with the dose increased every four weeks to reach a maintenance dose of 15 mg by week 20	N/A

N/A: Not applicable

\*Lifestyle modification includes caloric restriction and increased physical activity.

## Cost Inputs

All costs used in the model, except for drug costs, were updated to 2024 dollars using the consumer price index for health care via Bureau of Economic Analysis data.<sup>116</sup> Drug costs were based on the most recent data available as of the first quarter of 2025.

### Drug Costs

The annual net prices for injectable semaglutide and tirzepatide were derived directly from SSR Health as of Q1 2025, as its estimates reflect aggregated net prices that account for the use of direct-to-patient option available through NovoCare and LillyDirect.<sup>114</sup> As the price of oral semaglutide is not yet available, it was assumed to be the same as that of injectable semaglutide. The annual cost of lifestyle modification was assumed to be approximately \$605, based on a prior economic evaluation.<sup>69</sup>

**Table E2.15. Drug Costs**

Drug	Annual net price
<b>Injectable Semaglutide (Wegovy®)</b>	\$6,829†
<b>Oral Semaglutide</b>	\$6,829*
<b>Tirzepatide (Zepbound®)</b>	\$7,973†

WAC: wholesale acquisition cost; N/A: Not Applicable

\*Given the lack of available data, the net price of oral semaglutide was assumed to match those of injectable semaglutide.

†The annual net price already accounts for the use of direct-to-patient option available through NovoCare and LillyDirect.

### **Non-Drug Costs**

Non-drug health care costs included both related and unrelated components. Related health care costs attributable to each obesity-related outcome were sourced from existing literature. An additive approach was used to estimate costs for health states involving multiple outcomes, consistent with the previous cost-effectiveness studies in obesity.<sup>69,83,84</sup> In addition, related health care costs for short-term events—such as MI, stroke, knee or hip replacements, and severe GI AEs—were applied additively to individuals who experience these events.

For individuals who experience an MI or stroke, acute care costs were applied based on a study that estimated nationally representative hospitalization costs for CVD events using the National Inpatient Sample.<sup>189</sup> Following the acute phase, long-term health care costs associated with MI and stroke were applied based on studies that estimated the excess direct medical costs using nationally representative data from the US Medical Expenditure Panel Survey (MEPS).<sup>190,191</sup> Ongoing excess direct health care costs for individuals who develop diabetes, heart failure post-MI, or other cardiovascular disease were derived from a study using MEPS data to estimate costs attributable to multiple cardiovascular risk factors and conditions.<sup>192</sup> Ongoing health care costs for ESKD and cirrhosis were sourced from the USRDS Annual Data Reports and a study of patients with cirrhosis based on IQVIA Ambulatory Electronic Medical Records, respectively.<sup>193,194</sup> Health care costs attributable to OSA were obtained from a costing study from the American Academy of Sleep Medicine, including costs of diagnosis, testing, follow-up, non-surgical and surgical treatment.<sup>195</sup> One-time costs for knee and hip replacements were derived from a study that reported total costs per procedure.<sup>196</sup> The one-time costs of grade 3-4 nausea served as a proxy for one-time costs associated with severe 3-4 GI AE costs.<sup>197</sup>

Gender- and age-specific unrelated health care costs were additive to the related health care costs associated with obesity-related outcomes or events and were obtained from Jiao et al.<sup>115</sup>

**Table E2.16. Related Health Care Costs**

Input	Value	Source
Acute MI (One-Off)	\$34,151	Tajeu, 2024 <sup>189</sup>
Post MI (Annual)	\$9,248	Bishu, 2020 <sup>190</sup>
Acute Stroke (One-Off)	\$25,816	Tajeu, 2024 <sup>189</sup>
Post Stroke (Annual)	\$5,642	Girotra, 2020 <sup>191</sup>
HF Post MI (Annual)	\$19,294	Kazi, 2024 <sup>192</sup>
Other CVD (annual)	\$10,719	Kazi, 2024 <sup>192</sup>
T2D (Annual)	\$7,825	Kazi, 2024 <sup>192</sup>
ESKD (Annual)	\$96,283	NIH NIDDK USRDS, 2022 <sup>193</sup>
Cirrhosis (Annual)	\$38,708	Younossi, 2024 <sup>194</sup>
OSA (Annual)	\$2,786	American Academy of Sleep Medicine, 2016 <sup>195</sup>
Knee Replacement (One-Off)	\$31,341	Palsis, 2018 <sup>196</sup>
Hip Replacement (One-Off)	\$23,630	Palsis, 2018 <sup>196</sup>
Severe GI AE (One-Off)	\$9,148	McGregor, 2023 <sup>197</sup>

AE: Adverse events; CVD: Cardiovascular disease; T2D: Type2 diabetes; EDS: Excessive Daytime Sleepiness; ESKD: End-stage kidney disease; G3-4: Grade 3-4; HF: heart failure; MI: myocardial infarction; OSA: Obstructive sleep apnea

### **Productivity Costs**

The costs of lost patient productivity associated with obesity-related outcomes were included. The model focused on chronic condition productivity costs, as these represent the primary drivers of overall productivity impact, while acute event costs including hip and knee replacement, acute stroke and MI are expected to have minimal impact on results relative to chronic condition costs and limited data availability.

**Table E2.17. Annual Patient Productivity Costs**

Input	Value	Source
Post MI*	\$10,287	American Heart Association, 2017 <sup>198</sup>
Post Stroke*	\$4,575	American Heart Association, 2017 <sup>198</sup>
Other CVD*	\$6,199	American Heart Association, 2017 <sup>198</sup>
HF Post MI*	\$11,791	American Heart Association, 2017 <sup>198</sup>
T2D*	\$2,713	Parker, 2024 <sup>199</sup>
ESKD <sup>†</sup>	\$25,015	van Haalen, 2020; US Bureau of Labor Statistics, 2025; US Bureau of Labor Statistics, 2025 <sup>200-202</sup>
Cirrhosis	\$23,752	ICER, 2023; O'Hara, 2020 <sup>182,203</sup>
OSA <sup>‡</sup>	\$4,893	American Academy of Sleep Medicine, 2016; Malhotra, 2024 <sup>72,195</sup>

MI: myocardial infarction; CVD: Cardiovascular disease; HF: heart failure; T2D: Type2 diabetes; ESKD: End-stage kidney disease; OSA: Obstructive sleep apnea

\*Estimated using the ratio between indirect and direct costs

†Estimated based on the percentage productivity loss of 38.7%, an average working hours per week (34.3 hours), and average hourly wage (\$36.24)

‡Productivity loss was applied to the proportion of patients with EDS (34%), estimated from baseline Epworth Sleepiness Scale (ESS) scores reported in the SURMOUNT-OSA trial, assuming a normal distribution.

### E3. Results

Results are described in [Section 4.3](#) of the report.

### E4. Sensitivity Analyses

To demonstrate effects of uncertainty on both costs and health outcomes, we varied input parameters using available measures of parameter uncertainty (i.e., standard errors) or reasonable ranges to evaluate changes in cost per additional QALY. One way sensitivity results are displayed in Figures 4.2, 4.3, and 4.4. Probabilistic sensitivity results are presented in Tables 4.6 and 4.7 and the mean probabilistic sensitivity analysis results with 95% intervals for qualities are detailed in Tables E4.1, E4.2, and E4.3.

**Table E4.1. Results of Probabilistic Sensitivity Analysis for Injectable Semaglutide Added to Lifestyle Modification versus Lifestyle Modification Alone**

	Injectable Semaglutide Mean (95% CI)	Lifestyle Modification Mean (95% CI)	Incremental
<b>Costs</b>	\$459,313 (\$439,271, \$484,531)	\$385,579 (\$361,389, \$415,602)	\$73,734
<b>QALYs</b>	16.57 (15.49, 17.48)	15.28 (14.02, 16.39)	1.29
<b>evLYs</b>	16.6 (15.52, 17.5)	15.28 (14.02, 16.39)	1.32
<b>Incremental CE Ratio per QALY</b>			\$57,158
<b>Incremental CE Ratio per evLY</b>			\$55,859

CE: cost-effectiveness, evLYs: equal-value life year, QALY: quality-adjusted life year, CI: Credible Interval

**Table E4.2. Results of Probabilistic Sensitivity Analysis for Oral Semaglutide Added to Lifestyle Modification versus Lifestyle Modification Alone\***

	Oral Semaglutide Mean (95% CI)	Lifestyle Modification Mean (95% CI)	Incremental
<b>Costs</b>	\$461,968 (\$437,370, \$490,798)	\$386,542 (\$362,404, \$417,832)	\$75,426
<b>QALYs</b>	16.45 (15.35, 17.42)	15.29 (14.01, 16.46)	1.16
<b>evLYs</b>	16.48 (15.38, 17.44)	15.29 (14.01, 16.46)	1.19
<b>Incremental CE Ratio per QALY</b>			\$65,022
<b>Incremental CE Ratio per evLY</b>			\$63,383

CE: cost-effectiveness, evLYs: equal-value life year, QALY: quality-adjusted life year, CI: Credible Interval

\*Based on an assumed price of oral semaglutide

**Table E4.3. Results of Probabilistic Sensitivity Analysis for Tirzepatide Added to Lifestyle Modification versus Lifestyle Modification Alone**

	Tirzepatide Mean (95% CI)	Lifestyle Modification Mean (95% CI)	Incremental
<b>Costs</b>	\$469,902 (\$449,238, \$497,192)	\$386,133 (\$360,728, \$419,606)	\$83,293
<b>QALYs</b>	17.03 (15.99, 17.89)	15.34 (14.07, 16.42)	1.69
<b>evLYs</b>	17.05 (16.04, 17.91)	15.34 (14.07, 16.42)	1.71
<b>Incremental CE Ratio per QALY</b>			\$49,286
<b>Incremental CE Ratio per evLY</b>			\$48,709

CI: confidence interval, evLY: equal-value life year, QALY: quality-adjusted life year

## E5. Scenario Analyses

Alternative plausible scenarios have been explored. Additionally, since the cost-effectiveness of treatment may vary by baseline obesity status (e.g., overweight, obesity, and severe obesity), we performed an analysis for patient groups stratified by the following baseline BMI: BMI <30, BMI ≥30, BMI ≥35, and BMI ≥40.

### Scenario Analysis 1

#### *Modified Societal Perspective*

This scenario adopts a modified societal perspective, incorporating patient productivity costs associated with obesity-related outcomes.

**Table E5.1. Results for Scenario 1:**

Treatment	Intervention Acquisition Costs	Total Costs	Number of Stroke or MI events (per 100)†	QALYs	evLYs	Life Years
<b>Injectable Semaglutide*</b>	\$132,229	\$488,176	47	16.61	16.63	20.39
<b>Oral Semaglutide*‡</b>	\$132,475	\$491,355	51	16.50	16.52	20.35
<b>Tirzepatide*</b>	\$158,493	\$495,170	45	17.02	17.04	20.49
<b>Lifestyle Modification</b>	\$9,036	\$426,765	69	15.37	15.37	20.01

evLYs: equal value of life years gained, QALY: quality-adjusted life year, MI: Myocardial infarction

\*Each treatment is added to lifestyle modification; therefore, intervention acquisition costs also include the costs of lifestyle modification.

†Undiscounted values are shown. Per 100 individuals.

‡Based on an assumed price

## Scenario Analysis 2

### *Exclusion of Unrelated Health Care Costs*

Health care costs not attributable to obesity or obesity-related outcomes were excluded.

**Table E5.2. Results for Scenario 2:**

Treatment	Intervention Acquisition Costs	Total Costs	Number of Stroke or MI Events (per 100) <sup>†</sup>	QALYs	evLYs	Life Years
<b>Injectable Semaglutide*</b>	\$132,229	\$222,032	47	16.61	16.63	20.39
<b>Oral Semaglutide*‡</b>	\$132,475	\$224,736	51	16.50	16.52	20.35
<b>Tirzepatide*</b>	\$158,493	\$232,112	45	17.02	17.04	20.49
<b>Lifestyle Modification</b>	\$9,036	\$150,960	69	15.37	15.37	20.01

evLYs: equal value of life years gained, QALY: quality-adjusted life year, MI: Myocardial infarction

\*Each treatment is added to lifestyle modification; therefore, intervention acquisition costs also include the costs of lifestyle modification.

<sup>†</sup>Undiscounted values are shown. Per 100 individuals.

<sup>‡</sup>Based on an assumed price

## Scenario Analysis 3

### *Alternative Source for the Association between BMI and ESKD risk*

In this scenario, the association between BMI and ESKD risk was derived from another US-based study that, while older, had a larger sample size.<sup>118</sup> However, clinical experts noted that its findings are likely outdated and that the magnitude of the association may be overestimated, given advancements in the management of obesity-related comorbidities over time.

**Table E5.3. Results for Scenario 3:**

Treatment	Intervention Acquisition Costs	Total Costs	Number of Stroke or MI Events (per 100) <sup>†</sup>	QALYs	evLYs	Life Years
<b>Injectable Semaglutide*</b>	\$132,229	\$452,971	47	16.61	16.64	20.39
<b>Oral Semaglutide*‡</b>	\$132,475	\$455,086	51	16.50	16.53	20.35
<b>Tirzepatide*</b>	\$158,726	\$461,541	45	17.05	17.07	20.52
<b>Lifestyle Modification</b>	\$9,015	\$381,340	69	15.32	15.32	19.96

evLYs: equal value of life years gained, QALY: quality-adjusted life year, MI: myocardial infarction

\*Each treatment is added to lifestyle modification; therefore, intervention acquisition costs also include the costs of lifestyle modification.

<sup>†</sup>Undiscounted values are shown. Per 100 individuals.

<sup>‡</sup>Based on an assumed price

## Scenario Analysis 4

### *Alternative direct diabetic impacts of injectable and oral semaglutide*

In the base case, the direct diabetic impact of injectable semaglutide was derived from the SELECT trial population with obesity and a history of CVD, and that of oral semaglutide was assumed to be the same as injectable semaglutide. The direct diabetic impact of tirzepatide was obtained from the prediabetes population in the SURMOUNT-1 trial. Although these represent the best available evidence, differences in the source populations may bias the estimates. In this scenario, therefore, the direct diabetic impacts of injectable and oral semaglutide were estimated using tirzepatide's direct diabetic impact (HR = 0.07), adjusted by the ratio of year-1 BMI effects for injectable and oral semaglutide relative to tirzepatide. The HRs for diabetes were estimated at 0.10 for injectable semaglutide and 0.11 for oral semaglutide in this scenario.

**Table E5.4. Results for Scenario 4:**

Treatment	Intervention Acquisition Costs	Total Costs	Number of stroke or MI events (per 100)†	QALYs	evLYs	Life Years
<b>Injectable Semaglutide*</b>	\$132,643	\$445,762	45	16.70	16.73	20.45
<b>Oral Semaglutide*‡</b>	\$132,869	\$448,371	50	16.59	16.61	20.41
<b>Lifestyle Modification*</b>	\$9,036	\$376,503	69	15.37	15.37	20.01

evLYs: equal value of life years gained, QALY: quality-adjusted life year, MI: myocardial infarction

\*Each treatment is added to lifestyle modification; therefore, intervention acquisition costs also include the costs of lifestyle modification.

†Undiscounted values are shown. Per 100 individuals.

‡Based on an assumed price

## Scenario Analysis 5

### *Alternative Baseline Incidence of Diabetes*

In the basecase, the annual probability of diabetes was determined based on multiple studies.<sup>56,59,89,90</sup> Although these studies were conducted among individuals with obesity but without diabetes at baseline, their generalizability may be limited, as the populations do not perfectly match the modeled US population—three were multinational studies involving individuals with obesity and either prediabetes or a history of CVD, and one was a Swedish study of individuals with obesity. To address uncertainty around the generalizability of the basecase estimates, we conducted a scenario analysis using an alternative US-based study used in the ICER 2022 report.<sup>91</sup> We assumed an annual diabetes incidence of approximately 4.1% in the lifestyle modification arm, based on study findings among individuals with a BMI > 30 and high-normal HbA1c (5.6%–6.0%). A higher estimate was considered to overstate the risk based on clinical expert opinion, advances in prediabetes management, and findings from other studies.

**Table E5.5. Results for Scenario 5:**

Treatment	Intervention Acquisition Costs	Total Costs	Number of Stroke or MI Events (per 100) <sup>†</sup>	QALYs	evLYs	Life Years
<b>Injectable Semaglutide*</b>	\$131,790	\$460,754	49	16.52	16.55	20.32
<b>Oral Semaglutide*‡</b>	\$132,027	\$462,840	53	16.41	16.43	20.28
<b>Tirzepatide*</b>	\$158,332	\$466,766	46	16.99	17.01	20.47
<b>Lifestyle Modification</b>	\$8,968	\$395,563	74	15.16	15.16	19.85

evLYs: equal value of life years gained, QALY: quality-adjusted life year, MI: myocardial infarction

\*Each treatment is added to lifestyle modification; therefore, intervention acquisition costs also include the costs of lifestyle modification.

<sup>†</sup>Undiscounted values are shown. Per 100 individuals.

<sup>‡</sup>Based on an assumed price

## Scenario Analysis 6

### *A Subgroup with Baseline BMI < 30 kg*

The population subgroup with a baseline BMI < 30 was modeled. Their baseline characteristics are listed in Table E.2.12.

**Table E5.6. Results for a Subgroup with Baseline BMI < 30**

Treatment	Intervention Acquisition Costs	Total Costs	Number of stroke or MI events (per 100) <sup>†</sup>	QALYs	evLYs	Life Years
<b>Injectable Semaglutide*</b>	\$120,387	\$416,986	34	15.94	15.95	18.55
<b>Oral Semaglutide*‡</b>	\$120,853	\$417,757	34	15.90	15.90	18.55
<b>Tirzepatide*</b>	\$144,079	\$431,504	33	16.22	16.22	18.61
<b>Lifestyle Modification</b>	\$8,228	\$341,032	54	14.95	14.95	18.18

evLYs: equal value of life years gained, QALY: quality-adjusted life year, MI: myocardial infarction

\*Each treatment is added to lifestyle modification; therefore, intervention acquisition costs also include the costs of lifestyle modification.

<sup>†</sup> Undiscounted values are shown. Per 100 individuals.

<sup>‡</sup>Based on an assumed price

### **A Subgroup with Baseline BMI $\geq 30$**

The population subgroup with a baseline BMI  $\geq 30$  was modeled. Their baseline characteristics are listed in Table E.2.12.

**Table E5.7. Results for a Subgroup with Baseline BMI  $\geq 30$**

Treatment	Intervention Acquisition Costs	Total Costs	Number of Stroke or MI Events (per 100) <sup>†</sup>	QALYs	evLYs	Life Years
<b>Injectable Semaglutide*</b>	\$131,566	\$450,822	50	16.44	16.46	20.28
<b>Oral Semaglutide*‡</b>	\$132,079	\$453,475	50	16.35	16.38	20.28
<b>Tirzepatide*</b>	\$157,538	\$465,307	47	16.81	16.83	20.36
<b>Lifestyle Modification</b>	\$8,996	\$374,494	72	15.20	15.20	19.92

evLYs: equal value of life years gained, QALY: quality-adjusted life year, MI: myocardial infarction

\*Each treatment is added to lifestyle modification; therefore, intervention acquisition costs also include the costs of lifestyle modification.

<sup>†</sup>Undiscounted values are shown. Per 100 individuals.

<sup>‡</sup>Based on an assumed price

### **A Subgroup with Baseline BMI $\geq 35$**

The population subgroup with a baseline BMI  $\geq 35$  was modeled. Their baseline characteristics are listed in Table E.2.12.

**Table E5.8. Results for a Subgroup with Baseline BMI  $\geq 35$**

Treatment	Intervention Acquisition Costs	Total Costs	Number of stroke or MI events (per 100) <sup>†</sup>	QALYs	evLYs	Life Years
<b>Injectable Semaglutide*</b>	\$133,268	\$458,383	59	16.30	16.32	20.55
<b>Oral Semaglutide*‡</b>	\$133,659	\$465,134	59	16.16	16.19	20.53
<b>Tirzepatide*</b>	\$159,593	\$472,962	57	16.69	16.72	20.63
<b>Lifestyle Modification</b>	\$9,132	\$387,691	74	14.97	14.97	20.22

evLYs: equal value of life years gained, QALY: quality-adjusted life year, MI: myocardial infarction

\*Each treatment is added to lifestyle modification; therefore, intervention acquisition costs also include the costs of lifestyle modification.

<sup>†</sup>Undiscounted values are shown. Per 100 individuals.

<sup>‡</sup>Based on an assumed price

### **A Subgroup with Baseline BMI $\geq$ 40**

The population subgroup with a baseline BMI  $\geq$  40 was modeled. Their baseline characteristics are listed in Table E.2.12.

**Table E5.9. Results for a Subgroup with Baseline BMI  $\geq$  40**

<b>Treatment</b>	<b>Intervention Acquisition Costs</b>	<b>Total Costs</b>	<b>Number of Stroke or MI Events (per 100)<sup>†</sup></b>	<b>QALYs</b>	<b>evLYs</b>	<b>Life Years</b>
<b>Injectable Semaglutide*</b>	\$137,512	\$475,953	61	16.27	16.31	21.21
<b>Oral Semaglutide*‡</b>	\$138,049	\$477,040	61	16.19	16.23	21.21
<b>Tirzepatide*</b>	\$164,687	\$485,058	58	16.76	16.80	21.29
<b>Lifestyle Modification</b>	\$9,411	\$393,673	82	14.92	14.92	20.85

evLYs: equal value of life years gained, QALY: quality-adjusted life year, MI: myocardial infarction

\*Each treatment is added to lifestyle modification; therefore, intervention acquisition costs also include the costs of lifestyle modification.

<sup>†</sup>Undiscounted values are shown. Per 100 individuals.

<sup>‡</sup>Based on an assumed price

## E6. Prior Economic Models

Several economic models evaluated the cost-effectiveness of semaglutide and tirzepatide.

ICER's 2022 obesity model found that injectable semaglutide was not cost-effective compared to lifestyle modification alone, with an incremental cost-effectiveness ratio of \$237,000 per QALY gained—higher than the results observed in the current model.<sup>69</sup> The primary reason for this difference is the lower annual net price of injectable semaglutide used in the current model (\$6,829 in the current model vs. \$13,618 in the 2022 model). In addition, the current model included a broader range of obesity-related outcomes and incorporated direct treatment effects on CV outcomes, which were larger than the indirectly estimated effects used in the prior model—leading to improved clinical outcomes (incremental QALY of 1.24 vs. 0.90 in the current model vs. previous ICER model for injectable semaglutide). ICER's 2022 model also evaluated the cost-effectiveness of tirzepatide in a scenario analysis, assuming the same annual drug cost as injectable semaglutide (\$13,618). Tirzepatide yielded greater incremental QALYs and evLYs compared to injectable semaglutide, resulting in a more favorable cost-effectiveness ratio (\$145,000 per QALY gained)—a finding consistent with our model.

Novo Nordisk has published a cost-effectiveness analysis of injectable semaglutide in the US.<sup>82</sup> At an annual maintenance treatment cost of \$17,597, injectable semaglutide was found to be cost-effective, with an incremental cost-effectiveness ratio of \$122,549 per QALY gained. The primary reason injectable semaglutide appeared cost-effective despite the higher drug cost was the assumption in Kim et al. of a two-year maximum treatment duration in the base case analysis. This assumption also contributed to the substantially lower incremental QALYs (0.18) compared to those estimated in the ICER models. The study demonstrated that the model was highly sensitive to this assumption, with the incremental cost-effectiveness ratio rising to approximately \$250,000 per QALY if the treatment duration was extended to 10 years, largely due to the high cost of the drug. The same two-year maximum treatment duration assumption was also used in the NICE technical appraisals for injectable semaglutide, contributing to a lower incremental QALY gain of 0.092.<sup>84</sup>

Recently, Eli Lilly published a cost-effectiveness analysis of tirzepatide compared to lifestyle modification from the perspective of the US health care system.<sup>180</sup> The study found that tirzepatide 15 mg was associated with an additional 0.61 QALYs and \$75,839 in incremental costs, resulting in an incremental cost-effectiveness ratio of \$125,053 per QALY gained. While the overall conclusion aligns with our model—that tirzepatide is cost-effective—the incremental cost-effectiveness ratio reported by Eli Lilly was higher than ours, primarily due to the higher annual cost of tirzepatide (\$12,720). Additionally, the study reported lower incremental QALYs, largely due to differences in treatment discontinuation assumptions. Eli Lilly's model applied longitudinal all-cause discontinuation at an annual rate of 10.6% for tirzepatide, whereas our model assumed treatment discontinuation patterns observed in the trial ITT population. In a scenario analysis where no

discontinuation occurred, the manufacturer estimated a substantially higher QALY gain and a lower incremental cost-effectiveness ratio of \$120,130 per QALY gained. Another reason for the lower incremental QALYs in Eli Lilly’s study may be the exclusion of direct treatment effects on obesity-related outcomes, such as cardiovascular disease.

Finally, Hwang et al. evaluated the cost-effectiveness of tirzepatide and injectable semaglutide compared to lifestyle modification and found that neither treatment was cost-effective, despite using net prices for both drugs (\$6,236 for tirzepatide and \$8,412 for semaglutide, annually).<sup>75</sup> The incremental QALYs were lower than those in the current model—0.35 for tirzepatide and 0.25 for semaglutide. This may be partly due to differences in the modeled population: the study included individuals both with and without diabetes and assumed smaller weight loss in the subgroup with diabetes. Additionally, the use of an NHANES-based cohort, with most individuals classified as overweight (BMI < 30) or having Class 1 obesity (BMI 30–34.9), likely contributed to less favorable cost-effectiveness results. Although the incremental life years gained were similar to our model (0.5 for tirzepatide and 0.35 for semaglutide), the lower QALYs may reflect differences in utility estimates or other model assumptions.

## F. Potential Budget Impact: Supplemental Information

### **Methods**

We used results from the same model employed for the cost-effectiveness analyses to estimate total potential budget impact. Potential budget impact was defined as the total differential cost of using each new therapy rather than relevant existing therapy for the treated population, calculated as differential health care costs (including drug costs) minus any offsets in these costs from averted health care events. All costs were undiscounted and estimated over one- and five-year time horizons.

To estimate the size of the potential candidate population for treatment, we used inputs for the prevalence of adults in the US with obesity (42.4%), and the prevalence of adults in the US who are overweight (30.7%)<sup>122</sup> multiplied by the percentage of overweight adults in the US that have multimorbidity (39.5%).<sup>123</sup> From this population, we excluded those who are already receiving medication treatment for obesity (22%).<sup>124</sup> We also excluded the population of US adults with type 2 diabetes (approximately 9.5% of the total population)<sup>125</sup> multiplied by the percentage of type 2 diabetes patients who are overweight or obese (approximately 90% of the type 2 diabetes population).<sup>126,127</sup> Applying these sources to the total US adult population averaged over the next five years (~270,900,000)<sup>106</sup> results in estimates of ~92,000,000 eligible patients.

We first conducted individual budget impact analyses for each intervention of interest (Figure 7.1), assuming that 20% of the eligible population would initiate the treatment in each of the five years, or ~18,400,000 patients per year. In these individual analyses, the new uptake was comprised solely of patients starting the intervention of interest (i.e. in the injectable semaglutide analysis, the new uptake comprised only patients starting injectable semaglutide). Separately, in a blended budget impact analysis (Figure 7.2), to account for multiple interventions of interest, we assumed that the 20% uptake includes patients initiating all three interventions of interest equally (i.e., 6.7% of patients initiating injectable semaglutide, 6.7% of patients initiating oral semaglutide, and 6.7% of patients initiating injectable tirzepatide), with ~30,700,000 patients initiating each treatment over the next five years, or ~6,100,000 patients per treatment each year. For both the individual and blended budget impact analyses, we assumed that all patients are on lifestyle modification alone at baseline.

ICER's methods for estimating potential budget impact are described in detail elsewhere and have recently been updated.<sup>170,204</sup> The intent of our revised approach to budgetary impact is to

document the percentage of patients that could be treated at selected prices without crossing a budget impact threshold that is aligned with overall growth in the US economy.

Once estimates of budget impact are calculated, we compare our estimates to an updated budget impact threshold that represents a potential trigger for policy mechanisms to improve affordability, such as changes to pricing, payment, or patient eligibility. As described in [ICER's methods presentation](#) (Value Assessment Framework), this threshold is based on an underlying assumption that health care costs should not grow much faster than growth in the overall national economy. From this foundational assumption, our potential budget impact threshold is derived using an estimate of growth in US gross domestic product (GDP) +1%, the average number of new drug approvals by the FDA over the most recent two-year period, and the contribution of spending on retail and facility-based drugs to total health care spending.

For 2024-2025, therefore, the five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is calculated to total approximately \$880 million per year for new drugs.